|
3rd International AIDS Society Conference on HIV Pathogenesis and TreatmentRio de Janeiro - July 24-27, 2005 |
Main TOC Monday TOC Tuesday TOC
Cite as: IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd: Abstract No. xx
where xx is the abstract number.
| Wednesday | |
| Forum • 02 | |
| WeFo02 Salvage therapy in different clinical settings |
|
 WeFo0201 |
Switching therapy: strategic approaches IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WeFo0201) Steve Deeks Power Point Presentation. There is no abstract available. |
| WeFo0202 |
Sequencing therapy in resource limited settings IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WeFo0202) Ian Sanne Power Point Presentation. There is no abstract available. |
| WeFo0203 |
Options for deep salvage therapy: now and the near future IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WeFo0203) Julio Montaner Power Point Presentation. There is no abstract available. |
| WeFo0204 | E-184V STUDY. LAMIVUDINE MONOTHERAPY VS TREATMENT INTERRUPTION IN FAILING HIV-1 INFECTED SUBJECTS, HARBOURING THE M184V MUTATION: 48-WEEK FINAL RESULTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WeFo0204) Castagna A.1, Danise A.1, Menzo S.2, Galli L.1, Boeri E.1, Gianotti N.1, Carini E.1, Tiberi S.1, Cernuschi M.1, Hasson H.1, Mammarella M.2, Guffanti M.1, Seminari E.1, Clementi M.1, Lazzarin A.1 3TC monotherapy induces less immunological and clinical failure than TI. This strategy is associated with maintenance of reduced viral fitness, low viral rebound and reduction of resistance mutations. |
| WeFo0205 |
Enfuvirtide (T20) plasma levels and injection site reactions (ISRs) using a novel needle-free gas-powered injection system (Biojector) for subcutaneous administration of T20 in treatment-experienced HIV+ patients IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WeFo0205) Montaner J.1, Joy R.1, Larsen G.1, Valyi M.1, Walker E.2, Harris M.1 Power Point Presentation. There is no abstract available. |
| Oral Abstracts | |
| WeOa01 Initiation of therapy |
|
| WeOa0101 | CLINICAL AND BIOLOGICAL FACTORS AT RECRUITMENT IN HIV INFECTED CHILDREN IN RELATION WITH THREE YEARS SURVIVAL IN ABIDJAN, CÔTE D'IVOIRE: THE EXPERIENCE OF THE ANRS 1244/1278 STUDY IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WeOa0101) Msellati P.1, Anaky M.F.2, Rouet F.3, Kouakoussui A.2, Mercier S.4, Wemin M.L.5, N'Gbeche M.S.2, Fassinou P.6, Blanche S.7 Very low weight for age Z-score, history of tuberculosis and viral load >5 log are strong predictors of poor survival at 3 years and CD4 >15% is a predictor of good survival. This confirms guidelines we use for HAART initiation and advocates for an early identification of HIV-infected children. |
| WeOa0102 | DEVELOPMENT OF A PAEDIATRIC HIV CHRONIC CARE MODEL TO IMPROVE QUALITY OF CARE AND ACCELERATE THE PROVISION OF ANTIRETROVIRAL THERAPY IN SOWETO, SOUTH AFRICA IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WeOa0102) Moultrie H.1, Meyers T.2, Barker P.3 Efficiency of the clinic has substantially improved and patient clinical outcomes are excellent. The feasibility and value of implementing chronic disease management and quality improvement systems in a government sector clinic in a resource poor setting is evident. The model is now being implemented at 2 primary care ART sites in Johannesburg. |
| WeOa0103 | EARLY EFFECTIVENESS OF TRIOMUNE IN HIV INFECTED UGANDAN CHILDREN IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WeOa0103) Barlow-Mosha L.1, Musoke P.2, Ajuna P.1, Luttajumwa M.1, Walabyeki J.1, Owor M.1, Mubiru M.1 The use of Triomune in HIV infected children is effective. Triomune therapy led to a significant increase in CD4 count and decrease in viral load after 36 weeks of therapy. Adherence to tablet formulations is better than to syrup formulations. We are still monitoring the effect of single-dose NVP on response to future NVP containing HAART regimens. |
| WeOa0104 | DELAYED COMPLICATIONS OF BACILLUS CALMETTE – GUERIN (BCG) VACCINATION IN HIV INFECTED CHILDREN IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WeOa0104) Fallo A., Torrado L., Sanchez A., Cerqueiro C., Shadgrosky L., Lopez E.L. We report a high frequency of complications and an increased risk of severe disease, therefore we believe that BCG vaccination should be reconsidered in children at risk of HIV infection. |
| WeOa02 Antiretroviral treatment strategies |
|
| WeOa0201 | INVESTIGATING CELLULAR ANTIRETROVIRAL RESISTANCE: PRELIMINARY RESULTS OF THE "ICARE" STUDY IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WeOa0201) Lafeuillade A.1, Hittinger G.1, Poggi C.2, Benech H.3, Cupo A.4 Huge differences in antiretroviral diffusion and metabolism are found in vivo in PBMC versus LNMC; these differences could be related to differences in MDR expression. These data may contribute to understanding the mechanisms of HIV-1 RNA persistence during effective. |
| WeOa0202 | SUPERIOR OUTCOME FOR TENOFOVIR DF (TDF), EMTRICITABINE (FTC) AND EFAVIRENZ (EFV) COMPARED TO FIXED DOSE ZIDOVUDINE/LAMIVUDINE (CBV) AND EFV IN ANTIRETROVIRAL NAÏVE PATIENTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WeOa0202) Pozniak A.L.1, Gallant J.E.2, DeJesus E.3, Campo R.4, Arribas J.R.5, Gazzard B.1, Lu B.6, McColl D.6, Enejosa J.6, Cheng A.K.6 Through week 48, the combination of TDF, FTC and EFV compared to CBV + EFV fulfilled the criteria for non inferiority and resulted in a superior outcome in terms of virologic suppression, CD4 response, and adverse events leading to study regimen discontinuation. |
| WeOa0203 | THE LEVEL OF PERSISTENT VIREMIA DOES NOT INCREASE AFTER SIMPLIFICATION OF MAINTENANCE ANTIRETROVIRAL THERAPY TO LOPINAVIR/RITONAVIR ALONE IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WeOa0203) McKinnon J.E.1, Arribas J.R.2, Pulido F.3, Delgado R.3, Mellors J.W.1 The level of persistent viremia in patients suppressed to <50 copies/ml on combination therapy did not change at 4 or 8 weeks after simplification to LPV/r alone, implying that suppression of HIV-1 replication was maintained. |
| WeOa0204 | VIRAL SUPPRESSION IN CSF AND GENITAL TRACT IN RITONAVIR-BOOSTED "ATAZANAVIR ONLY" MAINTENANCE THERAPY (ATARITMO-STUDY) IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WeOa0204) Vernazza P.1, Daneel S.1, Schiffer V.2, Decosterd L.3, Hirschel B.2, and the Swiss HIV Cohort S.1 Ritonavir-boosted atazanavir mono therapy might be a potentially attractive strategy for long-term maintenance of ART. However, due to the limited penetration into compartments, more data on the safety and compartment penetration of protease-mono ART are needed. |
| WeOa0205 | TIPRANAVIR/RITONAVIR (TPV/R) 500 MG/200 MG BID DRIVES WEEK 24 VIRAL LOAD (VL) BELOW 400 COPIES/ML WHEN COMBINED WITH A SECOND ACTIVE DRUG (T-20) IN PROTEASE INHIBITOR EXPERIENCED HIV+ PATIENTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WeOa0205) Valdez H., McCallister S., Kohlbrenner V., Mayers D. Most PI-experienced patients who received a TPV/r -containing regimen achieved an IQ ≥60. With this IQ, 81% of patients who also included a new class of drug in the regimen achieved a week 24 viral load reduction of 1 log10 or more. Nearly 60% of these hard-to-treat patients achieved a week 24 VL <400 copies/mL. |
| WeOa0206 | SIGNIFICANTLY REDUCED FOOD EFFECT AND PHARMACOKINETIC VARIABILITY WITH A NOVEL LOPINAVIR/RITONAVIR TABLET FORMULATION IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WeOa0206) Awni W., Chiu Y.-L., Zhu T., Braun N., Klein C., Heuser R., Breitenbach J., Morris J., Doan T., Brun S., Hanna G. Lopinavir and ritonavir levels were similar between tablet and SGC formulations under reference meal conditions. There was considerably less food effect with the tablet formulation, and pharmacokinetic variability was significantly reduced under all meal conditions compared to the SGC. |
| WeOa03 Harm reduction |
|
| WeOa0301 | IDENTIFICATION OF SELECTION FACTORS THAT EXPLAIN ELEVATED RATES OF HIV SEROCONVERSION AMONG PARTICIPANTS IN ONE OF NORTH AMERICA'S LARGEST SYRINGE EXCHANGE PROGRAMS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WeOa0301) Lloyd-Smith E., Kerr T., Li K., Hogg R., Tyndall M., Montaner J., Wood E. These data demonstrate that the HIV seroconversion differences between frequent and non-frequent NEP attendees may be explained by the higher risk profile of frequent NEP attendees. |
| WeOa0302 | SPATIAL ANALYSIS OF DRUG PURCHASE AND USE LOCATIONS AMONG INJECTION DRUG USERS IN PHILADELPHIA: POTENTIAL ROLE IN HIV PREVENTION IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WeOa0302) Kraut-Becher J., Lynch K., Fiore D., Metzger D. Geographic information may aid in our understanding of HIV risk behaviors and help design and target new HIV prevention strategies. |
| WeOa0303 | NEW, INNOVATIVE APPROACH FOR HARM REDUCTION AND PRIMARY HIV PREVENTION IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WeOa0303) Mirzoyan A.1, Ter-Hovakimyan A.2, Bakhshinyan V.1, Minasyan H.2 1. PD approach is asset-based and enables target group to find own sustainable solution for prevention of HIV infection. 2. PD is widely acceptable by IDUs and FSWs, since based on "indigenous" knowledge. 3. PD participants are active actors in own development. 4. Input from community ensures low-cost, long-term and sustained impact. 5. PD is a behavioural change approach: Practice, Attitude and Knowledge (PAK). 6. Attraction of CAG facilitates reaching of target groups and shortens baseline assessment to 1-3 days. |
| LATE BREAKER ORAL ABSTRACTS Wednesday |
|
| WeOaLB0101 | COMPARATIVE DISEASE PROGRESSION OBSERVED IN NEWLY DIAGNOSED PATIENTS INFECTED WITH DRUG RESISTANT AND SUSCEPTIBLE HIV-1: NO SIGNS FOR INCREASED VIRULENCE IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WeOaLB0101) Wensinq A.M.J.1, Van de Vijver D.A.M.C.2, Vercauteren J.3, Albert J.4, Bratt G.5, Clumeck N.6, Coughlan S.7, Grossman Z.8, Hatzakis A.9, Horban A.10, Jevtovic D.11, Bruun Jørgensen L.12, Kuecherer C.13, Lange J.14, Nielsen C.12, Paraskevis D.9, Poggensee G.13, Puchhammer-Stöckl E.15, Schmit J.-C.16, Stanczak G.10, Stanojevic M.17, Vandamme A.-M.3, Boucher C.A.B.2 In this systematic approach patients recently diagnosed with resistant viruses experienced a similar disease progression as patients infected with drug-sensitive viruses. Currently there are no indications that multi-drug HIV variants with increased virulence are circulating in Europe. Further follow up is needed to determine whether clinical response to therapy once initiated may affect disease outcome. |
| WeOaLB0102 | TMC114/r OUTPERFORMS INVESTIGATOR-SELECTED PI(s) IN 3-CLASS-EXPERIENCED PATIENTS: WEEK 24 PRIMARY ANALYSIS OF POWER 1 (TMC114-C213) IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WeOaLB0102) Katlama C.1, Carvalho M.T.2, Cooper D.3, De Backer K.4, Lefebvre E.4, Pedro R.2, Rombouts K.4, Stoehr A.5, Vangeneugden T.4, Woehrmann A.6 The magnitude of viral suppression achieved with TMC114/r in 3-class-experienced patients was significantly greater than control PI(s) and similar to that seen in less experienced patients. An exceptional CD4 response was observed. |
| WeOaLB0103 | ANTIRETROVIRAL ACTIVITY AND TOLERABILITY OF REVERSET (D-D4FC), A NEW FLUORO-CYTIDINE NUCLEOSIDE ANALOG WHEN USED IN COMBINATION THERAPY IN TREATMENT-EXPERIENCED PATIENTS: RESULTS OF PHASE IIB STUDY RVT-203 IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WeOaLB0103) Cohen C.1, Katlama C.2, Murphy R.3, Gathe J.4, Brinson C.5, Richmond G.6, Girard P.-M7, Fessel J.8, Liappis A.9, Puglia E.10, Rodwick B.11, Nadler J.12, O'Brien W.13, Arasteh K.14, Otto M.15, Erickson-Viitanen S.16, Levy R.16 RVT 200 mg is active in ARV-experienced pts and generally well tolerated. Because of the risk of elevated lipase and pancreatitis, RVT should not be used with ddI. Data support continued development of RVT. |
| WeOaLB0201 | VERY SATISFACTORY OUTCOMES CAN BE ACHIEVED IN CHILDREN TREATED WITH HIGHLY ACTIVE ANTIRETROVIRAL TREATMENT UNDER PROGRAM CONDITIONS IN RESOURCE-LIMITED SETTINGS: THE EXPERIENCE OF MÉDECINS SANS FRONTIÈRES! IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WeOaLB0201) AIDS Working Group A.W.G.1, Epicentre2 This data shows very satisfactory outcomes (comparable to those in developed countries) among children offered HAART under routine program conditions in resource-limited settings. Our findings strongly favour the rapid integration of HAART for children within the scaling-up process in these settings. |
| WeOaLB0202 | DIRECTLY ADMINISTERED ANTIRETROVIRAL THERAPY (DAART) IN CONJUNCTION WITH METHADONE IS ASSOCIATED WITH IMPROVED HIV TREATMENT OUTCOMES IN HIV-INFECTED INJECTION DRUG USERS (IDUS) IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WeOaLB0202) Lucas G.M.1, Mullen B.A.1, Weidle P.J.2, Hader S.2, Moore R.D.1 The results of this study strongly suggest that DAART, in the framework of methadone therapy, is associated with clinically-meaningful improvements in treatment outcomes in HIV-infected IDUs. Additional studies of this intervention are indicated. |
| WeOaLB0203 | 48 WEEK VIROLOGICAL RESPONSE TO A TRIPLE NUCLEOSIDE/NUCLEOTIDE ANALOGUE REGIMEN IN ADULTS WITH HIV INFECTION IN AFRICA WITHIN THE DART TRIAL IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WeOaLB0203) Kaleebu P.1, DART Trial Team T.2 ZDV+3TC+TDF maintains good virological efficacy from 24 to 48 weeks in advanced disease. In this population infected with HIV-1 subtypes A, C or D, M184V with or without NAMs was the most common route to resistance, whereas K65R was identified infrequently. |
| WePp01 New antiretroviral targets and compounds, mechanisms of drug resistance |
|
| WePp0101 | UNDERSTANDING THE ROLE OF INVARIANT THR80 IN HIV-1 PROTEASE IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePp0101) Foulkes J.1, O'Brien S.1, Prabu-Jeyabalan M.1, Osterhout J.J.2, Schiffer C.A.1 Threonine is the optimal amino acid at position 80. While protease can tolerate serine, mutation to valine, asparagine, or alanine significantly alters the function. This study demonstrates the functional relevance of this invariant residue, and the importance of studying other invariant residues in protease. |
| WePp0102 | THE L74V MUTATION IN HIV-1 RT IMPAIRS UNBLOCKING OF ZDV-TERMINATED DNA PRIMERS AND REDUCES SYNTHESIS OF VIRAL DNA IN REAL-TIME PCR IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePp0102) Frankel F., Marchand B., Götte M., Wainberg M.A. Although ATP-mediated excision was compromised in L74V RT, PPi-mediated excision showed differences only at early time points, potentially highlighting the biological significance of ATP vs PPi in excision reactions. Diminished viral replication capacity of L74V may be due to reduced synthesis of (-) ssDNA as well as full-length DNA. |
| WePp0103 | BINDING ENERGETICS ANALYSIS SHOWS A UNIQUE RESPONSE OF TIPRANAVIR TO HIV-1 PROTEASE MUTATIONS ASSOCIATED WITH DRUG RESISTANCE IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePp0103) Muzammil S.1, Kang L.-W.2, Armstrong A.A.2, Jakalian A.3, Bonneau P.R.3, Schmelmer V.4, Amzel L.M.2, Freire E.1 Most inhibitors lose affinity against mutations due to combined enthalpy and entropy loses. Good response to mutations is achieved when enthalpy and entropy changes mutually compensate each other. Inhibitors that respond well usually compensate enthalpic loses with entropic gains. TPV is the first inhibitor that has shown the ability to maintain high inhibitory potency by either gaining or sustaining minimal loses in binding enthalpy. |
| WePp0104 | MULTIVALENT COMPOUNDS FUNCTIONALIZED WITH THE CARBOHYDRATE HEADGROUPS OF IMMUNE CELL-SURFACE GSLS AS INHIBITORS OF HIV-1 INFECTION. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePp0104) Rosa Borges A.1, Puri A.2, Krebs F.C.3, Wigdahl B.3, Blumenthal R.2, Rawat S.S.2, Johnson B.T.2, Schengrund C.-L.1 The results show that multivalent carbohydrates carrying globotriose or 3'-sialyllactose moieties were effective inhibitors of HIV-1 infection of cells in vitro. More interestingly, inhibition of viral infection by our glycodendrimers suggests there may be a viral tropism dependence for cell-surface carbohydrates. These observations provide a novel approach for the design of new carbohydrate-based antiviral drugs. Based on their water-solubility, low cytotoxicity, and potent inhibition of cellular infection, these glycodendrimers merit consideration as prototypes for use in microbicide development, and possibly novel HIV-1 drug therapy. |
| WePp0105 | CRYSTALLOGRAPHIC STUDY WITH BILR 355 BS, A NOVEL NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) WITH A BROAD ANTI HIV-1 PROFILE IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePp0105) Coulombe R., Fink D., Landry S., Lessard I.A.D., McCollum R., Naud J., O'Meara J., Simoneau B., Yoakim C., Bonneau P.R. BILR 355 BS achieves a superior antiviral profile against NNRTI-resistant RTs through specific modifications to the core substitution pattern that make additional favorable binding interactions with both mutant and wild-type RTs. BILR 355 BS is currently in clinical trials. |
| WePp0106 | NOVEL COMPOUNDS THAT INHIBIT HIV REPLICATION BY ACTING THROUGH INHIBITION OF HIV REV FUNCTION IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePp0106) Rekosh D.1, Ptak R.2, Hammarskjold M.-L.1 These compounds are promising leads as therapeutic candidates that target HIV replication through inhibition of Rev function. |
| WePp02 Planning for Vaccine Efficacy Trials |
|
| WePp0201 | COMMUNITY BASED STUDY OF HIV-1 INFECTION AMONG PLANTATION WORKERS IN KERICHO, KENYA IN PREPARATION FOR HIV-1 VACCINE TRIALS. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePp0201) Foglia G.1, Langat L.1, Langat W.1, Kibaya R.1, Kimutai R.1, Kiptoo I.1, Sateren W.2, Bautista C.2, Renzullo P.3, Darden J.3, Wasunna M.4, Michael N.5, Robb M.2, Birx D.5 HIV-1 prevalence is high in this population. Risk factors are those observed in other African populations. Successful HIV-1 vaccine cohort development requires sensitizing the local communities and educating potential volunteers. |
| WePp0202 | FEASIBILITY OF HIV VACCINE EFFICACY TRIALS IN SOUTH AFRICAN ADOLESCENTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePp0202) Jaspan H.B.1, Berwick J.R.1, Mathews C.2, Myer L.3, Flisher A.J.3, Seebregts C.4, Bekker L.-G.1 These data suggest that incidence and sexual risk in this population is high enough to facilitate HIV vaccine efficacy trials. Adolescents in this setting seem willing to participate in HIV vaccine research, but full understanding of trial information will be important. Potential barriers must be overcome. |
| WePp0203 | RECRUITMENT AND RETENTION OF AN HIV DISCORDANT COUPLE COHORT IN KIGALI, RWANDA IN PREPARATION FOR VACCINE EFFICACY TRIALS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePp0203) Shutes E.1, Karita E.2, Kayitenkore K.2, Ketter N.3, Kambili C.4, Allen S.5, Rwanda/Zambia HIV Research Group P.5 The establishment and retention of a well-defined, high-risk cohort in preparation for vaccine efficacy trials is possible in developing countries. A run-in design, using an existing cohort provides an accurate assessment of HIV incidence and allows the recruitment of volunteers with good follow-up and compliance. Further, the opportunity to determine contraceptive acceptability, an inclusion criteria of vaccine trials, is critical in countries like Rwanda, where up to 75% of eligible women are pregnant or breastfeeding. The limiting factor to the development of such cohorts is the commitment of funding. |
| WePp0204 | PREPARATION FOR VACCINE EFFICACY TRIALS: BASELINE PREVALENCE, ESTIMATES OF INCIDENCE AND DEMOGRAPHIC RISK FACTORS IN POPULATIONS WILLING TO RECEIVE VOLUNTARY COUNSELING AND TESTING AND PARTICIPATE IN RESEARCH IN UGANDA AND KENYA IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePp0204) Ketter N.1, Kamali A.2, Sanders E.3, Katende M.4, Anzala O.5, Von Lieven A.6, Price M.1, Stevens G.7, Stoll L.1, Gilmour J.8, Thomson H.6, Kambili C.6, Fast P.8 Conduct of this prevalence study has prepared the community for research and VCT in addition to providing some baseline demographic and risk data that will allow for the selection of subgroups of potential volunteers at higher risk for HIV vaccine efficacy trials and strengthen referral networks for prevention and care. |
| WePp0205 | SCREENING AND ENROLLMENT IN TWO COHORT STUDIES WITH DIFFERENT PROCEDURES AND BENEFITS IN LUSAKA, ZAMBIA IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePp0205) Ntamwemezi J.-B. The enrollment rate for the two studies was similar, indicating that the different benefits and procedures associated with each study did not significantly affect couples’ decisions to participate. While a broad range of outpatient services is appreciated as a benefit for HT participants, it is costly in personnel time and medication. A higher per visit reimbursement with health care limited to reproductive health resulted in similar enrollment rates. |
| WePp0206 | A PROSPECTIVE STUDY TO ESTIMATE HIV INCIDENCE, RECRUITMENT AND RETENTION AMONG POTENTIAL VOLUNTEERS FOR AN HIV EFFICACY TRIAL IN RURAL UGANDA IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePp0206) Bwanika A.1, Ruzagira E.1, Nambowa R.1, Kamali A.1, Ketter N.2, Grosskurth H.1 The high enrollment and good follow up rates, which are necessary for future HIV vaccine efficacy trials are very encouraging. This general population study contains a significant proportion of persons at risk for HIV infection. |
| WePp03 Tuberculosis and other opportunistic infections |
|
| WePp0301 | TUBERCULOUS MENINGITIS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN ARGENTINA IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePp0301) Cecchini D., Ambrosioni Czyrko J., Brezzo C., Corti M., Perez M., Ambroggi M. Meningeal involvement due to MR-TB was very frequent in our study, with a higher mortality rate. An important percentage of patients had normal CSF protein levels (34%) and cell counts (20%), what could be related to the very low CD4 T-cell count found in our population. |
| WePp0302 | MYCOBACTERIUM LEPRAE: AN OPPORTUNISTIC INFECTION IN HIV/AIDS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePp0302) Bartholomew C.1, Suite M.2, Edwards J.3, Boyce G.3, Valdez S.3 The average incubation period of Hansen's disease is probably about 4 years for tuberculoid leprosy and twice that for lepromatous leprosy. Latent and subclinical infection with Mycobacterium leprae may be expressed clinically by superinfection with HIV. There are also a few case reports in the literature suggesting the presentation of leprosy from immune reconstitution after therapy with HAART. |
| WePp0303 | TB/HIV CO-INFECTED PATIENTS ON RIFAMPICIN CONTAINING TREATMENT HAVE EQUIVALENT ART TREATMENT OUTCOMES, AND CONCURRENT USE OF NEVIRAPINE IS NOT ASSOCIATED WITH INCREASED HEPATOTOXICITY IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePp0303) Van Cutsem G.1, Cohen K.2, Bedelu M.1, Sarunchuk P.1, Hilderbrand K.1, Coetzee D.3, Boulle A.3 Although there are many studies reporting high rates of tuberculosis immune reconstitution syndrome, concurrent tuberculosis treatment in this cohort has not to date been associated with inferior clinical outcomes when looking at survival, and virological and immunological outcomes. There is ongoing concern about the concurrent use of rifampicin and nevirapine in terms of hepatotoxicity. The lack of an association between the concurrent use of these drugs and increases in ALT in this observational study are encouraging should pharmacokinetic studies (ongoing) endorse their use together. |
| WePp0304 | EARLY HEPATITIS C VIRAL KINETICS PREDICTION OF SVR IN HIV/HCV CO-INFECTED PATIENTS TREATED WITH PEGYLATED INTERFERON ALFA-2B (PEG-LFN) AND RIBAVIRIN (RBV) IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePp0304) Neumann A., Wu L., McLaughlin M., Koratich C., Rehm C., Masur H., Kottilil S., Polis M. SVR in HIV/HCV co-infected patients treated with Peg-IFN alfa-2b and RBV in this study can be accurately predicted at 4 weeks, or even as early as 3 days, of treatment. With the limitation of comparison across studies, HCV kinetics among HIV co-infected patients seem to be predominantly influenced by race and HCV genotype. |
| WePp0305 | THE HEPADOSE STUDY: EVALUATION OF PROTEASE INHIBITORS AND NON NUCLEOSIDE ANALOGUE PLASMA CONCENTRATIONS IN HIV/HCV AND HIV INFECTED PATIENTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePp0305) Dominguez S.1, Peytavin G.2, Guiguet M.1, Calvez V.1, Costagliola D.1, Bricaire F.1, Poynard T.1, Katlama C.1, Benhamou Y.1 In HIV/HCV patients Cmin did not change significantly for PI except for lopinavir, but NNRTI were strongly overdosed in HIV-HCV pts suggesting the need of drug monitoring in this population. |
| WePp0306 | IMMUNOLOGICAL STATUS AND PROGNOSIS OF HIV-INFECTED PATIENTS WITH ACTIVE TUBERCULOSIS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePp0306) Scano F.1, Toskin I.1, Nunn P.1 One decade ago it was thought that tuberculosis occurred across a wide range of CD4 cell counts (Lancet. 1993 Jul 17;342(8864):143-6 and Lancet. 1995 Mar 11;345(8950):607-10); however, our results, based on prognostic significance and CD4 counts, show that all TB, irrespective of diagnoses, should be considered as advanced/late HIV-opportunistic infection. We hypothesize that maturing of the HIV epidemic results in a stronger epidemiological and immunological link between TB and HIV, explaining the difference between observations made ten years ago and data collected more recently. This is also supported by modelling studies that indicate that there is a temporal gap of 6 years between the surging of the HIV epidemic and its impact on the TB burden. |
| POSTER EXHIBITS | |
| WePe3.2C Pharmacological monitoring of ARV therapy |
|
| WePe3.2C01 | THERAPEUTIC DRUG MONITORING (TDM) FOR NEVIRAPINE (NVP) IN A ONCE DOSING REGIMEN (OD) IN HIV PATIENTS WHO HAD INTERRUPTED ANTIRETROVIRAL THERAPY (TARV): 48 WEEKS OF FOLLOW UP IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe3.2C01) Martinelli C., Fiorelli C., Giuntini R., Leoncini F. PK results show that NVP 400 mg OD is safe and effective, as also demonstrated by immuno-virological outcomes. OD administration increases adherence and improves patients' quality of life. |
| WePe3.2C02 | PHARMACODYNAMICS OF LOPINAVIR IN A COHORT OF 84 HIV INFECTED PATIENTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe3.2C02) Wateba M.1, Billaud E.1, Dailly E.2, Raffi F.1 In this retrospective study, patients with a low LPV Ct within 10 days after initiation were more likely to have a virological failure at month 3. Considering the small number of patients it is not possible to find a risk factor for low LPV Ct. Larger prospective studies are needed to address this issue. |
| WePe3.2C03 | CONCENTRATIONS OF ENFUVIRTIDE DO NOT CORRELATE WITH CONCENTRATIONS OF CONCOMITANT PROTEASE INHIBITORS IN HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe3.2C03) Stocker H.1, Breske A.2, Kruse G.2, Schulbin H.1, Kreckel P.1, Weber C.1, Goebel F.3, Roeling J.3, Staszewski S.4, Plettenberg A.5, Moecklinghoff C.6, Arastéh K.1, Kurowski M.2 The lack of correlation between ENF and PI concentrations indicates that complete non adherence involving both enfuvirtide and the concomitant PI is not the cause of low ENF concentrations. |
| WePe3.2C04 | INTRACELLULAR CONCENTRATIONS OF 3TC-TRIPHOSPHATE, CARBOVIR-TRIPHOSPHATE AND TENOFOVIR-DIPHOSPHATE REMAIN STABLE THROUGHOUT 36 WEEKS OF NRTI TREATMENT INTERRUPTED BY NRTI FREE TREATMENT PERIODS IN PATIENTS WITH MULTIRESISTANT HIV IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe3.2C04) Stocker H.1, Kruse G.2, Weber C.1, Breske A.2, Kreckel P.1, Walter H.3, Sopper S.4, Kurowski M.2, Arastéh K.1 Intracellular concentrations of phosphorylated NRTI remain stable throughout prolonged NRTI treatment. After intercurrent interruptions of NRTI treatment concentrations promptly return to pre-interruption values. In patients with multiresistant HIV the intracellular drug levels do not have a significant impact on virus load. |
| WePe3.2C05 | IMMUNOLOGIC AND VIROLOGIC RESPONSES WITH COMBINATION DIDANOSINE/TENOFOVIR COMPARED TO OTHER NUCLEOSIDE REGIMENS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe3.2C05) Furtek K.1, Crum N.F.2, Powell T.1, Hale B.2, Bavaro M.2, Truett A.2, Wallace M.R.2 Combination ddI/TDF produced similar immunologic response rates, but less VL reduction than 3TC/FTC+TDF among treatment-experienced patients. Though this combination may not be an optimal backbone, it may be a viable backbone in highly experienced patients. |
| WePe3.2C06 | THE IMPACT OF CO-INFECTION WITH HEPATITIS C OR HEPATITIS B ON LOPINAVIR PHARMACOKINETICS IN PATIENTS INFECTED WITH HIV IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe3.2C06) Dickinson L.1, Micheli V.2, Meraviglia P.2, Tjia J.1, Almond L.1, Regazzi M.3, Back D.1, Cargnel A.2 In the cohort of patients studied, LPV total and unbound PK was not affected by hepatic impairment. Given the small number of cirrhotic patients, further studies are warranted to characterise LPV PK in this group. |
| WePe3.2C07 | EFFECT ON ATAZANAVIR (ATZ) AND RITONAVIR (RTV) PLASMA LEVELS OF INCREASING ATZ/RTV DAILY DOSING FROM 300/100 MG TO 300/200 MG AND 400/200 MG IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe3.2C07) Harris M., Alexander C., Joy R., Guillemi S., Phillips E., Langridge S., Harrigan R., Montaner J. A subset of patients with suboptimal ATZ levels on ATZ/rtv 300/100mg daily will experience improved ATZ levels when rtv alone is increased to 200mg daily. However, increasing both ATZ and rtv to 400/200mg daily may more reliably increase ATZ levels without increasing cost (compared to 300/200mg daily). The effect of this dose increase on ATZ-related toxicity remains to be determined. |
| WePe3.2C08 | SAFETY OF LOPINAVIR PHARMAKOKINETICS IN COMBINATION WITH EFAVIRENZ OR NEVIRAPINE IN A NUKE-FREE REGIMEN IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe3.2C08) Langmann P.1, Trein A.2, Zilly M.1, Klinker H.1, Schnaitmann E.2 Pharmacokinetics of LPV in a nuke free treatment regimen consisting of NVP or EFV required dose adjustment of LPV to 533/133mg bid. Trough plasma levels of LPV and the coadministered NNRTI were save over 36 weeks. |
| WePe3.2C09 | THERAPEUTIC DRUG MONITORING OF LOPINAVIR/RITONAVIR (LPV/R) CONTAINING REGIMEN IN PREGNANT HIV-INFECTED WOMEN IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe3.2C09) Cassard B., Rouault A., Damond F., Pattyn A., Batallan A., Legac S., Peytavin G., Matheron S. This study confirms the suboptimal LPV Cmin during pregnancy. Therapeutic drug monitoring could be useful to optimise efficacy of LPV/r containing regimen. |
| WePe3.2C10 | DUAL BOOSTED ATAZANAVIR/LOPINAVIR/RITONAVIR CONTAINING REGIMEN IN HIV-1 INFECTED PRETREATED PATIENTS : PLASMA TROUGH CONCENTRATION AND EFFICACY RESULTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe3.2C10) Duvivier C.1, Peytavin G.2, Ait-Mohand H.1, Wirden M.3, Ktorza N.4, Agher R.4, Calvez V.3, Katlama C.1 These results showed no detrimental pharmacological interaction between ATV and r/LPV. This dual PI appears an effective and safe therapy. |
| WePe3.2C11 | EFAVIRENZ PLASMA CONCENTRATION IS PREDICTIVE OF VIROLOGIC SUCCESS IN A COHORT OF HIV-1-INFECTED PATIENTS TREATED IN LIBREVILLE, GABON. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe3.2C11) Clevenbergh P.1, Okome-Nkoumou M.2, Descamps D.3, Obiang Ndong G.P.2, Okome-Miame F.2, Kouna P.2, Boukobza S.4, Peytavin G.4 In this cohort of Black African pts, CEFV were within the expected therapeutic ranges compared to historical data obtained in White Caucasian pts. A strong correlation between a single time point CEFV and pVL was found. |
| WePe3.2C12 | PLASMA CONCENTRATIONS OF EFAVIRENZ (EFV) IN PREGNANT HIV-INFECTED WOMEN TREATED WITH EFV CONTAINING REGIMEN IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe3.2C12) Cassard B., Rouault A., Damond F., Pattyn A., Batallan A., Legac S., Peytavin G., Matheron S. In our study, 75% of EFV Cmin were in the therapeutic range suggesting minor or no PK modifications of EFV during pregnancy. Even if EFV containing regimens are not recommended during pregnancy, the safety and the antiretroviral efficacy were good during pregnancy and at delivery in mothers and newborns. |
| WePe3.2C13 | VARIABILITY OF ATAZANAVIR PLASMA CONCENTRATIONS IN HIV-INFECTED PATIENTS: RESULTS OF A PROSPECTIVE FRENCH COHORT IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe3.2C13) Guiard-Schmid J.-B.1, Poirier J.-M.2, Bonnard P.1, Meynard J.-L.3, Lukiana T.1, Slama L.1, Rozenbaum W.1, Jaillon P.2, Pialoux G.1 Correlation between plasma concentration and virological efficacy of ATV is not clarified yet. But marked inter and intraindividual ATV Cmin variability should lead to individual therapeutic drug monitoring assessment. If NNRTI is combined with ATV, only RTV boosted 400/100 mg ATV regimen can overcome NNRTI's inducer effect. |
| WePe3.3 Drug interactions |
|
| WePe3.3C01 | COMPARING TWO DOSAGES OF DDI-EC, 250MG VS. 400MG, COMBINED WITH TENOFOVIR-DF FOR BOTH PROTEASE INHIBITOR AND NNRTI BASED HAART IN TREATMENT EXPERIENCED HIV-INFECTED PATIENTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe3.3C01) Berger D., Hargan R.T., Zalski A., Staszkow K., Thomas T., Wilson J., Delaney K. In treatment experienced patients, combination ddI-EC + TDF demonstrated significant viral RNA decrease. However, CD4 response in NNRTI treated pts appeared blunted. More robust CD4 response and HIV-RNA suppression occurred in the PI-based LDR. ddI-EC + TDF in NNRTI based regimens appear less effective and warrant further study. |
| WePe3.3C02 | INCREASING NEVIRAPINE DOSE CAN OVERCOME REDUCED BIOAVAILABILITY DUE TO RIFAMPICIN CO-ADMINISTRATION IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe3.3C02) Ramachandran G.1, Hemanth Kumar A.K.1, Rajasekaran S.2, Padmapriyadarsini C.1, Narendran G.1, Sukumar B.1, Swaminathan S.1 Rifampicin significantly reduced the bioavailability of NVP, and the Cmin to sub-therapeutic levels in a high proportion (62%) of patients. This could be overcome by increasing the dose of NVP from 200 mg to 300 mg b.i.d., without any short term adverse events. However, this needs to be confirmed on a larger sample size. |
| WePe3.3C03 | SAFETY, EFFICACY AND PHARMACOKINETICS OF RITONAVIR 400 MG - SAQUINAVIR 400 MG AND RIFAMPICIN COMBINED THERAPY IN HIV NAïVE PATIENTS WITH TUBERCULOSIS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe3.3C03) Cavalcanti Rolla V.1, da Silva Vieira M.A.2, Ferreira Filho M.1, da Silva de Jesus C.3, da Silva Lourenço M.C.1, Gonçalves Morgado M.3, Pereira Pinto D.1, Werneck-Barroso E.1 Although therapeutic levels of the studied drugs were achieved and VL reduced we do not recommend this regimen for naïve patients because AE are the major cause of treatment abandon. |
| WePe3.3C04 | EVALUATION OF CONCOMITANT USE OF PROTEASE INHIBITOR (PI)-ATAZANAVIR (ATV) WITH PROTON PUMP INHIBITOR (PPI) IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe3.3C04) Chang J., Towner W., Kerrigan H.L., Wang L. Most patients on ATV and PPI evaluated did not experience a NTO. Also, four sample trough levels did not suggest sub-therapeutic levels. More clinical research is needed to address the correlation between clinical outcome and ATV plasma concentration, when combined with a PPI. |
| WePe3.3C05 | IN VITRO EVALUATION OF THE ANTI-HIV ACTIVITY AND METABOLIC INTERACTIONS OF TENOFOVIR AND EMTRICITABINE IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe3.3C05) Myrick F.1, Vela J.E.2, Ray A.S.2, Borroto-Esoda K.1, Miller M.D.2 The combination of tenofovir and emtricitabine produced synergistic anti-HIV activity in vitro and this activity correlated with increased levels of intracellular phosphorylation observed for the drugs in combination. These results support the use of these drugs as a dual NRTI backbone in combination therapy for the treatment of HIV. |
| WePe3.3C06 | IN-VITRO EVALUATION OF THE EFFECT OF AZT IN COMBINATION WITH TWO ANTIOXIDANTS AND A NF-KB INHIBITOR IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe3.3C06) Riva D.A.1, Fernández Larrosa P.N.2, Martínez Peralta L.2, Coulombié F.C.1, Mersich S.E.1 Increased cytotoxicity of AZT plus BHA could be related to a higher permeability to AZT, thus, increase of p24 (p<0.05), would be the result of an increase in cell death. Although Sul plus AZT was cytotoxic to H9+ cells, p24 production was significantly reduced (p<0.05) as compared to individual drugs, suggesting that the relationship between virus expression and NF-kB activity could be a clue in this reduction. Thus, combination of AZT with BHA or Sul might represent two different ways to modulate infection in chronically infected cells. |
| WePe3.3C07 | PHARMACOKINETIC INTERACTION BETWEEN TENOFOVIR AND ATAZANAVIR IN HEALTHY SUBJECTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe3.3C07) Agarwala S., Eley T., Child M., Wang Y., Hughes E., Grasela D. Neither of the dosing regimens employed in this study provided comparable exposures of either ATV or TDF, relative to either ATV 400 mg QD or TDF 300 mg QD. |
| WePe3.3C08 | PHARMACOKINETIC INTERACTION BETWEEN ATAZANAVIR AND OMEPRAZOLE IN HEALTHY SUBJECTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe3.3C08) Agarwala S., Gray K., Eley T., Wang Y., Hughes E., Grasela D. PPIs should not be used with ATV for the regimens studied. The 43% increase in OMP AUC by ATV does not suggest clinically significant CYP2C19 inhibition by ATV, since the AUC of OMP in CYP2C19 poor metabolizers is increased by approximately 5-fold. |
| WePe3.3C09 | MULTIDRUG RESISTANCE PROTEIN-2 (MRP2) INHIBITION BY RITONAVIR INCREASES TENOFOVIR-ASSOCIATED RENAL EPITHELIAL CELL CYTOTOXICITY IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe3.3C09) Louie S., Lam J., Neely M., Beringer P. In the presence of TFV, inhibition of MRP2 inversely correlates with MDCK proliferation. However, MDCK-MRP2 cells are resistant to TFV even at the highest concentrations, suggesting that overexpression of MRP2 may prevent accumulation of TFV. This study suggests the role of MRP2 inhibition in TFV-associated. |
| WePe3.3C10 | METHADONE DOSING STRATEGIES WHEN STARTING OR CHANGING HAART REGIMENS IN HIV-INFECTED INJECTION DRUG USERS (IDUS) ENROLLED IN A DIRECTLY OBSERVED THERAPY (DOT) PROGRAM IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe3.3C10) Tossonian H.1, Raffa J.1, Grebely J.1, Trotter B.1, Tyndall M.2, Fraser C.3, DeVlaming S.4, Conway B.1 Pharmacokinetic data suggest that ATV and Kaletra® do not effect serum methadone levels, while NVP would lead to their significant reduction. Our clinical data support these observations and would help guide the selection of HAART in patients for whom methadone dose adjustments are problematic or provide guidelines for such dose adjustments when NVP-based therapy is initiated. Data on efavirenz-based therapy will soon to be generated in our center to provide additional guidelines in this regard. |
| WePe3.3C11 | INTERACTION BETWEEN ATAZANAVIR AND FOSAMPRENAVIR IN THE TREATMENT OF HIV-INFECTED PATIENTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe3.3C11) Khanlou H., Bhatti L., Farthing C. These results appear to indicate that a combination of atazanavir 150 or 200 mg BID and fos-amprenavir 700 mg BID with low dose RTV could offer adequate TCs for both drugs. |
| WePe3.3C12 | ANALYSIS OF TENOFOVIR - DIDANOSINE CONTAINING REGIMENS IN ANTI-RETROVIRAL NAÏVE AND EXPERIENCED PATIENTS INFECTED WITH HIV-1 IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe3.3C12) Khanlou H., Farthing C. The regimens containing TDF+ddI+EFV or NVP appear to be inferior to other standard regimens with the paradoxical CD4 decline. However, There was no CD4-blunting effect with boosted PIs. The use of TDF+ddI together, should be avoided, particularly with a NNRTIs based-regimen. |
| WePe3.3C13 | PHARMACOKINETICS OF TMC114: EFFECT OF OMEPRAZOLE AND RANITIDINE IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe3.3C13) Sekar V.1, Hoetelmans R.2, De Marez T.1, De Pauw M.2, Vangeneugden T.2, Godderis F.2, Parys W.1, Lefebvre E.1 The combination of 20 mg omeprazole q.d. or 150 mg ranitidine b.i.d. with TMC114/RTV did not affect the pharmacokinetics of TMC114. The combination of omeprazole or ranitidine and TMC114/RTV was generally safe and well tolerated. No dose adjustments are necessary when TMC114 is combined with low-dose RTV and omeprazole or ranitidine. |
| WePe3.3C14 | DYNAMICS AND RISK FACTORS FOR CD4±T CELL DECLINE DURING THE CO-ADMINISTRATION OF TENOFOVIR AND DDI-HIGH DOSE IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe3.3C14) Lacombe K.1, Pacanowski J.2, Meynard J.-L.2, Trylesinski A.3, Girard P.-M.2 These results emphazise the need for a close surveillance of CD4+-T cells count and renal function, as well as a decrease in ddI dosage, during the co-prescription of ddI and tenofovir. |
| WePe3.3C15 | PHARMACOKINETIC INTERACTION BETWEEN THE NOVEL NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) TMC278 AND TENOFOVIR DISOPROXIL FUMARATE (TDF) IN HEALTHY VOLUNTEERS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe3.3C15) Hoetelmans R., Kestens D., Stevens M., Peeters M., Williams P., Bastiaanse L., Buffels R., Woodfall B. The interaction study between TMC278 and TDF showed that the pharmacokinetics of TMC278 are not affected when combined with TDF. Exposure to tenofovir was statistically significantly increased by 24% when combined with TMC278. This interaction is not clinically relevant. The combination of TMC278 and TDF was generally safe and well tolerated. No dose adjustments are necessary when TMC278 and TDF are combined. TMC278 is currently being studied in Phase IIb with TDF and other NRTIs. |
| WePe3.3C16 | NO SIGNIFICANT INTERACTION BETWEEN TMC125 AND DIDANOSINE (DDI) IN HEALTHY VOLUNTEERS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe3.3C16) Scholler M., Hoetelmans R., Bollen S., Vandermeulen K., Peeters M., Bastiaanse L., Debroye C., Woodfall B. No clinically relevant interaction was observed between TMC125 800 mg b.i.d. and ddI 400 mg q.d. in healthy volunteers. The combination of TMC125 and ddI was generally safe and well tolerated. No dose adjustments are necessary when TMC125 and ddI are combined. |
| WePe3.3C17 | DIFFERENTIAL ANTI-VIRAL EFFECT OF PEG-IFN ON HIV AND HCV IN TREATMENT OF HIV/HCV CO-INFECTED PATIENTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe3.3C17) Neumann A.1, Wu L.2, McLaughlin M.2, Koratich C.2, Rehm C.2, Masur H.3, Kottilil S.2, Polis M.2 These novel results indicate that IFN suppresses HIV by blocking de novo infection effectively, rather than blocking production as seen with HCV. In vitro studies are currently conducted to corroborate these results experimentally. |
| WePe3.3C18 | NON SIGNIFICANT DRUG INTERACTION BETWEEN ATAZANAVIR AND PROTON PUMP INHIBITORS IN RITONAVIR BOOSTED REGIMEN IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe3.3C18) Guiard-Schmid J.-B.1, Bonnard P.1, Poirier J.-M.2, Slama L.1, Lukiana T.1, Meynard J.-L.3, Rozenbaum W.1, Jaillon P.2, Pialoux G.1 ATV Cmin are dramatically reduced by co-administration of PPI when ATV (400mg) is not boosted with ritonavir. This reduction can lead to undetectable ATV concentrations (2/4 patients). However, we do not experienced significant reduction of ATV concentrations in boosted ATV regimen (300/100mg). If reduced plasma concentrations of ATV are expected when ATV is given alone with PPI, ritonavir boosted regimen may overcome the drug interaction between ATV and PPI. |
| WePe3.3C19 | NO EVIDENCE OF DECREASE IN CD4 CELL COUNT WHEN TENOFOVIR IS COMBINED WITH AN ADJUSTED DOSE OF DIDANOSINE IN EXPERIENCED PATIENTS TREATED WITH DIFFERENT HAART REGIMENS Nasta P., Matti A., Paraninfo G., Gatti F., Carosi G. Based on our data to switch to a Tenofovir plus a weight didanosine adjusted dose containing regimen does not lead a decrease in CD4-cell-count,maintaining the viral-control in HAART experienced patients. |
| WePe4.1 Resistance surveillance |
|
| WePe4.1C01 | CHARACTERIZATION OF MUTATIONS IN HIV TYPE 1 ISOLATES FROM 135 CAMBODIAN PREGNANT WOMEN AND RECENTLY INFECTED PATIENTS, NAÏVE TO ANTIRETROVIRAL DRUGS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe4.1C01) Ly N.1, Recordon-Pinson P.2, Phoung V.3, Kruy Leang S.4, Koum K.5, Chhum V.6, Glaziou P.1, Fleury H.2, Reynes J.M.1 This is the first study on HIV-1 drug resistance in ARV naïve patients of Cambodia. Within a predominant of CRF01_AE, the prevalence of viral strains bearing drug resistance mutations seems to be low. Extension of available ARV treatments will require follow up studies in the next future. |
| WePe4.1C02 | UPDATE ON PRIMARY HIV-1 RESISTANCE IN ARGENTINA: THE FIRST REPORT OF MUTATIONS CONFERRING HIGH-LEVEL RESISTANCE TO NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIS) IN DRUG-naïve PATIENTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe4.1C02) Petroni A.1, Deluchi G.1, Bortolozzi R.2, Garone D.3, Lopardo G.4, Pryluka D.5, Rodriguez C.6, Calanni L.7, Lazaro M.8, Maranzana A.9, Puga L.1, Benetucci J.1 This is the first report of K103N in primary infections from Argentina, suggesting that the rates of primary resistance to NNRTIs may be higher than those supposed. |
| WePe4.1C03 | CHARACTERISTICS OF HIV-1 GENOTYPING TEST AFTER FAILURE WITH HIGH STRENGH SCHEME WITH NELFINAVIR AS FIRST PROTEASE INHIBITOR IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe4.1C03) Tupinambás U., Aleixo A., Greco D. These data are in accordance with the data already published in the literature, showing that the sequence therapy after failure with nelfinavir may be more change of successful as D30N mutation does not present cross-resistance with other protease inhibitors. |
| WePe4.1C04 | POL GENE MUTATIONS ASSOCIATED WITH DRUG RESISTANCE IN ANTIRETROVIRAL-NAÏVE PATIENTS OF NORTH INDIA WITH HIV INFECTION. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe4.1C04) Sachdeva N., Arora S., Datta U., Sehgal S. The data indicates high prevalence of codon - 70 and codon - 184 mutant variants coexisting with the wild type of virus in the HIV - infected patients in this region with an increase in the transmissionof mutant variants more recently. |
| WePe4.1C05 | LOW PREVALENCE OF GENOTYPIC DRUG RESISTANCE MUTATIONS AMONG ANTIRETROVIRAL-NAÏVE HIV-1 PATIENTS IN MALAYSIA IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe4.1C05) Tee K.K., Kamarulzaman A., Ng K.P. Baseline prevalence of major mutations associated with resistance to antiretroviral drugs was low among antiretroviral-naïve HIV-1 patients in Kuala Lumpur. As Malaysia begins to introduce large scale access to antiretrovirals, ongoing surveillance for HIV drug resistance in patients beginning initial antiretroviral will be important in monitoring treatment programs. |
| WePe4.1C06 | PREVALENCE AND PATTERN OF DRUG RESISTANCE MUTATIONS AMONG ANTIRETROVIRAL-TREATED HIV-1 PATIENTS WITH DETECTABLE VIRAL LOAD IN MALAYSIA IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe4.1C06) Tee K.K., Kamarulzaman A., Ng K.P. The prevalence of major drug resistance mutations among ARV-treated patients with detectable VL is high in Kuala Lumpur. Genotypic drug resistance testing is therefore important for patients experiencing ARV regimen failure. |
| WePe4.1C07 | RESISTANCE MUTATIONS BEFORE AND AFTER TENOFOVIR REGIMEN FAILURE IN HIV-1 INFECTED PATIENTS. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe4.1C07) Wirden M., Marcelin A.-G., Simon A., Kirstetter M., Tubiana R., Valantin M.-A., Paris L., Bonmarchand M., Katlama C., Calvez V. TDF-regimen failure is associated with a strong selection of K65R in absence of TAMs at baseline and with regimens only based on TDF/NRTIs. No obvious impact was shown on TAMs or other NRTI mutations, although a trend towards emergence of L74V, V75I, V118I, Y115F and K219Q/E/N mutations was observed. |
| WePe4.1C08 | ESTIMATING THE NUMBER OF PATIENTS DIAGNOSED AT THE TIME OF PRIMARY INFECTION EVERY YEAR IN FRANCE USING A CAPTURE-RECAPTURE APPROACH. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe4.1C08) Lievre L.1, Deveau C.2, Gerbe J.3, Enel P.4, Tran L.2, Costagliola D.1, Meyer L.2 The number of patients diagnosed at the TPI per year represents only 5% of the estimated number of new diagnosis of HIV infection in France (about 6000 cases per year), and only 8% of the estimated number of new infections (about 4000 cases per year). This must be kept in mind when trying to assess trends in transmitted drug-resistance by using data from patients diagnosed during primary infection. |
| WePe4.1C09 | TRANSMISSION AND PERSISTENCE OF MULTIPLE DRUG RESISTANCE STRAINS IN NEWLY DIAGNOSED HIV-1 PATIENTS INFECTED WITH DIFFERENT GENETIC FORMS IN GALICIA, SPAIN. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe4.1C09) Muñoz M.1, Perez-Alvarez L.1, Carmona R.1, Sierra M.1, Casado G.1, Delgado E.1, Vazquez de Parga E.1, Vega Y.1, Miralles C.2, Thomson M.1, Contreras G.1, Medrano L.1, Taboada J.A.3, Nájera R.1 A high frequency of non-B genetic forms(24.3%) were detected among the newly diagnosed HIV-1 patients in Galicia. The presence and the persistence of RT and PR mutations associated with high level of resistance to different class of drugs, support the importance of resistance testing for guidance of the first line therapy. |
| WePe4.1C10 | TRENDS IN TRANSMITTED GENOTYPIC ANTIRETROVIRAL RESISTANCE IN PRIMARY VERSUS LONGSTANDING HIV INFECTION IN A UK COHORT. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe4.1C10) Pao D.1, Aderogba K.1, Dean G.1, Cane P.2, Smit E.3, Kellar I.4, Pillay D.5, Fisher M.1 TAR remains of significant clinical importance despite high levels of effective viral suppression. We demonstrate that rates remain stable and furthermore are comparable in individuals diagnosed at non-PHI as well as PHI. All new HIV diagnoses should have baseline resistance testing performed irrespective of time since infection. |
| WePe4.1C11 | PRIMARY HIV-1 RESISTANCE IN RECENTLY AND CHRONICALLY INFECTED INDIVIDUALS IN NAÏVE SUBJECT FROM 1999-2004 IN LIGURIA, ITALY IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe4.1C11) Icardi G.1, Ventura A.1, Setti M.2, Bruzzone B.1, Nigro N.1, Frabetti M.1, Villa R.2, Ansaldi F.1 The presence of M184V in the first group is particularly surprising as it is known to significantly affect viral fitness. On the whole, however the prevalence of mutations in naïve subjects kept above the limit recognized by the international guide lines for resistance testing recommendations. |
| WePe4.1C12 | PRIMARY ANTIRETROVIRAL RESISTANCE AND MOLECULAR DIVERSITY OF HIV-1 IN ANTIRETROVIRAL THERAPY PATIENTS ENROLLED INTO THE NIGERIAN NATIONAL ART PROGRAMME IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe4.1C12) Agwale S.1, Tanimoto L.2, Womack C.3, Njoku M.1, Sawa M.1, Audu I.1, Odama L.4, Busu S.4, Graham B.3, Ziermann R.2 Results confirms the complexity HIV-1 molecular diversity and the emergence of drug resistance HIV in Nigeria and provides baseline data for resistance monitoring and ARV use in a pre-therapeutic context in non-B HIV-1 subtypes. The data is timely and could guide the massive treatment plan underway in Nigeria and also in the development of a more robust treatment guidelines and assessment of efficacy. |
| WePe4.1C13 | THE IDU-A HIV-1 VARIANTS HARBOURING BOTH V77I PROTEASE AND A62V RT MUTATIONS ARE SPREADING RAPIDLY WITHIN THE TERRITORY OF RUSSIA IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe4.1C13) Sukhanova A.L.1, Bogoslovskaia E.V.1, Roudinskii N.I.2, Shipulin G.A.1, Mikhailovich V.M.2, Pokrovsky V.V.1, Bobkov A.F.3 Our data demonstrate low level of transmitted drug resistance in Russia, but growing incidence of associated V77I protease and A62V RT polymorphisms, although the last one had never been found previously among untreated patients. Monitoring of HIV-1 drug resistance in Russia is thus of great importance. |
| WePe4.1C14 | PREVALENCE OF DRUG-RESISTANCE ASSOCIATED MUTATIONS AMONG NEWLY DIAGNOSED HIV-1 INFECTED INDIVIDUALS AT TWO VOLUNTARY TESTING CENTERS IN THE CITY OF BUENOS AIRES, ARGENTINA. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe4.1C14) Dilernia D.A.1, Lourtau L.2, Marone R.3, Carobene M.1, Pampuro S.1, Ebensrtejin J.2, Losso M.2, Salomón H.1 We found an unexpected high prevalence of resistance mutations (7.8%) in recently diagnosed individuals wich suggest an increase over the last years in Argentina when compared with our previous study (Kijak et al 2001). This data alerts us about the increasing prevalence of resistant variants circulating in our population and shows the necessity of developing greater scale studies for drug resistance survaillance in our region. |
| WePe4.1C15 | BASELINE HIV-1 DRUG RESISTANCE MUTATIONS IN SEROPOSITIVE PREGNANT WOMEN IN YAOUNDÉ-CAMEROON. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe4.1C15) Vessière A.1, Nerrienet E.1, Menu E.2, Kfutwah A.1, Tejiokem M.3, Pinson-Recordon P.4, Fleury H.4, Ayouba A.1, and the FSP/ARV teams of the Pasteur network supported by the French Ministry of Foreigns Affairs Genetic diversity and scarcity of major drug resistance mutations in PR/RT genes characterized our data. Polymorphisms in the PR at positions associated with drug resistance in HIV-1/B emphasize the need for genotypic drug resistance interpretation's algorithms adapted to non-subtype-B HIV-1. |
| WePe4.1C16 | ASSESSING HIV-1 DRUG RESISTANCE MUTATIONS AND VIRAL POLYMORPHISM IN DRUG-NAÏVE INJECTION DRUG USERS OF RIO DE JANEIRO, BRAZIL, IN PRE AND POST-HAART ERAS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe4.1C16) Teixeira S.L.M.1, Bastos F.I.2, Hacker M.A.2, Guimarães M.L.1, Morgado M.G.1 The identification of 7.9% of drug-naïve IDUs already bearing RT/PR primary resistance mutations in the post-HAART era group constitutes a major concern in terms of dissemination of drug resistant viruses. The resistance mutations profile of the IDUs may reflect the context of antiretroviral treatment in Brazil at the sample collection periods (1994-1997 and 1999-2001). The distribution of HIV subtypes followed a similar pattern between the two IDU groups, although with a suggestive reduction in the frequency of subtype F samples. |
| WePe4.1C17 | HIV-1 MOLECULAR CHARACTERIZATION OF POL REGION FROM SEROPOSITIVE USERS OF A VCT AT THE SOUTH OF BRAZIL. RCP STUDY: PRELIMINARY DATA. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe4.1C17) Stella I.M.1, Rodrigues R.2, Scherer L.3, Franco H.M.2, Castro S.3, Sperhacke R.D.4, Brigido L.F.5 This low prevalence of ARV resistance is consistent with previous studies at the site, but the frequency of HIV-1 C is greater then of studies in the region and warrants close monitoring. |
| WePe4.1C18 | PERSISTENCE OF TRANSMITTED T215 REVERTANT MUTATIONS IN ACUTE PRIMARY HIV-1 INFECTION. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe4.1C18) Ammaranond P.1, Leas L.2, Cunningham P.2, Grey P.1, Ramacciotti T.1, Finlayson R.3, Suzuki K.2, Cooper D.1, Kaldor J.1, Kelleher A. on behalf of the PHAEDRA Steering committee1 T215 revertant mutants persisted for at least 2 years with 0/7 developing T215Y/F in the presence of HAART suggesting that these mutants are stable in the presence of low viral turnover. The persistence of drug-resistance reversion variants has significant implications for the ongoing treatment of HIV-infected patients. |
| WePe4.1C20 | DISTRIBUTION OF HIV-1 SUBTYPES AND PREVALENCE OF ANTIRETROVIRAL DRUG RESISTANCE IN TREATMENT NAÏVE PATIENTS IN GONDAR, ETHIOPIA IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe4.1C20) Kassu A.1, Fujino M.2, Matsuda M.2, Nishizawa M.2, Sugiura W.2, Ota F.1 Our study demonstrated that subtype C is the major subtype in Northwest-Ethiopia followed by subtypes A and D. It also revealed the presence of drug resistance related mutations and polymorphisms in the HIV-1 isolates from antiretroviral treatment-naïve individuals. These warrant the need for routine monitoring of drug resistance mutations in the circulating viruses since such mutations could lead to rapid treatment failure and development of drug-resistant HIV-1 in individuals undergoing antiretroviral therapy. |
| WePe4.1C21 | DEVELOPMENT OF HIGH RESISTANCE TO NNRTIS DURING THERAPY WITH 2 NRTIS IN HIV-INFECTED CHILDREN IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe4.1C21) Machado E.S.1, Afonso A.O.2, Lambert J.S.3, Cunha S.M.4, Oliveria R.H.4, Sill A.M.3, Soares M.A.2 NNRTIs primary resistance mutations occurred in 3.7% of children on treatment with 2 NRTIs. Also, these results suggest that transmission of a minority HIV-1 resistant strain can occur with a frequency as low as 4%. These may compromise treatment in newly-infected infants and raise an important concern in the primary resistance in pediatric settings. |
| WePe4.1C22 | A SCORE TO EVALUATE PROTEASE AND REVERSE TRANSCRIPTASE POLYMORPHISMS RELATED TO TRANSMITTED RESISTANCE IN MEXICAN POPULATION. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe4.1C22) Fuentes-Romero L.L., Rodríguez-Díaz R.A., Zurita Macías-Valadez L.C., Viveros-Rogel M., Villagrán-Villegas V.L., Soto-Ramírez L.E. A score based on the frequency in treated patients/ frequency in untreated individuals is useful to separate polymorphisms in the RT but not in the protease. This score can be useful to determine significant resistance transmitted mutations. |
| WePe4.1C23 | EARLY DETECTION AND QUANTIFICATION OF MIXED POPULATIONS OF DRUG RESISTANT HIV BY A NOVEL MUTIPLEX RT-PCR PLATFORM IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe4.1C23) Schinazi R.F.1, Moser M.J.2, Swearingen A.J.2, Ruckstuhl M.1, Kozlowski M.1, Bassit L.1, Prudent J.R.2 MultiCode RTx could be applied to other drug selected HIV-mutations in the viral genome or for other applications where single base changes in DNA or RNA occur at frequencies reaching 0.01% to 1% respectively. |
| WePe4.1C24 | LINKING HIV-1 AND ANTIRETROVIRAL DRUG RESISTANCE SURVEILLANCES: LOW PREVALENCE OF HIV-1 DRUG RESISTANCE IN PERU. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe4.1C24) Lama J.R.1, Suarez L.2, Laguna A.3, Acuña M.1, Olson J.3, Sanchez J.L.4, Celum C.5, Sanchez J.1, Grant R.M.6 The prevalence of HIV-1 drug resistance in Peru is low, reflecting the low treatment rates documented in this surveillance, and the high frequency of wild-type drug failure among treated persons. We demonstrate how drug resistance surveillance can be integrated into national HIV-1 sentinel surveillance. Our findings prior to nationwide ART roll-out, currently being conducted in Peru, contrasts with the history of ART in developed countries, where high levels of NRTI resistance occurred prior to introduction of ART. |
| WePe4.4 Resistance testing in clinical practice |
|
| WePe4.4C01 | NATURALLY OCCURING POLYMORPHISM IN NON-SUBTYPE B HIV-1 GROUP M STRAINS OCCURING AMONG TREATMENT-NAÏVE PATIENTS IN RURAL NORTHWEST CAMEROON IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe4.4C01) Ndembi N.1, Tameh T.1, Abraha A.2, Mbanya D.S.1, Arts E.J.2, Kaptue L.1 Given the likelihood that the most commonly used first line ART regimens in Cameroon contains an NNRTI and PI baseline resistance testing in treatment naïve individuals should strongly be considered in many settings. |
| WePe4.4C02 | NATURALLY OCCURING POLYMORPHISM IN NON-SUBTYPE B HIV-1 GROUP M STRAINS OCCURING AMONG TREATMENT-NAÏVE PATIENTS IN RURAL NORTHWEST CAMEROON IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe4.4C02) Nicaise N.1, Theodore T.1, Awet A.2, Dora M.1, Eric J A.2, Lazare K.1 Given the likelihood that the most commonly used first line ART regimens in Cameroon contains an NNRTI and PI baseline resistance testing in treatment naïve individuals should strongly be considered in many settings. |
| WePe4.4C03 | DETERMINANTS OF HIV DRUG RESISTANCE MUTATIONS IN PLASMA VIRUS FOLLOWING TREATMENT INTERRUPTION IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe4.4C03) Chilton D.1, Dervisevic S.2, Pillay D.2, Rider A.3, Copas A.3, Miller R.F.3, Edwards S.G.1 We demonstrate that a significant minority maintain detectable resistant virus following TI, particularly those with extensive antiretroviral history, and those who have had previous virological failure on NNRTIs. In addition to current guidelines, these data suggest that resistance testing following TI is useful up to three months and may confer utility after twelve. |
| WePe4.4C04 | DO THE MUTATIONS M046I AND I047A CONFER RESISTANCE TO KALETRA? IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe4.4C04) Nelson M., Stevanovic M., Price H., Jones R., Mandalia S., Bower M., Gazzard B. Prior exposure to Kaletra is not required in the development of the mutations M046I and I047A. Presence of these mutations does not adversely affect virological response to Kaletra therapy as part of an HAART regimen. |
| WePe4.4C05 | THE ANALYSIS OF GENOTYPIC RESISTANCE TESTING RESULTS OF ARV-NAÏVE CHILDREN INFECTED WITH HIV-1C IN BOTSWANA IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe4.4C05) Yarosh O.1, Jibril H.1, Rankopo O.2, Kerumotswe M.1, Musa-Aisien S.1, Kurup S.1, Kostova E.1 Despite the fact that resistance testing has been only recently available we were able to identify the most common resistance mutations among children being on first line of HAART in Botswana.It has also proven useful in the selecting salvage treatment and shows that adherence level in the 60% to 95% range has the highest likelihood of causing resistance to both NRTI's and NNRTI's. |
| WePe4.4C07 | DETERMINATION OF PHENOTYPIC CLINICAL CUTOFFS FOR THE VIRCO® TYPE HIV-1 RESISTANCE ANALYSIS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe4.4C07) Bacheler L.1, Winters B.2, Harrigan P.R.3, Montaner J.3, Perez-Elias M.4, Miller M.5, Emery S.6, van Leth F.7, Robinson P.8, Baxter J.9, Pozniak A.10, Gazzard B.10 Clinically relevant breakpoints (CCOs) for virco®TYPE phenotypic resistance data have been defined and validated based on virologic outcome in treated patients. The CCOs were more predictive of virologic outcome than BCOs. CCOs should enhance the clinical utility of virco®TYPE in the selection of optimal antiretroviral treatment regimens for HIV-1+ subjects. |
| WePe4.4C08 | DEVELOPMENT OF DE NOVO PI-RESISTANCE IN LOPINAVIR/RITONAVIR-MONOTHERAPY IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe4.4C08) Wolf E.1, Walter H.2, Eckerlein B.3, Koegl C.1, Jaegel-Guedes E.3, Jaeger H.3 In this PI-naïve patient LPV/r-monotherapy failed and led to LPV-resistant virus. Genotypic resistance pattern was divergent from two other single cases that have been reported to fail under LPV/r-first line therapy indicating that LPV-resistance can develop via completely different resistance pathways. Broad PI-cross resistance - especially due to M46V and I84V - was selected in our case. L76V did not lead to a clinically relevant re-sensitization of SQV- and ATV-resistance. |
| WePe4.4C09 | SELECTION OF TAMS DURING FIRST-LINE HAART INFLUENCE VIROLOGIC OUTCOME OF SECOND-LINE HAART IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe4.4C09) Maggiolo F., Callegaro A., Airoldi M., Quinzan G., Gregis G., Ripamonti D., Arici C., Suter F. Most of patients included in our analysis started their first-line HAART with very low CD4 counts (<200 cells/mcl). The selection of TAMs during the first-line therapy significantly reduced the virologic response to second-line HAART. Although not directly correlated with a worst prognosis, in our cohort, the use of thymidine analogues, as first line drugs, may limit future therapeutic options. Thymidine-sparing regimens may result of choice as first-line HAART. |
| WePe4.4C10 | ANALYSIS OF HIV-1 GP41 HR1 AND HR2 REGIONS OF DIFFERENT GENETIC FORMS FROM RUSSIA IN RELATION TO NATURAL RESISTANCE-ASSOCIATED MUTATIONS TO T-20 AND POLYMORPHISMS. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe4.4C10) Vázquez de Parga E.1, Rakhmanova A.2, Pérez-Álvarez L.1, Vinogradova A.3, Carmona R.1, Muñoz M.1, Delgado E.1, Vega Y.1, Thomson M.M.1, Sierra M.1, Casado G.1, Contreras G.1, Medrano L.1, Osmanov S.4, Nájera R.1 Different frequencies of natural resistance-associated mutations to T-20 among several HIV-1 genetic forms were observed. It is necessary to study the level of phenotypic resistance to T20 associated with these substitutions, including the S138A mutation. The high frequency of N42S, associated with an increased susceptibility to T-20, could suggest an influence in a possible better response to T20 in these patients. |
| WePe4.4C11 | MUTATIONS AND POLYMORPHISMS AT DRUG RESISTANCE SITES IN NON-B SUBTYPES OF HIV-1 IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe4.4C11) Vega Y.1, Pérez-Álvarez L.1, Delgado E.1, Muñoz M.1, Sierra M.1, Casado G.1, Carmona R.1, Vázquez de Parga E.1, Thomson M.1, Contreras G.1, Medrano L.1, Nájera R.1, Group for resistance study in Galicia X.G.2, Group for resistance study in Basque Country S.V.d.S.3 There is a higher frequency of PR polymorphisms (positions 10, 20, 36, 82 and 93) than in RT region in non-B isolates, showing differences between subtypes. Subtype G treated-naïve harboured a 100% frequency of PR polymorphisms at K20I, M36I and V82I, while all subtype C naïve-treated presented I93L mutation. These differences in patterns of resistance-associated-mutations in non-B in comparison with subtype B isolates are important in order to assess drug treatment strategies, since there is an increasing number of non-B subtypes and recombinants worldwide. |
| WePe4.4C12 | RESISTANCE MUTATIONS IN ARV-NAÏVE PATIENTS TREATED WITH RITONAVIR-BOOSTED SAQUINAVIR IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe4.4C12) Ananworanich J.1, Ruxrungtham K.2, Sirivichayakul S.2, Ubolyam S.1, Jupimai T.1, Schutz M.3, Snowden W.3, Cooper D.4, Hirschel B.5, and the Staccato Study Team1 There was a very low incidence of VF in ART-naïve patients receiving SQV/r (3.9%). No patient acquired major PI-resistance mutations. The protease polymorphisms detected at VF are similar to those seen with other boosted PIs in ARV-naïve patients, and are natural polymorphisms/secondary mutations that may contribute to reduced susceptibility in the presence of primary mutations. The incidence of genotypic NRTI-resistance at VF was low. Most patients with VF achieved VL <50 copies/ml after increasing SQV/r dosing or switching to another regimen. |
| WePe4.4C13 | DRUG RESISTANCE AMONG HIV PATIENTS WHO DISCONTINUED ARV TREATMENT IN BRAZIL IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe4.4C13) Kalmar E.1, Chen S.2, Ferreira S.3, Barreto C.3, McFarland W.4, Sabino E.3 Presence of stable resistance mutations was common in patients who have discontinued treatment. Policy changes resulting in discontinuation of ARV may impact the spread of drug resistance. |
| WePe4.4C14 | CHANGES IN UTILIZATION OF DRUG RESISTANCE TESTING IN THE HOPS COHORT (1999-2003) IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe4.4C14) Young B.1, Baker R.2, Wood K.2, Buchacz K.3, Moorman A.3, Holmberg S.3, Brooks J.3, HOPS Investigators 3 Presence of stable resistance mutations was common in patients who have discontinued treatment. Policy changes resulting in discontinuation of ARV may impact the spread of drug resistance. |
| WePe4.4C15 | HIV-1 SUBTYPE A MAY BE LESS SUSCEPTIBLE TO THE DEVELOPMENT OF K65R IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe4.4C15) Gupta R.K.1, Chrystie I.2, O'Shea S.2, Mullen J.2, Kulasegaram R.2, Tong C.W.2 Resistance testing is becoming more common among HOPS patients, although the proportion thus far tested remains <25%. Patients with more advanced HIV disease were more likely to receive resistance testing, but utilization did not differ by socioeconomic characteristics in this cohort of US patients receiving routine outpatient care. |
| WePe4.4C17 | OUTCOME OF HIV PATIENTS WITH MULTI-CLASS DRUG RESISTANT VIRUS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe4.4C17) Suh J., Baron P., Polsky B., Sharp V. Only one patient achieved virologic suppression (<400 copies/mL). Moreover, at 3 year follow-up, mortality rate was very worrisome (31%) in this cohort. Treatment of HIV patients with 3-DCR-HIV remains a difficult challenge marked by high rates of clinical and virologic failures. Studies are needed to define factors associated with ARV failures and to prevent progression to severe drug resistance in this population. |
| WePe4.4C18 | NRTIS SUSCEPTIBILITY IN HIV-1 INFECTED CHILDREN FAILING ANTIRETROVIRAL THERAPY IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe4.4C18) Almeida F.1, Rodrigues R.2, Berezin E.1, Safadi M.A.1, Oliveira C.M.2, Brigido L.F.2 Our results, albeit the small sample size reflects the use of the ARV class in children and suggest that DDI and Tenofovir have the best susceptibility profile for consideration in salvage therapy of patients failing antiretroviral therapy after using most or all NRTIs. |
| WePe4.4C19 | IS PREDICTED SUSCEPTIBILITY TO TIPRANAVIR/RITONAVIR (TPV/R) IN TREATMENT-EXPERIENCED PATIENTS BETTER THAN FOR OTHER PI-BOOSTED REGIMENS ? IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe4.4C19) Boulmé R.1, Gonzalez D.1, Struck D.2, Arendt V.2, Staub T.2, Hemmer R.2, Schmit J.-C.2 Using the cumulative number of mutations, predicted susceptibility to tipranavir/r in experienced patients with more than three genotypes is comparable to susceptibilities predicted using standard algorithms for other protease-boosted regimens, except for indinavir/r. We suggest that taking into account past and current mutations for the prediction of ARV resistance in treatment-experienced patients may be useful. |
| WePe4.4C20 | NRTI RESISTANCE IN RELATIONSHIP TO K65R: A STUDY OF INNER CITY HIV PATIENTS WHO PRESENT WITH VIROLOGICAL FAILURE. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe4.4C20) Fernandes H.1, Sultana M.1, Chew D.1, Reilly E.1, Fisher A.2, Burstin S.2 K65R continues to occur infrequently in 2004 (4.6%); M184V is more common, and L74V was seen in a higher frequency (6.7%). Patients who developed K65R had extensive prior therapy with multiple drugs that select for K65R. |
| WePe4.4C21 | SEQUENCING PROTEASE INHIBITORS AFTER FIRST PI-FAILURE IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe4.4C21) Zurita Macías Valadez L.C., Fuentes Romero L.L., Rodríguez Díaz R.A., Viveros Rogel M., Hernández Flores M., Villasís Keever A., Sierra Madero J.G., Soto Ramírez L.E. Failing to a first PI-ARV regimen in Mexico represents a late failure as evidence by the high number of RAMs. The availability of GR in Mexico and other developing countries is limited, so it is important to select the PI with the highest chance of response, that in this study was LPV over ATV. |
| WePe4.4C22 | RESISTANT PATHWAYS IN MEXICAN PATIENTS FAILING TO ZDV+3TC OR ZDV+DDI + PI/NNRTI IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe4.4C22) Rodríguez-Díaz R.A., Zurita Macías Valadez L.C., Fuentes Romero L.L., Viveros Rogel M., Villasis-Keever A., Soto-Ramírez L.E. We corroborated that the use of ZDV+ddI correlated after first HAART failure with a unfavorable resistance pathway to NRTIs however this combination is associated with less resistance to NNRTIs due to the higher genetic barrier of ddI. These findings should be considered for ARV treatment guidelines in countries where monitoring is limited. |
| WePe6.2 Clinical trials of new drugs/pro-drugs |
|
| WePe6.2C01 | ACUPUNCTURE TRIAL: MANAGING DIGESTIVE SIDE-EFFECTS OF ANTIRETROVIRAL TREATMENT IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe6.2C01) Sommers E., Porter K. Treatment with acupuncture was well-tolerated and safe, with no adverse effects being reported. The pilot study demonstrated that treatment was feasible and acceptable. Results from this pilot trial are being used to design a more rigorous and larger trial which will be implemented without the cross-over design. |
| WePe6.2C02 | POLYCLONAL CAPRINE IGG PEHRG214 (HRG): ANTI-HIV ACTIVITY AND MAPPING OF NOVEL ANTIBODY SPECIFICITIES IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe6.2C02) Sanford J.1, Dezube B.2, Perera T.1, Crumpacker C.2, Gelder F.1 HRG contains potent anti-HIV neutralizing activity. Correlation of HRG reactivities with human anti-HIV reactivities demonstrated novel specificities unique to HRG, not previously recognized by either human anti-HIV sera or helper cells. These novel specificities may in part be responsible for the anti-HIV activity observed in previously reported clinical trials. |
| WePe6.2C03 | ANTIVIRAL ACTIVITY AND SAFETY OF GW695634, A NOVEL NEXT GENERATION NNRTI, IN NNRTI-RESISTANT HIV-1 INFECTED PATIENTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe6.2C03) Becker S.1, Lalezari J.2, Walworth C.3, Kumar P.4, Cade J.5, Ng-Cashin J.6, Kim Y.6, Scott J.6, St. Clair M.6, Jones L.6, Symonds W.6 This 7-Day study in HIV-1 infected patients with documented NNRTI-resistance demonstrates the potent antiviral activity of GW695634 in this patient population and provides 'proof-of-concept' to support further clinical development of GW695634 in patients failing currently marketed NNRTI medications. |
| WePe6.2C04 | FIRST-IN-HUMANS TRIAL OF PRO 140, A HUMANIZED CCR5 MONOCLONAL ANTIBODY FOR HIV-1 THERAPY IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe6.2C04) Olson P., Doshan H., Zhan C., Mezzatesta J., Assumma A., Czarnecky R., Maddon P., Kremer A., Israel R. PRO 140 has been administered to healthy volunteers in this ongoing first-in-humans study. The study findings support further development of PRO 140 for HIV-1 therapy. |
| WePe6.2C05 | A LONG-TERM OPEN-LABEL ROLLOVER TRIAL ASSESSING THE SAFETY AND TOLERABILITY OF COMBINATION TIPRANAVIR AND RITONAVIR (TPV/R) USE IN HIV-1-INFECTED PATIENTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe6.2C05) Pierone G.1, Drulak M.2, Arasteh K.3, Walmsley S.4, Katlama C.5, Lazzarin A.6, Miki J.2, Mayers D.2 In this cohort of treatment-experienced patients who had received TPV/r for up to 4 years, AEs were generally mild or mild-to-moderate in intensity and were not associated with treatment discontinuation. |
| WePe6.3 Phase III/IV trials |
|
| WePe6.3C01 | THE USE OF INTRAVAGINAL PRODUCTS AND VAGINAL HYGIENE PRACTICES AMONG WOMEN IN LAGOS STATE NIGERIA IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe6.3C01) Otuonye N.M. The success of phase III clinical trial of microbicides will largely depend on the acceptability of intravaginal product and vaginal hygiene, which is frequently practiced among women population. This could influences the studies of virginal microbicides. The understanding of this factor will help in the design and implementation of Microbicides clinical trial. 80% of the women are anxiously waiting for microbiocides. |
| WePe6.3C02 | THE EFFECT OF "STRENGTH OF EVIDENCE" REQUIREMENTS AND HIV INCIDENCE ON THE SIZE OF PHASE III TRIALS FOR MICROBICIDES IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe6.3C02) Coplan P., Rosenberg Z. The sample size required for one pivotal efficacy trial is 22% smaller than two Phase III trials. Changes in HIV incidence have a large effect on sample size between 1 to 3% and relatively smaller effects above 4%. |
| WePe6.3C03 | QUADRUPLE NUCLEOSIDE/TIDE REGIMEN OF TRIZIVIR (TZV) + TENOFOVIR (TDF) IS EFFECTIVE FOLLOWING EARLY VIROLOGIC FAILURE ON AN INITIAL REGIMEN CONTAINING A THYMIDINE ANALOG + LAMIVUDINE IN COMBINATION WITH A PROTEASE INHIBITOR (PI) OR NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) (ESS30005, ZIP) IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe6.3C03) Rodriguez A.1, Hill-Zabala C.2, Sloan L.3, Jefferson T.4, Yau L.2, Watson M.2, Irlbeck D.2, Shaefer M.2 TZV BID + TDF QD was an effective and well-tolerated regimen in subjects experiencing early failure on ZDV or d4T + 3TC + PI or NNRTI. Using a quad nucleoside/tide regimen following failure on a PI or NNRTI-based regimen may preserve future treatment options with other classes of antiretrovirals. |
| WePe6.3C04 | ADVERSE EVENTS ARE THE MAIN CAUSE OF FAILURE IN A PROSPECTIVE, RANDOMIZED, OPEN-LABEL, MUTICENTRE TRIAL IN NAÏVE, HIV-1-INFECTED PATIENTS, COMPARING ZDV/3TC VS D4T/DDI, PLUS EFAVIRENZ, NEVIRAPINE OR INDINAVIR/RITONAVIR (AMADEUS 01 STUDY). IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe6.3C04) Antela A.1, Iribarren J.A.1, Mahillo B.2, Santos I.1, Ribera E.1, Gutiérrez C.1, Esteban H.2, Labarga P.1, González J.1, Andía A.1, Martí-Belda P.1 Tolerability was the main factor influencing efficacy, with a better response with AZT/3TC when compared to d4T/ddI, mainly due to a higher rate of adverse events with d4T/ddI. Immunological recovery was significantly better on patients receiving d4T/ddI. Virological failure was unfrequent and most failures where due to adverse events, significantly more frequent in patients receiving IDV/RTV. |
| WePe6.3C05 | TENOFOVIR DF (TDF) IN COMBINATION WITH LAMIVUDINE (3TC) AND EFAVIRENZ (EFV) IN ANTIRETROVIRAL-NAÏVE HIV-INFECTED PATIENTS: 4-YEAR FOLLOW-UP IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe6.3C05) Cassetti I.1, Madruga J.V.R.2, Suleiman J.M.A.H.3, Zhong L.4, Enejosa J.4, Cheng A.K.4 Once daily TDF+3TC+EFV demonstrated sustained antiretroviral activity and was well tolerated in antiretroviral-naïve patients through 4 years of therapy. |
| WePe6.3C06 | 2-YEAR FOLLOW-UP LOPINAVIR/RITONAVIR (LPV/R)-EFAVIRENZ (EFV) COMBINATION (BIKS STUDY) IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe6.3C06) Allavena C.1, Bonnet B.1, Michelet C.2, Lafeuillade A.3, Delfraissy J.F.4, Besnier J.M.5, Drogoul M.P.6, Bentata M.7, Cohen Codar I.8, Raffi F.1 LPV/r-EFV combination was associated with a durable and high rate of virologic response, a sustained and consistent immunologic gain and an acceptable safety profile through 2 years, with no majoration of lipid abnormalities during the second year. |
| WePe6.3C07 | TIPRANAVIR/RITONAVIR (TPV/R) DEMONSTRATES SUPERIOR TREATMENT RESPONSE TO LOPINAVIR/R (LPV/R), AMPRENAVIR/R (APV/R) OR SAQUINAVIR/R (SQV/R) IN PI-EXPERIENCED PATIENTS FROM THE TPV RESIST-1 AND RESIST-2 TRIALS. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe6.3C07) Lazzarin A.1, Mukwaya G.2, Clumeck N.3, Workman C.4, Gathe J.5, Trottier B.6, Villacian J.2, Neubacher D.2, McCallister S.2 TPV/r provides a statistically superior VL response compared with either LPV/r, APV/r or SQV/r in a cohort of 2 PI-regimen—experienced HIV+ patients. |
| WePe6.3C08 | PATIENT SATISFACTION WITH ABACAVIR (ABC)-LAMIVUDINE (3TC) FIXED DOSE COMBINATION (FDC) TABLET ONCE DAILY (QD) COMPARED WITH ABC AND 3TC TWICE DAILY (BID) IN HIV-1 INFECTED PATIENTS (ESS30008) IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePeWePe6.3C08) Watson M.1, Hill-Zabala C.1, Sosa N.2, DeJesus E.3, Florance A.1 Satisfaction with treatment convenience and flexibility were enhanced by switching patients from ABC BID+3TC BID to ABC/3TC FDC QD. Symmetrical dosing regimens appear to increase patient satisfaction. |
| WePe6.3C09 | AN EVALUATION OF HIV-PATIENT QUALITY OF LIFE (QOL) AND TOLERABILITY AFTER ADMINISTRATION OF ENFUVIRTIDE (ENF)-BASED HAART USING A SMALLER NEEDLE IN A COMMUNITY PRACTICE SETTING (QUALITÉ) IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe6.3C09) True A.1, Luo R.2, DeMasi R.1, Falcon R.2 The incidence of any ISR sign or symptom ≥ grade 2 was low (average <1 ISR per visit) and the majority of patients experienced minor or no ISRs at week 12. These encouraging results demonstrate that ENF administered through a smaller needle has a favorable effect on QOL over 12 weeks in a community practice setting. |
| WePe6.3C10 | SAFETY AND EFFICACY OF ANTIRETROVIRAL TREATMENT (ART) REGIMENS CONTAINING TENOFOVIR DF (TDF) AND ATAZANAVIR/RITONAVIR (ATV/R) IN HIV-INFECTED ADULTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe6.3C10) Owen Jr. W.F.1, Chamberlain L.2, Warren D.R.3, Ebrahimi R.3, Flaherty J.F.3, Dong B.J.2 ART with regimens including TDF and ATV/r are well tolerated and associated with favorable virologic, immunologic and lipid responses. |
| WePe6.3C11 | THE USE OF STATINS MAY IMPROVE THE VIROLOGICAL OUTCOME IN HIV-INFECTED PATIENTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe6.3C11) Khanlou H., Farthing C. The beneficial effect of statins on HIV-RNA could have been minimized in our heterogeneous study. However, the use of statins may improve, although modestly, the virological outcome, warranting further comparative studies. |
| WePe6.3C12 | CLINICAL PRACTICE OF ATAZANAVIR IN THE REAL LIFE : RESULTS FROM A FRENCH PROSPECTIVE DATABASE OF 570 PATIENTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe6.3C12) Pugliese P.1, Duvivier C.2, Cuzin L.3, Agher R.2, Barone M.3, Billaud E.4, Druart P.5, Enel P.5, Gérard Y.6, Jovelin T.4, Marchou B.3, Poizot-Martin I.7, Raffi F.4, Salmi D.8, Yazdanpanah Y.6, Katlama C.2, Dellamonica P.1 Atazanavir appears as an effective therapy both in switch and in failing patients. Atazanavir was safe and exhibit a good lipid profile. |
| WePe6.3C13 | EFFICACY AND SAFETY OF A ONCE DAILY FIXED-DOSE COMBINATION OF ABACAVIR/LAMIVUDINE (ABC/3TC) [FDC ] VERSUS ABC TWICE DAILY AND 3TC ONCE DAILY AS SEPARATE ENTITIES [SE] IN ART-EXPERIENCED HIV-1 INFECTED SUBJECTS (CAL30001): 48 WEEK DATA. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe6.3C13) Clumeck N.1, LaMarca A.2, Fu K.3, Gordon D.4, Craig C.4, Zhao H.3, Paes D.4, Scott T.3 The FDC arm was shown to be non-inferior to the SE arm as part of a four-drug antiretroviral therapy (ART) regimen in ART-experienced subjects and was generally well tolerated over 48 weeks. The once daily ABC/3TC FDC is a simple and effective NRTI backbone for both ART naïve and experienced patients. |
| WePe6.3C14 | NRTI SPARING TRIAL (CTN 177): ANTIVIRAL AND METABOLIC EFFECTS OF NEVIRAPINE (NVP) + LOPINAVIR/RITONAVIR (LPV/R) VS. ZIDOVUDINE/LAMIVUDINE (AZT/3TC) + NVP VS. AZT/3TC + LPV/R IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe6.3C14) Harris M.1, Ochoa C.2, Allavena C.3, Negredo E.4, Thorne A.1, Cahn P.2, Zala C.2, Raffi F.3, Clotet B.4, Singer J.1, Montaner J.1 After 48 weeks of treatment in antiretroviral-naïve adults, NVP/LPV/r and AZT/3TC/NVP resulted in an increase in HDL and decrease in TC/HDL. Increases in fasting triglycerides and glucose were seen with NVP/LPV/r and AZT/3TC/LPV/r. Lactate decreased in the NRTI-sparing arm and increased in the NRTI-containing arms. No differences were observed between arms with respect to CD4 or virologic outcomes. |
| WePe6.3C15 | EFFICACY OF ATAZANAVIR (ATV) BASED HAART IN PATIENTS SWITCHED FROM A STABLE PI OR BOOSTED PI (PI/R) TREATMENT. PLANNED WEEK 24 ANALYSIS OF A PHASE IIIB 48 WEEK MULTICENTER, OPEN-LABEL, RANDOMIZED, PROSPECTIVE TRIAL. THE SWAN STUDY. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe6.3C15) Gatell J.M.1, Salmon-Ceron D.2, Lazzarin A.3, Van Wijngaerden E.4, Antunes F.5, Leen C.6, Horban A.7, Gruber C.8, Odeshoo L.9, Wirtz V.9, Ledesma E.9 Switching to ATV maintained antiviral suppression and resulted in fewer viral rebounds with comparable overall safety, improved GI tolerance and significant lipid improvements compared with continued therapy. Incidence of scleral icterus/jaundice on ATV was low. |
| WePe8.1B T-cell homeostatis |
|
| WePe8.1B01 | EVALUATION OF THE PATHOGENESIS OF DECLINING CD4+T CELL COUNTS IN HIV-1 INFECTED PATIENTS RECEIVING SUCCESSFULLY SUPPRESSIVE ANTIRETROVIRAL THERAPY IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8-1B01) Dybul M.1, Nies-Kraske E.1, Condoluci D.2, Schacker T.3, Orenstein J.4, Brenchley J.1, Fox C.5, Daucher M.1, Dewar R.6, Maldarelli F.7, Hallahan C.1, Planta M.1, Douek D.1, Coffin J.7, Fauci A.1 Observed levels of HIV RNA, DNA, and p24 were commensurate with those reported for patients receiving suppressive ART without CD4+T cell decline. There was no evidence that CD4+T cell decline was a result of HIV replication in LT, or altered thymic output. Fibrosis of the TZ is the likely mechanism of failure to reconstitute normal turnover of peripheral CD4+T cells due to damaged homeostatic mechanisms in LT. |
| WePe8.1B02 | CHARACTERIZATION OF MECHANISMS INVOLVED IN HEMATOPOIESIS FAILURE DURING HIV/SIV INFECTION. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8.1B02) Le Dantec M., Prost S., Thiebot H., Derdouch S., Vaslin B., Auregan G., Delache B., Kirszenbaum M., Le Grand R. This study demonstrates (i) that HIV/SIV infection results in impaired myeloid and lymphoid hematopoietic compartments, (ii) the involvement of STAT5 in the mechanisms of haematopoiesis failure. |
| WePe8.1B03 | DISCORDANT IMMUNE RESPONSES TO ANTIRETROVIRAL THERAPY ARE RELATED TO DECREASES IN CD4+ TERMINAL EFFECTOR MEMORY CELLS, CD25 (IL-2R) AND CD127 (IL-7R) EXPRESSION AND INCREASES IN VIRAL CO-RECEPTOR EXPRESSION IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8.1B03) Boulassel M.-R.1, Mercier F.1, Grignon C.1, Young M.1, Gimmig S.2, Yassine-Diab B.2, Sekaly R.-P.2, Tremblay C.2, Legault M.1, Routy J.-P.1 These findings suggest that DR may be related to a decrease in TPEM cells, cellular activation and cytokine receptor expression and an increase in viral co-receptor expression. |
| WePe8.1B04 | PERSISTENCE OF HIV INFECTION AFFECTS THE HOMEOSTASIS OF MEMORY COMPARTMENT OF SPECIFIC CD4 AND CD8 T CELLS. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8.1B04) Yassine Diab B.1, Kernaleguen A.E.1, Chambenoit O.1, Boulassel R.2, Grignon C.2, Tremblay C.1, Rouleau D.2, Routy J.-P.2, Sékaly R.-P.1 Our results will allow us to correlate if the generation of escape mutations that occurs rapidly, affects specially the immunogenic epitopes recognized either by CD4 and CD8 specific cells and abolish the development of a potent T cell memory compartment. |
| WePe8.1B05 | INCREASED TGF-β CBL-B AND CTLA-4 LEVELS, LEADING TO IMMUNOSUPPRESSION, IN ASSOCIATION WITH CHRONIC IMMUNE ACTIVATION IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8.1B05) Quibin L.1, Borkow G.1, Bentwich Z.2 1) Higher levels of CTLA-4, together with the higher levels of TGF-β, are both involved in the induction of Cbl-b, and are associated with the state of chronic immune activation. 2) These elements significantly contribute to the general and antigen-specific hyporesponseviness, characteristic for chronic immune activation associated with chronic infections such as helminthic infections and HIV infection. 3) This state of hyporesponsiveness/anergy is at least detrimental for generation of potent protective immunity in response to vaccination. |
| WePe8.3B Biology of transmission |
|
| WePe8.3B01 | ASPERGILLUS FUMIGATUS CONIDIA INDUCTION OF TRANS-EPITHELIAL LAMINA PROPRIA DENDRITIC CELL EXTENSIONS AS A MODEL OF HIV-1 TRANSMISSION VIA DC-SIGN IN MONOLAYER MUCOSA IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8.3B01) Eberhard A.1, Eberhard A.2, Landsman L.2, Jung S.2, Verrier B.1 Our observations highlight the importance of lpDC dendrites in the capture of particulate pathogens. Future experiments will address dendrite/HIV-1 virion interactions and the outcome of HIV-1 uptake via the lpDC and M cell routes. |
| WePe8.4B Primary infection |
|
| WePe8.4B01 | STUDY OF THE QUASISPECIES EVOLUTION OF HIV SHOWING MONOCYTE-DERIVED CELL MEMBRANE MARKERS DURING PRIMARY INFECTION AND IN FOLLOW-UP IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8.4B01) Rozera G., Abbate I., D'Offizi G., Corpolongo A., Calcaterra S., Capobianchi M.R. This approach could give the opportunity to study viral population actually replicating in the different cellular reservoirs, with possible different rates of evolution. The presence of a monophyletic cluster comprising the majority of the clones from CD36-captured virions deriving from different subjects, together with the lower diversity found in these viral quasispecies, suggests that circulating virions originating from monocytes show common features, in a genome region not known to be directly involved in cell tropism, that may overcome the patient's related variability. If confirmed in a larger number of subjects, these findings can be relevant for both pathogenetic and therapeutic aspects. |
| WePe8.4B02 | EARLY ANTIRETROVIRAL THEARPY (ART) AND TREATMENT INTERRUPTION IN HIV-1 INFECTION: THE IMPACT ON THE IMMUNE RESPONSE, VIRAL FITNESS AND VIRUS CONTROL IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8.4B02) Arnott A.1, Verity E.1, Wilson K.1, James H.1, Jardine D.1, Gorry P.2, Merlin K.3, Grey P.3, Kelleher A.3, Smith D.3, McPhee D.1 There was no correlation between virus neutralisation in vitro and virus control upon interruption. As the observed neutralisation of autologous and heterologous virus replication was unexpected, we are investigating complement in subject plasma and natural killer cells in donor PBMCs mediating antibody-dependant cell-mediated cytotoxicity as possible causes. There was a correlation between viral replication phenotype and virus control upon interruption. Using real time PCR, we are examining early virus replication kinetics as a measure of viral fitness. These results will provide important insight into the impact of early ART and treatment interruption on viral fitness, the immune response and the importance of initial viral phenotype as a clinical marker for virus control. |
| WePe8.4B03 | PREFERENTIAL RECRUITMENT OF HIGH-AFFINITY HIV-1-SPECIFIC CD8+ T CELLS IN ACUTE HIV-1 INFECTION IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8.4B03) Lichterfeld M., Yu X., Mui S., Brockman M., Waring M., Cheng M., Rosenberg E., Walker B., Altfeld M. In acute infection, HIV-1-specific CD8+ T cells with high-avidity TCRs seem to be preferentially recruited. The absence of these high-affinity TCRs in chronic infection suggests a progressive deletion or exhaustion of initially recruited HIV-1-specific CD8+ T cells during the chronic disease phase. |
| WePe8.4B04 | GREATER CD4+ T CELL RATE OF GAIN DURING ANTI-RETROVIRAL THERAPY IS ASSOCIATED WITH LOWER PRE-TREATMENT VIRAL POL REPLICATION CAPACITY INDEPENDENT OF VIROLOGIC RESPONSE IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8.4B04) Barbour J.D.1, Hecht F.M.1, Markowitz M.2, Little S.J.3, Daar E.S.4, Kelleher A.5, Routy J.P.6, Campbell T.7, Rosenberg E.8, Schafer K.9, Wood K.10, Segal M.11, Weidler J.12, Bates M.12, Grant R.M.13 HIV-1 of lower pol RC predicts greater average rate of CD4+ T cell count increase over the period of observation, independent of virological responses. This may be due to lower T cell activation and sparing of T cell precursors, which have been observed in association with lowered with lowered polRC. |
| WePe8.5B Dendric cells in HIV pathogenesis |
|
| WePe8.5B01 | MONITORING DENDRITIC CELLS IN HIV INFECTION USING A NEW WHOLE BLOOD ASSAY IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8.5B01) Lichtner M.1, Mastroianni C.M.1, Rossi R.1, Kamga I.2, Mengoni F.1, Vignoli S.1, Germani A.1, Hosmalin A.2, Vullo V.1 The study of circulating DC absolute counts in whole blood may represent a simple and adjunctive method for the immunological monitoring of HIV infection. This assay seems to be useful in antiretroviral naïve asymptomatic patients when the progression of the disease is not clearly evident in terms of HIV-RNA and CD4 counts. |
| WePe8.5B02 | PERSISTENT ABNORMALITIES IN THE NUMBER, PHENOTYPE AND FUNCTIONALITY OF PERIPHERAL BLOOD DENDRITIC CELLS AND MONOCYTES FROM HIV-1+ PATIENTS AFTER ONE YEAR OF ANTIRETROVIRAL THERAPY. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8.5B02) Almeida M.1, Cordero M.2, Almeida J.1, Orfao A.1 These abnormalities were specially pronounced in HIV-1+ patients with <200 CD4+T-cells/ul, which could be probably related to the persistence of undetected viral replication and a sustained activation of the immune system. |
| WePe8.5B03 | IMPACT OF CXCL12 PRODUCTION BY DENDRITIC CELLS IN HIV INFECTION OF LYMPHOCYTES BY X4 STRAINS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8.5B03) Bermejo M.1, Gonzalez N.1, Pablos J.L.2, Sanchez-Verde L.3, Baleux F.4, Arenzana F.4, Alcami J.1 These results suggest that the production of CXCL12 by MDC represents an antiviral mechanism in the immune synapse and could account for the lack of emergence and low propagation of X4-HIV strains in early and chronic stages of infection. |
| WePe8.6B Cytokines in HIV pathogenesis |
|
| WePe8.6B01 | CONTRIBUTION OF HMGB1 PROTEIN TO IMMUNOACTIVATION IN HIV-1 INFECTION. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8.6B01) Nowak P.1, Treutiger C.J.2, Andersson J.2, Sonnerborg A.1 HMGB1 seems to play an essential role in HIV-1 infection and our data suggest that release of extracellular HMGB1 contributes to immunoactivation state. |
| WePe8.6B02 | CSF PRODUCTION OF MCP-1 AND MIF IS RELATED TO SPECIFIC MANIFESTATIONS OF AIDS. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8.6B02) Lafeuillade A.1, Hittinger G.1, Poggi C.2 CNS production of some cytokines, MCP-1 and MIF, appears to be related to specific manifestations like HIV encephalitis. |
| WePe8.6B03 | THE INFLUENCE OF AGE ON IL-7 PRODUCTION IN ARV-SUPPRESSED PATIENTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8.6B03) Carnevalini M., Andreoni C., d'Ettorre G., Sebastiani M., Miccoli A., Vullo V., Mastroianni C.M. The blood levels of IL-7 has been proposed as a predictive marker of immune reconstitution in HIV-infected patients receiving HAART. Controversial data concerning the influence of age on the quantitative and qualitative immune response to HAART are reported. The results presented here suggest that the degree of immunologic restoration in ARV-suppressed patients is more evident in children and young subjects as indicated by lower circulating levels of IL-7. In adult patients the age had no influence on the amount of CD4 count increase and the blood levels of IL-7. |
| WePe8.6B04 | THE ROLE OF PGE2, PAF AND VITRONECTIN RECEPTOR IN THE ENHANCEMENT OF HIV-1 REPLICATION UPON INTERACTION OF MACROPHAGES WITH APOPTOTIC CELLS. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8.6B04) Lima R.G., Moreira L., Leme J.P., Castro-Faria-Neto H.C., Bozza P.T., Bou-Habib D.C. Our results show that PGE2 and PAF increase HIV-1 growth in primary macrophages and contribute to amplify HIV-1 growth in macrophages upon uptake of apoptotic cells, and that stimulation of VnR up-modulates viral replication in HIV-1-infected macrophages. |
| WePe8.6B05 | INTRACELLULAR OF HIV-1 TAT DOWN-REGULATES THE SURFACE EXPRESSION OF CXCR4 IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8.6B05) Hidalgo Estévez A.1, Danelon-Sargenti G.2, Sebastiani S.2, Uguccioni M.2, Fresno M.1 In this study, we observed the increased CXCR4 down-regulation due to the intracellular presence of HIV-1-tat in both basal and under SDF-1 stimulation. Tat also affects the activation of other intracellular signals, as the MAPK pathway. Our results provide new information on the mechanisms by which HIV-1 alters the expression and activity of the HIV-1 co-receptor CXCR4. |
| WePe8.6B06 | DEFECTIVE RESPONSES OF PBMC FROM HIV-1 PATIENTS TO IL-12 ARE NOT CORRECTED BY EXOGENOUS IL-12 IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8.6B06) Patel V.1, Valentin A.1, Yarchoan R.2, Pavlakis G.1 Our results support the notion of impairment in IL-12 induced T helper responses in HIV-1 infected individuals. This impairment is not compensated by the addition of exogenous IL-12 and may contribute to the defects of cellular immunity in AIDS patients. |
| WePe8.8B Anatomical and cellular reservoirs |
|
| WePe8.8B01 | LACK OF ASSOCIATION OF HIV-1 BIOLOGICAL OR MOLECULAR PROPERTIES WITH NEUROTROPISM FOR NEURONAL AND GLIAL CELLS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8.8B01) Álvarez S., Jiménez J.L., Serramía M.J., González M., Cantó-Nogués C., Muñoz-Fernández M.A. Our results failed to show a particular phenotypic property of the HIV-1 that may explain its neurovirulence and/or neurotropism. This suggests that more than one factor may account for neurotropism/neurovirulence of HIV-1. |
| WePe8.8B02 | HIV-1 ENVELOPE GLYCOPROTEIN 120 INDUCES CYCLOOXYGENASE-2 EXPRESSION IN ASTROCYTES THROUGH A NUCLEAR FACTOR-κβ MEDIATED MECHANISM. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8.8B02) Álvarez S.1, Serramía M.J.1, Fresno M.2, Muñoz-Fernández M.A.1 The major finding of this study is that the transcriptional regulation of COX-2 by gp120 in human U87 cells is highly induced in a NFκß dependent way. |
| WePe8.8B03 | UNCOUPLING T CELL ACTIVATION AND HIV REPLICATION IN CD4+ T CELLS OF INFECTED LYMPHOID HISTOCULTURES BY PERTUSSIS TOXIN B-OLIGOMER IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8.8B03) Poli G.1, Alfano M.1, Grivel J.-C.2, Ghezzi S.1, Margolis L.2 PTX-B and PT-9K/129G inhibited both R5 and X4 HIV-1 replication in human lymphoid histocultures infected ex vivo. They also promoted proliferation of CD4+ T lymphocytes emigrating from lymphoid tissue, but, in contrast to PHA and IL-2, without triggering virus replication. CD4+ T cells emigrated ex vivo from lymphoid tissues thus represent a model of a latent but inducible HIV reservoir. PTX-B and the clinically approved PT-9K/129G molecule should be considered potentially new antiretroviral agents also endowed with immunostimulatory capacity. |
| WePe8.8B04 | CD4 CD25 REGULATORY T CELLS: A SITE FOR HIV PERSISTENCE IN PATIENTS ON PROLONGED AND EFFECTIVE HAART IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8.8B04) Tran T.A.1, Le Nevot E.2, Hendel H.2, De Goer De Herve M.G.1, Abbed K.2, Lambotte O.1, Gasnault J.1, Balazuc A.M.3, Delfraissy J.F.1, Taoufik Y.1 Our results suggest that CD4+CD25high T cells are a virus reservoir in patients on prolonged HAART. Via their lower responsiveness to activation which may favour viral latency, infected CD4+CD25 high T cells could better escape destruction by virus or CD8 T cell-mediated cytotoxicity. |
| WePe8.9B Host genetic factors |
|
| WePe8.9B01 | ANALYSES OF HOST GENETIC FACTORS THAT MODULATE PROGRESSION OF HIV/SIV/AIDS IN INDIA IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8.9B01) Banerjea A. The HIV-1 protective mutation -CCR5delta32 is extremely rare in India. SDF-1 mutation is quite common but shows no correlation with protection against HIV-1.The conservation of HIV-1 disease modifying mutations in monkeys provide us the unique opportunity to study its role in pathogenesis in molecular details. |
| WePe8.9B02 | A NOVEL 24-BP DELETION IN THE CODING REGION OF CCR5 IN AN AFRICAN POPULATION IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8.9B02) Masquelier C.1, Servais J.-Y.1, Rusanganwa E.2, Roman F.1, Havuga E.3, Servais J.4, Tuyizere S.2, Omes C.3, Karasi J.-C.3, Courteille O.4, Hemmer R.1, Schmit J.-C.1, Arendt V.5 Our study is the first to report a 24-bp deletion in the coding region of CCR5 in humans. The allele frequency in Rwanda is 0.003 and 0.000 in Luxembourg. The deletion affects highly conserved amino acids among the G-protein-coupled receptor family. Although this deletion does not prevent HIV-1 infection in heterozygous individuals, it is likely to lead to a truncated protein with impaired HIV coreceptor functions, and might influence HIV transmission or disease progression in Rwanda. |
| WePe8.9B03 | OVEREXPRESSION OF FASCICULATION AND ELONGATION PROTEIN ZETA-1 (FEZ1) INDUCES A POSTENTRY BLOCK TO RETROVIRUSES IN CULTURED CELLS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8.9B03) Naghavi M.H.1, Hatziioannou T.2, Gao G.3, Goff S.P.1 Our data suggests that FEZ1 overexpression is sufficient to explain the resistant phenotype of R3-2 cells. |
| WePe8.9B04 | ANALYSIS OF CYTOKINE GENES (IFN-γ, IL-4 AND IL-10) IN KOREAN HIV-1 INFECTED PERSONS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8.9B04) Kang M.-W.1, Wie S.-H.1, Kim S.-Y.2, Choi H.-B.2, Kim Y.-R.1, Pyo C.-W.2, Kim T.-G.2 In the study about polymorphism of IFN-? gene, the absence of allele #2-positive gene at the CA repeat region in the first intron is correlated with HIV-1 infection, but not closely related with the progression to AIDS and incidence of opportunistic infections. |
| WePe8.9B05 | RNA INTERFERENCE OF P53 BLOCKS HIV REPLICATION WITHOUT AFFECTING ENVELOPE FUNCTION IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8.9B05) Pauls E., Senserrich J., Clotet B., Esté J.A. First, we have validated RNA interference as a tool for the study of cellular factors involved in HIV infection. Second, our results suggest that p53 expression is required for efficient HIV replication in lymphoid cells but its role appears to be independent on HIV-envelope and the HIV entry process. |
| WePe8.9B06 | INHIBITION OF THE ARP2/3 COMPLEX LIMITS INFECTION OF BOTH PRIMATE LENTIVIRUSES AND INTRACELLULAR MATURE VACCINIA VIRUS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8.9B06) Yamamoto N., Miyauchi K., Matsuda Z., Komano J. These data suggested the existence of an Arp2/3 complex-dependent event during the early phase of the life cycles of both primate lentiviruses and IMV. Since actin has been shown to play a role in the infection of all the viruses tested in this study, our data suggest that MLV, HSV-1, and adenovirus might enter cells in an Arp2/3 complex-independent manner. Perhaps, other functional aspects of actin are important for these viruses to infect cells such as the actin cable-dependent trafficking system. Inhibiting the HIV-1's ability to activate Arp2/3 complex could be a potential chemotherapeutic intervention for acquired immunodeficiency syndrome (AIDS). |
| WePe8.9B07 | FREQUENCIES FOR T280M, V249I OF CX3CR1 AND CCR5 DELTA 32 POLYMORPHISMS IN HIV-1 INFECTED PATIENTS. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8.9B07) Parczewski M.1, Leszczyszyn-Pynka M.2, Ciechanowicz A.1, Boron-Kaczmarska A.2 1.Frequencies for I/I and M/M genotypes were lower to the ones previously described in Caucasian populations 2.CCR5 delta 32 occurred at the usual frequencies noted for the Caucasian population. 3. Lack of I/I genotype in subjects heterozygous for delta 32 might be additional factor of slower progression to AIDS. |
| WePe8.9B08 | EFFECT OF GENETIC HOST FACTORS ON TREATMENT SUCCESS IN HIV1-INFECTED PATIENTS: IDENTIFICATION OF RESPONDERS AND NON-RESPONDERS BY GNAS GENOTYPING. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8.9B08) Potthoff A., Brockmeyer N.H. These data suggest that IL2-induced CD4 rises are genetically determined and that genotyping the GNAS G(-1211). A polymorphism could identify treatment responders. This finding could be of utmost clinical significance. |
| WePe8-10B Disease progresion |
|
| WePe8.10B02 | SUDDEN, RAPID CD4 COUNT DECLINE WITH RECENTLY-ACQUIRED MULTIDRUG RESISTANT HIV-1 DESPITE VERY LOW VIRAL LOAD. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8.10B02) Pao D.1, Imami N.2, Fisher M.1 Anti-HIV-1 T-cell responses were maintained despite the decline in CD4 T-cell counts. This case highlights questions regarding our current understanding of the contribution of immunological and virological factors to HIV pathogenesis and the management of primary multidrug resistance. |
| WePe8.10B03 | HIV-1 FITNESS: COMPARING THE RARE SUBTYPE C SYNCYTIUM INDUCING CXCR4 ISOLATES WITH OTHER GROUP M ISOLATES IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8.10B03) Nankya I.1, Abraha A.1, Fraundorf E.1, Marozsan A.1, Johnston B.2, Katzenstein D.2, Arts E.1 The decreased replicative capacity of subtype C HIV-1 isolates appears to be intrinsic and may be related to the dominance of this subtype in the epidemic. This may result in slower progression and longer survival of the human host and thus more time for transmission. |
| WePe8.10B04 | GENETIC EVIDENCE FOR DIFFERENT TRANSCRIPTION REGULATION IN HIV-1 INFECTED INDIVIDUALS WITH LONG-TERM NON-PROGRESSION IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8.10B04) Ramirez de Arellano E.1, Martin C.1, Soriano V.1, Alcami J.2, Holguin A.1 LTR genetic variability in some motifs involved in the binding of cellular proteins Sp1 and USF, which are essential for HIV-1 transcription regulation, may account for differences in HIV-1 disease progression. It may determine distinct interactions between cellular transcription factors and infecting viruses, which could lead to different HIV-1 transcriptional. |
| WePe8.10B05 | ASSOCIATIONS BETWEEN NONPROGRESSIVE HIV-1 INFECTION AND VIRAL SEQUENCES REVEALED BY THE ANALYSIS OF NEAR COMPLETE VIRAL GENOMES IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8.10B05) Sierra M.1, Thomson M.1, Bru F.2, Colomo C.2, Perez-Alvarez L.1, Contreras G.1, Najera R.1 Major disruptions of HIV-1 open reading frames are infrequently associated with long-term nonprogression. However, the analysis of frequencies of amino acid residues reveals strong correlations between viral genetic features and absence of disease progression. |
| WePe8.10B06 | EARTH COHORT: ARTIFICIAL INTELLIGENCE-BASED TIME-DEPENDENT MODELS TO LONGITUDINALLY ASSESS HIV CLINICAL OUTCOMES IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8.10B06) Tsoukas C.1, Mather M.1, Gilbert L.1, Demetriades I.2, Patel A.3, Maniar J.4, Gill J.5, Wanchu A.6, Panos G.7, Kovacs C.8, Taty-Taty R.9, Loemba H.10, Hatzakis G.1 TR-NN outperform Cox Regression when predicting HIV-associated clinical outcomes. TR-NN structures can learn individual patients' patterns of progression, incorporating temporal information while re-training on new data and incrementally building on previously acquired knowledge. Our study results warrant further investigation. |
| WePe8.10B07 | COURSE OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTION AFTER SEROCONVERSION IN A COHORT OF MEN WHO HAVE SEX WITH MEN (MSM) IN RIO DE JANEIRO, BRAZIL IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8.10B07) Djomand G.1, Duerr A.1, Struchiner C.2, Pacheco G.2, Barroso P.3, Melo F.3, Schechter M.3 Although viral load dynamics were analogous to those observed in developed countries, CD4 counts appear to decline at a faster rate. Clinical and survival data are needed to assess the impact of interventions, such as ART, on the clinical course of HIV infection in Brazil. |
| WePe8.10B08 | CEM15 MAY PROMOTE S1 GENOTYPE IN HIV-1 SPECIES IN LONG-TERM, NON-PROGRESSOR IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8.10B08) A. Kiessling A., Neville N., Desmarais B., Yin H.-Z. These data suggest that G to A transitions accumulate more slowly in seminal plasma virus than blood plasma virus, but more rapidly in infected cell provirus in semen than in blood. The appearance of SI variants is associated with a threshold number of G to A transitions, perhaps resulting from an incomplete vif blockade of the CEM15 defense against retroviral infection. |
| WePe8.10B09 | VIRAL INFECTIVITY AND CD4 DOWNREGULATION ARE IMPAIRED BY NEF ALLELES OBTAINED FROM HIV-1-INFECTED HEMOPHILIACS WITH NON-PROGRESSING HIV-1 DISEASE IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8.10B09) Crotti A.1, Neri F.1, Corti D.1, Heltai S.1, Coradin T.1, Santagostino E.2, Vicenzi E.1 Functional alterations of the nef gene are present in LTNP that have been remaining healthy for at least twenty years since infection in the absence of anti-retroviral therapy. |
| WePe8.10B10 | GENDER DIFFERENCES IN HIV PROGRESSION IN A MULTICENTRE HOSPITAL BASED COHORT IN SPAIN IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8.10B10) Garcia de la Hera M.1, Ferreros I.2, Perez-Hoyos S.2, Iribarren J.A.3, Moreno S.4, Viciana P.5, Martínez N.M.6, Gutierrez F.7, Navarro V.8, Alemán Valls R.9, Saumoy M.10, Oteo J.A.11, Leal M.5, Oliva J.12, CoRIS-R y.13 There were no gender differences in time to AIDS nor in survival from AIDS in this setting. Although women seem to have earlier presentations, both men and women have a very high uptake of HAART. |
| WePe8.11B Biomarkers for HIV disease |
|
| WePe8-11B01 | THE SERUM AND URINARY TRYPSIN INHIBITORS LEVEL CORRELATE WITH PROGRESSION OF HIV INFECTION IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8-11B01) Papuashvili M. Inhibitors of serine proteases might belong to a system of sufficiently active endogenous suppressors of HIV-1. As soon as HIV-infection is proceeding to AIDS, the decompensation of non-specific protection system of inflammatory reactions provoke the biochemical disorders which are turned into inflammatory disaster of organism in general. |
| WePe8-11B02 | RELATIONSHIP BETWEEN CD38 EXPRESSION ON PERIPHERAL BLOOD T-CELLS AND MONOCYTES AND RESPONSE TO ANTIRETROVIRAL THERAPY (ART): A ONE-YEAR LONGITUDINAL STUDY OF A COHORT OF CHRONICALLY INFECTED ART-NAÏVE HIV-1+ PATIENTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8-11B02) Almeida M.1, Cordero M.2, Almeida J.1, Orfao A.1 The quantitative measurement of CD38 expression on PB CD8+ T-cells as well as on both CD4+ T-cells and monocytes is a useful tool for monitoring HIV-1+ patients under ART. |
| WePe8-11B03 | THE PROGNOSTIC VALUE OF SUPAR IN HIV-1 INFECTION IS NOT INFLUENCED BY UPAR PROMOTER POLYMORPHISMS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8-11B03) Vest Schneider U.1, Lyngaa Nielsen R.1, Pedersen C.2, Eugen-Olsen J.1 This study confirms that suPAR, which is easy to measure using a simple ELISA, is a strong marker of HIV-1 disease progression. Importantly, the prognostic value of suPAR is not influenced by promoter mutations. |
| WePe8-11B04 | HOST AND VIRAL ENCODED MICRORNAS EXPRESSION IS ALTERED DURING HIV INFECTION-ROLE IN THE CONTROL OF THE INFECTION AND LATENCY? IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8-11B04) Sharon E.1, Meiri E.1, Aharonov R.1, Spector Y.1, Shemer Y.2, Bentwich I.1, Bentwich Z.2 1) HIV infection is associated with upregulation and downregulation of several host MIRs as well as the expression of viral encoded MIRs. 2) At least some of the host and of the viral encoded MIRs may have a direct effect on viral replication and latency. 3) Control of MIR expression or its modulation offers a novel approach for therapy of HIV infection. 4) The changed expression of host MIRs with HIV infection, may offer new approaches of therapy directed towards host response to HIV infection. |
| WePe8.12B Targets of HIV infection |
|
| WePe8.12B01 | TELOMERASE ACTIVITY AND TELOMERIC LENGTH REMAIN UNCHANGED IN JURKAT CELLS INFECTED WITH HIV-1 IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8.12B01) Minces L.R., Reynoso R.P., Bolcic F.M., Salomon H., Quarleri J.F. Considering that neither telomerase activity was reduced nor telomeric length was shortened in infected leukemic cells, we can infer that HIV-1 does not have a measurable impact on senescence in our in vitro model. Since these results are not congruent with previously reported findings in other cellular models, we hypothesize that, although HIV-1 infection might down-regulate telomerase activity in Jurkat cells, it is not reflected by using the present experimental conditions due to the elevated intrinsic telomerase activity that this cell line displays. |
| WePe8.12B02 | TELOMERASE ACTIVITY REMAINS UNCHANGED AFTER HIV-1 TAT EXPRESSION IN GHOST CELLS: COMPARATIVE ANALYSIS BETWEEN HIV-1 SUBTYPE B AND BF ISOLATES IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8.12B02) Reynoso R.P., Vignoles M., Turk G.J., Minces L.R., Saracco M., Salomon H., Quarleri J.F. HIV-Tat produced on GHOST transfected cells could not be essential on telomerase activity down-regulation. Likewise, no differences were observed between B and BF-based constructions. It has been previously reported that extracellular Tat down-regulates telomerase activity; our observations could imply that Tat action might be ascribed to a bystander pathogenic effect promoting ageing on infected cells. |
| WePe8.12B03 | NEUROLOGICAL EVALUATION OF UNTREATED HIV INFECTED ADULTS IN ETHIOPIA IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8.12B03) Clifford D.1, Teshome M.2, Mekonnen Y.3, Zenebe G.2, Melaku Z.2, Zewde A.2, Gessesse N.3, Wolday D.3, Messele T.3, Teshome M.1 While untreated Clade C infected HIV patients had higher neurological complication than controls, the overall lower than anticipated prevalence of deficits in this well controlled cohort suggests that, Clade C virus prevalent in Ethiopia might be less neurotoxic than the usual clades prevalent in developed countries. This finding deserves closer follow-up and further evaluation during and after initiation of antiretroviral therapy. |
| WePe8.12B04 | INCREASED SERUM OSTEOPROTEGERIN IS ASSOCIATED WITH INFLAMMATORY ACTIVITY IN HIV-INFECTION IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8.12B04) Wiercinska-Drapalo A.1, Jaroszewicz J.1, Tarasow E.2, Pierzchalska K.1, Prokopowicz D.1 Increased OPG is associated with inflammatory activity in HIV-infection. OPG augment together with TIMP-1 increase may be explained by compensatory protection mechanism against bone loss. |
| WePe8.12B05 | INFECTION OF DIFFERENT T-CELL SUBSETS (NAÏVE AND CENTRAL MEMORY) DURING HIV-1 DISEASE PROGRESSION IN TWO HIV-1 INFECTED INDIVIDUALS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8.12B05) Geels M.1, Baan E.1, Pollakis G.1, Ambrozak D.2, Schuitemaker H.3, Goudsmit J.4, Koup R.2, Paxton W.1 In two HIV-1 infected individuals with increasing viremia equal viral evolution and infection of different T-cell subsets occurs with variants uniformly distributed amongst the naïve and central memory T lymphocyte compartments. |
| WePe8.12B06 | HIV-1 INFECTS HUMAN NEURONAL CELLS AND INDUCES DIRECT CELL DEATH VIA ITS ENVELOPE IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8.12B06) Suzanne S.1, Chasserot-Golaz S.2, Aunis D.1, Schaeffer E.1 Our data reveal that HIV-1 is able to infect via endocytosis human CD4-negative neuronal cells in a non-productive manner. They further show that neurotoxicity is not related to the replicative ability of HIV-1, but to the presence and type of a functional envelope. |
| WePe8.13B Viral compartments and reservoirs |
|
| WePe8.13B01 | COMBINATION STIMULATORY APPROACHES WITH INTERLEUKIN-7 TARGETING RESIDUAL HIV-1 DISEASE: HIGHLY ACTIVE ANTI-LATENCY THERAPY (HAALT) IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8.13B01) Pomerantz R., Wang F.-X., Xu Y., Nunnari G. These studies demonstrated that combination approaches will be necessary to both molecularly interrogate and stimulate various diverse viral strains from subtypes of CD4+ T-lymphocytes within the peripheral blood of virally-suppressed patients on HAART. As such, a combination "highly active anti-latency therapy (HAALT)" approach has been modeled in vitro, for now translational utility in humans. |
| WePe8.13B02 | SIV INFECTION OF THE GENITAL TRACT OF ASYMPTOMATIC MALE MACAQUES IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8.13B02) Le Tortorec A.1, Le Grand R.2, Jégou B.1, Dejucq-Rainsford N.1 Our results suggest that SIV infection can be found at different levels of the reproductive tract of asymptomatic animals. This infection is associated with the presence of inflammatory infiltrates, which are mainly composed of T lymphocytes. |
| WePe8.13B03 | IDENTIFICATION OF T CELL SUBSETS THAT CONSTITUTE THE HIV-1 RESERVOIR IN HAART TREATED PATIENTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8.13B03) Chomont N., Yassine-Diab B., Trautmann L., Boulassel R., Routy J.-P., Sékaly R.-P. These results have important implications for the clinical management of HIV-1 infected individuals and for the development of virus eradication strategies. |
| WePe8.13B04 | HIV SEQUENCE EVOLUTION IN THE BRAIN: DISTINCTLY DIFFERENT EVOLUTIONARY PATHWAYS BETWEEN HAD AND PRIMARY CNS LYMPHOMA ASSOCIATED STRAINS OF HIV IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe8.13B04) McGrath M.S.1, Lamers S.L.2, Salemi M.3 In this study, HAD related HIV sequences were uniquely different from those in parallel ARL within HAD brains showing evolutionarily related HIV sequence compartmentalization. The data suggest that CNS ARL HIV does not evolve directly from HAD HIV and in this preliminary study suggests the existence of ARL specific strains of HIV distinct from those involved in the pathogenesis of HAD. |
| WePe10.3P Post-exposure prophylaxis |
|
| WePe10.3P01 | HIV POST- EXPOSURE PROPHYLAXIS (PEP) AFTER SEXUAL ASSAULT - EXPERIENCE AT A RESOURCE - LIMITED PEDIATRIC CLINIC SETTING IN WESTERN KENYA. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe10.3P01) Gitonga M.M. This study advocates improved efforts in recording and expediting HIV PEP provision at the base hospital's emergency department, such as educating practitioners on accurate recording, proper use of PEP guidelines and availing HIV PEP drugs for direct dispensation from the emergency department. |
| WePe10.3P02 | A SURVEY OF OCCUPATIONAL AND NON-OCCUPATIONAL HIV POST-EXPOSURE PROPHYLAXIS (PEP) AT A HIV CARE CENTER IN A RURAL KENYA REFERRAL HOSPITAL IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe10.3P02) Gitonga M.M. Establishment of clear guidelines for HIV PEP provision, active patient follow-up, educating of practitioners, informative recording by clinicians and the in-co-operation of risk reduction counseling to help prevent future exposures is vital. |
| WePe10.3P03 | KNOWLEDGE AND USE OF PRE-EXPOSURE PROPHYLAXIS AMONG ATTENDEES OF MINORITY GAY PRIDE EVENTS, 2004 IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe10.3P03) Kellerman S., Hutchinson A., Begley E., Boyett B., Clark H., Sullivan P. A surprising percentage of MGP attendees demonstrated awareness and use of PREP, and PREP users reported distrust of generally accepted HIV information. The effectiveness of PREP is still unknown so its use should be monitored among persons at risk for HIV infection who may use PREP as a surrogate for proven prevention methods. Future surveys should also consider what medications are being taken as PREP, on what schedule they are taken, from where they are obtained, and whether their use is associated with higher risk sexual behaviors. |
| WePe10.3P04 | OCCUPATIONAL POST-EXPOSURE PROPHYLAXIS: KNOWLEDGE LEVEL AMONG MEDICAL STAFF IN TUMBI SPECIAL HOSPITAL IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe10.3P04) Dattani P., Maruchu I. 1. While occupational accidents continue to occur, blood exposure prevention remains the primary method for reducing occupational HIV transmission. 2. Staff knows exposure prevention; partially know proper treatment of exposure site but almost half of them do not know post-exposure prophylaxis at all. 3. Employer should educate all HCW about reporting, evaluation, counseling, treatment, and follow-up after risky occupational accident; provide a 24hours access to drugs. |
| WePe10.3P05 | MANAGEMENT OF NON-VOLUNTARY HIGH-RISK SEXUAL EXPOSURES (HRSE) IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe10.3P05) Cabrini M., Mensa F., Fried P., Sisto A., Laufer N., Cando O., Perez H., Cahn P. In our series patients requiring care for SE do so relatively short time after exposure. Providing PEP was not associated in this group with new exposures in the ASE group. One seroconversion occurred in a patient receiving 3AR (ASE group). We noticed poor compliance with follow-up, which prompt us to develop an active program to tackle this problem. |
| WePe10.3P06 | OCCUPATIONAL POST- EXPOSURE PROPHYLAXIS: ANALYSIS OF 237 CASES IN A 2 YEAR PERIOD IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe10.3P06) Fink V., Laufer N., Fonio S., Rolon M.J., Cando O., Perez H., Cahn P. In spite of ongoing medical education programs, occupational exposure is still frequent. The low compliance with follow up observed should prompt the active search of injured HCW. Higher risk was observed in less experienced HCW in surgical and emergency areas, particularly among residents, with obvious educational implications. |
| WePe10.3P07 | POST EXPOSURE PROPHYLAXIS IN VICTIMS OF SEXUAL ASSAULT AT AN HIV TREATMENT CLINIC, PORT OF SPAIN, TRINIDAD. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe10.3P07) Jones A., Lezama S., Bartholomew C. Although adherence was unsatisfactory there were no seroconversions to date following sexual assault in Trinidad and Tobago. |
| WePe10.3P08 | TENOFOVIR/3TC FOR NON-OCCUPATIONAL POST-EXPOSURE PROPHYLAXIS (NPEP): IMPROVED TOLERABILITY AND ADHERENCE COMPARED TO AZT/3TC IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe10.3P08) Mayer K.1, Goldhammer H.2, Cohen D.2, Grasso C.2, Bill R.2, Maldonado A.2, Vanderwarker R.2, Fisher A.3 TDF/3TC is well tolerated for NPEP, with higher completion rates than AZT/3TC-containing regimens. Better tolerated QD regimens for NPEP may optimize adherence and minimize loss to follow-up. |
| WePe10.3P09 | AN OUTBREAK OF HIV INFECTION IN A TUBERCULOSIS HOSPITAL, ALMATY, KAZAKHSTAN, 2003. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe10.3P09) Akilbekov S.1, Ajeilat S.2, Sinclair M.3, Favorov M.4 There is some indication that injecting drug-use during hospitalization might be the main mode of HIV transmission in the treatment facility.A syringe-exchange post was opened in the hospital and health education was provided to the patients there. Monitoring of prophylactic control effectiveness is conducted up to present time. |
| WePe10.3P10 | FIVE YEARS OF NON-OCCUPATIONAL POST-EXPOSURE PROPHYLAXIS (NONOPEP) IN A SOUTH LONDON TEACHING HOSPITAL. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe10.3P10) Day S., Mears A., Bond K., Kulasegaram R. NONOPEP prescription has increased in the last six months possibly due to enhanced public awareness. NONOPEP is prescribed following predominantly "high-risk" exposures with recommended combinations. Considering two thirds recipients knew their source one should actively encourage confirmation of the source's HIV status, treatment history and surrogate markers to tailor a regimen accordingly. Follow up attendance rates are poor. |
| WePe10.3P11 | A STUDY TO EVALUATE THE AWARENESS OF HIV POST-EXPOSURE PROPHYLAXIS IN AN URBAN CLINIC POPULATION. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe10.3P11) De Silva S.1, Miller R.1, Walsh J.2 This study demonstrates that most men attending this centre are unaware of PEP as an intervention to reduce HIV transmission. This includes those at highest risk of acquiring HIV and HIV+ men having UAI with multiple partners. |
| WePe10.3P12 | RANDOMIZED TRIAL OF LOPINAVIR VERSUS EFAVIRENZ CONTAINING HAART COMBINATIONS FOR POST-EXPOSURE PROPHYLAXIS (PEP) FOLLOWING HIGH-RISK SEXUAL ACTIVITY IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe10.3P12) Torres R.1, Kassous J.1, Young T.2, Patterson J.2 Lopinavir-containing regimens for post-exposure prophylaxis following high risk sexual activity are more tolerable and adhered to than efavirenz-containing regimens. |
| WePe10.4P Harm reduction and IDU-related strategies |
|
| WePe10.4P01 | UNSTABLE HOUSING, ASSOCIATED RISK BEHAVIOUR, AND INCREASED RISK FOR HIV INFECTION AMONG INJECTION DRUG USERS. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe10.4P01) Corneil T.A.1, Kuyper L.M.2, Shoveller J.1, Hogg R.S.1, Li K.2, Spittal P.M.1, Schechter M.T.1, Wood E.2 Describing the relationships between unstable housing, HIV, and associated risk behaviours has important implications for policy makers and program planners. We add quantitative support to ethnographic and social literature describing the importance of sustainable housing as a determinant of health in IDUs. |
| WePe10.4P02 | ART AS HARM REDUCTION FOR HIV POSITIVE DRUG USERS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe10.4P02) Kuzenna O. Outcomes of the programme include the provision of ARV treatment to drug users, development of peer education and outreach projects and strengthening the capacity of organisations representing HIV positive drug users. Progress in this programme has been constrained by both programmatic and political challenges. This paper will describe both outcomes and challenges. |
| WePe10.4P03 | RELATIONSHIPS BETWEEN CHILD ABUSE EXPERIENCES AND HIV RISK BEHAVIORS IN ADULTHOOD AMONG FEMALE INJECTION DRUG USERS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe10.4P03) Plotzker R., Metzger D. The findings suggest that HIV prevention and harm reduction strategies should involve abuse counseling, in addition to targeting female survivors of abuse for preventative HIV education. |
| WePe10.4P04 | RAPID ASSESSMENT OF SITUATION ON INTRAVENOUS DRUG USE RELATED HIV/AIDS IN AZERBAIJAN. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe10.4P04) Nasibov R. Injecting drug use is increasing and make a good precondition for spreading the virus. Unfavorable socio-economic factors and availability of drugs aggravate the situation. There are many problems of drug users are unmet due to inadequate response of medical system and society in general. Rehabilitation system is at the beginning of its forming, ARV treatment is absent at all. |
| WePe10.4P05 | EFFICACY OF A VOLUNTARY HIV AND HEPATITIS PREVENTION PROGRAMME IN THE ABSENCE OF LEGAL ACCESS TO NEEDLES AND SYRINGES AMONG DRUG USERS IN UPPSALA COUNTY, SWEDEN IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe10-4P05) Sylvan S.1, Ohlén G.1, Lundell E.2, Linglöf T.2, Olsson K.3, Carlsson A.4, Nytell B.5 The data suggest that a broad co-operation between public health, medical as well as social authorities and prisons and probation administrations can effectively reach individuals with heavy or lighter drug use, inform and motivate them to HIV and hepatitis testing as well as to accept hepatitis A and B vaccination. |
| WePe10.4P06 | NEED OF SENSITIZATION FOR MEDIA PERSONNEL ON RESPONSIBLE JOURNALISM IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe10-4P06) Razi K. A well planned intervention strategy should be chalked out to sensitize the media personnel for promoting responsible journalism especially for such type of delicate and sensitive issues. |
| WePe10.4P07 | HARM REDUCTION AND IDU-RELATED STRATEGIES IN FAISALABAD PAKISTAN IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe10-4P07) Akhtar A.1, Aslam M.1, Rehman K.2 This strategy proved to be very effective to decrease the risk factors, not only of the target individual but also the whole family, which is a part general population. |
| WePe10.4P08 | IDENTIFYING PROXY INDICATORS FOR AN HIV PREVENTION AND HARM REDUCTION PROJECT IN CEBU CITY, PHILIPPINES IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe10.4P08) Aquino C.1, Jereza L.2, Tac-an I.3, D'Agnes L.1 In low HIV prevalence settings, other proxy measures for HIV risk are needed to convince local leaders of threats associated with risky injecting practices, and to help create a supportive environment for improved HIV and consequently, Hepatitis C, prevention and control. |
| WePe10.4P09 | DRUG USE AND AIDS IN BRAZIL: AN ANALYSIS OF DATA COMPILED BY THE US CENSUS BUREAU IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe10.4P09) Shandera W.X. Reliable, sufficient data are available for analysis of the Brazilian epidemic among drug users. Prevalence data show limited utility in following outbreak trends. These studies however reveal declining seroprevalence among drug users in Rio de Janeiro, Sao Paolo, and Salvador. Data from Santos show continued increases in prevalence and signify a need for intensified prevention efforts in this area. The impact of immigration of uninfected users on these data is not known. |
| WePe10.4P11 | LOW THRESHOLD SERVICES AND SOCIAL REHABILITATION OF THE INJECTING DRUG USERS TO ASSURE BETTER ADHERENCE TO ANTIRETROVIRAL TREATMENT IN LITHUANIA IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe10.4P11) Caplinskas S. Strategically purposeful interventions as well as accessible and acceptable medical and social services impact safer behaviour of IDUs and provide an opportunity to expect better adherence to ARV. |
| WePe10.4P12 | TB PROPHYLAXIS/TREATMENT AMONG HIV-INFECTED DRUG USERS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe10.4P12) Bobrik A., Vasilieva N. TB control among drug using population groups can be improved by moving health services nearer to the target group and by reducing the number of barriers to health care. Low-threshold programs i.e. harm reduction sites can be effectively used for controlled administration of medications to IDUs. |
| WePe10.4P13 | EFFECTS OF A PROVIDER-INITIATED HIV PREVENTION INTERVENTION AMONG HIV+ PATIENTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe10.4P13) Fisher J.1, Fisher W.2, Cornman D.1, Amico K.R.1, Bryan A.3, Friedland G.4 HIV prevention interventions can and should be linked to treatment of HIV. |
| WePe10.4P14 | SEX AND DRUG BEHAVIORS AMONG HIV POSITIVE ACTIVE DRUG USERS POST HIV DIAGNOSIS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe10.4P14) Valverde E.E., Metsch L., Chitwood D. Findings in our study indicate that a large percentage of this population continues to engage in sexual behaviors after HIV diagnosis. "Abstinence only" initiatives may not be appropriate for this population. New modalities to engage HIV positive active drug users into drug abuse treatment need to be explored. |
| WePe10.4P15 | THE IMPACT OF SEX PARTNERS' HIV STATUS ON HIV SEROCONVERSION IN A PROSPECTIVE COHORT OF INJECTION DRUG USERS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe10.4P15) Kerr T.1, Strathdee S.2, Li K.1, Hogg R.1, Montaner J.1, Wood E.1 Having an HIV-positive sex partner was strongly and independently associated with seroconversion after adjustment for risk factors related to drug use, including syringe sharing. Our findings may aid public health workers in their efforts to identify IDUs who should be targeted with education and prevention efforts, and indicate the need for ongoing development of prevention interventions for IDU sex partners who are HIV-discordant. |
| WePe10.4P16 | FAST MONEY, SLOW SOLUTIONS: YOUNG SEX WORKERS IN OAKLAND, CALIFORNIA IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe10.4P16) Mathai S., Lockett G., Underwood N. We have presented our findings to county planning groups and started new projects targeting this population: health education within juvenile hall, case management, and drop-in centers. |
| WePe10.4P17 | THE IMPACT OF HIV INFECTION ON ABSCESSES AMONG A COHORT OF INJECTION DRUG USERS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe10.4P17) Lloyd-Smith E., Kerr T., Li K., Hogg R., Montaner J., Wood E. Abscess infections were common among IDU despite substantial harm reduction programming in this setting. Abscess infections have traditionally been under-recognized as a cause of morbidity among IDU, and the results of this study indicate the need for additional educational and structural interventions that target abscesses, particularly among HIV-infected among IDU. |
| WePe10.4P18 | RAPID ASSESSMENT AND RESPONSE (RAR) ON HIV/AIDS AMONG ROMA POPULATION IN SERBIA IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe10.4P18) Mescovic D Spreading the network of peer educators, out-reach workers, establishing functional links between Roma community and medical service providers, VCCT are some of recommended ways of targeting this population. |
| WePe10.4P19 | HIV PREVALENCE AMONG INJECTION DRUG USERS ATTENDING NORTH AMERICA'S FIRST GOVERNMENT SANCTIONED SUPERVISED INJECTION SITE IN VANCOUVER, CANADA IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe10.4P19) Tyndall M.1, Kerr T.1, Zhang R.1, Buchner C.2, Lai C.1, Montaner J.1, Wood E.1 Attendance at the SIS provides an opportunity to reduce public injecting, promote safer use of syringes, and ultimately prevent HIV transmission. The HIV prevalence (17%) is lower than reports from other IDU studies in this community, although the factors associated with HIV infection are consistent. One explanation for the lower HIV prevalence is that IDUs who are HIV negative use the SIS in order to avoid infection. Several years of additional follow-up will be required to measure the impact of the SIS on HIV incidence rates. |
| WePe10.4P20 | HARM REDUCTION STRATEGIES TO PREVENT HIV TRANSMISSION IN INJECTING DRUG USERS OF MUMBAI IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe10.4P20) Donde S. The Harm minimisation programme should be integrated with the treatment,care and support program for the injecting drug users. IDU's should also have access to the ART therapy once they are rehabilitated. |
| WePe10.5P Occupational transmission |
|
| WePe10.5P01 | HIGH RISK BEHAVIOUR AND VARIOUS PRACTICES OF TRUCK DRIVERS REGARDING HIV/AIDS AND STD IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe10.5P01) Bhalla S.1, Somasundaram C.2, Bhalla V.1, Singh S.1 It appears that in the transport industry the accepted norms of life are totally different from those of general population. Habits, addictions and visit to prostitutes are routinely crried out but its consequences are not thought of. So, it becomes necessary, how the information regarding HIV/AIDS and STD be disseminated among them. |
| WePe10.5P02 | SHARING OF RAZOR-BLADE IN SALOONS AND RISK OF SPREADING HIV IN BANGLADESH IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe10.5P02) Chanda S.K.1, Khan K.H.2 Overall awareness about occupational risk of HIV is very poor. Lack of knowledge about HIV infection and high-risk behavior is an alert for risk of spreading HIV, may contribute seriously to HIV/AIDS epidemic in Bangladesh. It emphasizes the need for target-group oriented advocacy program to create awareness among barbers and conveying information in this concern, focused on motivation and to educate barbers for practicing modern and safe shaving equipment. |
| WePe10.5P03 | WHATMAN FTA CARDS, DESIGNED FOR COLLECTION, TRANSPORT, ARCHIVING AND ISOLATION OF NUCLEIC ACIDS AT ROOM TEMPERATURE, INACTIVATE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1). IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe10.5P03) Penezina O., Neal H. Whatman FTA cards inactivate human immunodeficiency virus type 1(HIV-1) at room temperature and therefore could be safely used for collection, transport, archiving and isolation of nucleic acids from samples infected with HIV-1. |
| WePe10.5P04 | ANXIETY IN HEALTH CARE WORKERS AFTER EXPOSURE TO POTENCIALLY HIV-CONTAMINATED BLOOD OR BODY FLUIDS, OUR EXPERIENCE IN ROSARIO, ARGENTINA. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe10.5P04) Evelyn-Liardet C., Van Kooy C., Galván M.R., Galindez J. Levels of AA are higher than SA in all situations, gender, age, type of exposure and duties. However our main finding is that it was much higher in no physicians maybe because the self risk perception is higher too. Educational efforts should be made to improve knowlekge in occupational exposure. |
| WePe10.5P05 | THE IMPORTANCE OF PROFESSIONAL CATEGORY FOR OCCUPATIONAL EXPOSURE ACCIDENTS-ANALYSIS OF THE ACCIDENT REPORTING SYSTEM OF THE STATE OF SÃO PAULO-SINABIO IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe10.5P05) Ramalho M.O.1, Monteiro A.L.C.2, Cotta I.N.2, Ruiz E.A.C.2, Tayra A.2 Assessment of accidents according to the professional category is essential as a cornerstone for control action. |
| WePe10.5P06 | OCCUPATIONAL EXPOSURE TO POTENCIALLY CONTAMINATED BLOOD AND OTHERS BODY FLUIDS. OUR EXPERIENCE IN ROSARIO, ARGENTINA. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe10.5P06) Galindez J., Evelyn-Liardet C., Galván M.R. Despite educational efforts in Heath Care Settings to promote Universal Precautions OE frequently occurs. PEP should be considered based in particular situations. |
| WePe10-5P07 | ASSESSING THE RISK OF THE HEALTH CARE WORKER FOR OCCUPATIONAL TRANSMISSION OF HIV, HEPATITIS B AND C IN IBADAN, NIGERIA IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe10-5P07) Lawoyin T.1, Stringer B.2, Haines T.3, Oluwatosin A.1, Adewole I.1 HCWs are at risk for accidental splash, sharp injuries and infection yet in some workplaces there is inadequate documentation of injury, no safety policy and inadequate measures put in place to protect workers. This study underlines the need to attend to efforts, which ensure occupational safety in these facilities. |
| WePe10.5P08 | COMPLIANCE OF HEALTH CARE PROVIDERS TO THE UNIVERSAL PRECAUTIONS IN THE ERA OF HIV/AIDS: A CALL FOR INTERVENTION. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe10.5P08) Malek A., Sallam S., Hassab A., Mahfouz A., Gawad E. There is an urgent need for HIV/ AIDS related CME training program to alley anxiety due to the over estimation of occupational risk among HCPs. It should emphasis on alleviation of attitudinal barriers and improving of preventive practices to enhance compliance of HCPs to the recommended universal precautions. |
| WePe10.5P09 | OCCUPATIONAL EXPOSURES TO BLOODBORNE PATHOGENS IN BRAZIL - A NATIONAL SURVEILLANCE SYSTEM AND WORLD WIDE WEB ENABLED EXPERTS MAILING LIST. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe10.5P09) Rapparini C.1, Saraceni V.2, Machado A.A.3, Fernandes G.C.4 Evaluation of the mailing list and of the quiz results showed an important lack of basic knowledge of occupational exposures to infections pathogens. Brazil is a large country with regional diversity - in several areas there is a limited access to medical information. The advantage of mailing list is that we were able to reach a great number of participants from several regions in Brazil in a short period of time. This finding indicates the possibility of using the World Wide Web as an efficient tool to disseminate information. |
| WePe10.6P Blood Safety |
|
| WePe10.6P01 | THE RISK OF TRANSFUSION-TRANSMISSIBLE VIRAL INFECTIONS IN THE NIGER DELTA AREA OF NIGERIA IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe10.6P01) Erhabor O., Ejele O.A., Nwauche C.A. This study confirms a high prevalence of transfusion-transmissible viral infections among blood donors and describes the groups that are at risk. This calls for the immediate implementation of a mandatory universal donor screening policy for screening all blood donor units intended for transfusion, the setting up of a national blood transfusion service, run on the basis of voluntary non remunerated, low risk blood donors, and health education of the entire Niger Delta Area aimed at behavioural change from high risk behaviour that makes people vulnerable. |
| WePe10.8P Microbicides |
|
| WePe10.8P01 | MICROBICIDE TRIALS AND EDUCATION: STRATEGIES FOR COMMUNITY PREPAREDNESS AND PARTICIPATION AT NIGERIAN OIL LOCATIONS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe10.8P01) Faleyimu B.-L.1, Ubuane L.2 There is still poor information on Microbicide as a potential prevention option amongst Communities at Oil Locations in Nigeria. A culturally sensitive community-based AIDS awareness campaign, gender-sensitive prevention options education and community involvement will facilitate community mobilization towards effective preparedness for Microbicide trials in Nigeria. |
| WePe10.8P02 | EXPLORING THE USE OF COITAL DIARIES TO ENSURE VALIDITY AND ACCEPTABILITY OF MICROBICIDE USE FOR HIV PREVENTION AMONG WOMEN IN MAZABUKA, ZAMBIA IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe10.8P02) Atsbeha T.1, Pool R.2, Allen C.3, Mushanga A.4, Ross D.2 Combining quantitative and qualitative methods in the evaluation of the coital diary tool allowed for comprehension of the negotiation between traditional and medical systems of knowledge. Beyond simple validation of questionnaires and biomarkers, diaries provide a source of data generated by the participant for private behaviours such as sex. Assessment of microbicide gel acceptability and effectiveness for HIV prevention will need multiple sources of data to fully capture the levels and context of use in upcoming Phase III Trials thus inclusion of the coital diary is imperative. |
| WePe10.8P03 | ANTIVIRAL ACTIVITY OF ALKYL SULFATES AND THE SYNTHETIC DERIVATE OCTYLGLYCEROL IN HUMAN MILK FOR PREVENTION OF TRANSMISSION OF HIV-1 IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe10.8P03) Urdaneta S.1, Neely E.B.2, Stiller C.3, Berlin C.M.4, Wigdahl B.5, Isaacs C.E.6, Howett M.K.1 It is possible that greater efficacy may be achieved at higher concentration without increase in toxicity. Edible microbicides may be an option to prevent transmission of HIV-1 through ingested breast milk. |
| WePe10.8P04 | INACTIVATION OF HIV-1 IN BREAST MILK WITH CARRAGEENAN-BASED MICROBICIDES IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe10.8P04) Urdaneta S.1, Neely E.B.2, Stiller C.3, Berlin C.M.4, Wigdahl B.5, Philips D.6, Howett M.K.1 All carrageenan-based microbicides substantially inhibited infection of both cell-free and cell-associated HIV-1 in media and in breast milk with concentrations between 0.1% and 1% (10 min at 37°C). |
| WePe10.8P05 | A BROAD-SPECTRUM MICROBICIDE FROM CILANTRO WITH ANTI-VIRAL ACTIVITY IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe10.8P05) Zafar K.1, Urdaneta S.1, Odesanya T.1, Fraietta J.1, Neha B.1, Krebs F.2, Howett M.K.1 Our observations suggest that trans-2-dodecenal is a promising drug candidate for in vivo evaluation as an effective antiviral and anti-bacterial topical microbicide. |
| WePe10.8P06 | ELECTROPHORETIC FINGERPRINTING OF HIV-1-CELL INTERACTION: A NOVEL TOOL FOR DEVELOPMENT OF CHARGE BASED INTERVENTION STRATEGIES IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe10.8P06) Fairhurst D.1, Rowell R.2, Key S.3, Morfesis A.4, Monahan I.5, Mitchnick M.1, Shattock R.5 These data provide core information on the physico-chemical properties of a model cellular target for HIV-1 infection and pave the way for rational development of charge based intervention strategies designed to prevent sexual transmission of HIV-1 infection. |
| WePe10.8P07 | MICROFLORA CHANGES WITH THE USE OF A VAGINAL MICROBICIDE. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe10.8P07) Nwando O., Uju B. Use of BufferGel once or twice daily for 14 days resulted in no clinically significant change in Lactobacillus colonization. |
| WePe10.8P08 | SULFATED CHYTOZAN - HUMIC ACID DERIVATIVE COMBINATION POSSESSIVE POTENT SYNERGISM AGAINST HIV IS AVAILABLE FOR THE DEVELOPMENT OF MICROBICIDES IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe10.8P08) Kornilaeva G., Pavlova T., Karamov E. Combination of SCh and HAD demonstrates strong synergism inhibiting HIV infection. The IC90 of SCh - HAD combination are 4000 and 760 times lower as compared with IC90 of these compounds used alone. |
| WePe10.8P09 | PHASE I SAFETY AND ACCEPTABILITY STUDY OF 0.5% PRO 2000 VAGINAL GEL AMONG HIV UN-INFECTED WOMEN IN PUNE, INDIA IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe10.8P09) Reynolds S.J.1, Dutta S.2, Joglekar N.2, Panchanadikar A.2, Bell B.3, Profy A.4, Kuruc J.3, Kwiecien A.3, Fang G.5, Cianciola M.5, Soto-Torres L.6, Risbud A.2, Mehendale S.2, Joshi S.2 Twice-daily use of 0.5% PRO 2000 Gel appears to be safe in HIV-uninfected women from Pune, India. Acceptability was high among all participants. Safety and acceptability will continue to be monitored carefully in ongoing efficacy trials. |
| WePe11.3 Prices of Drugs |
|
| WePe11.3C01 | SUPPLYING ARV DRUGS : AN INVESTIGATION OVER 18 AFRICAN FRANCOPHONE COUNTRIES DURING THE 3TH QUARTER 2004 IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe11.3C01) Boisseau C.1, Bruneton C.2, Rey J.-L.3, Degui H.4 Scalling up antiretroviral therapy is still a challenge for african countries, and therefore for PLWHA. Most of the efforts has focused to the management of care. But, today, the organization of the procurement and the supply chain are not still adapted to this challenge. After this investigation, ESTHER has implemented a project to support both treatments sites and the central level to organize ARV procurement and supply management. |
| WePe11.3C02 | AFFORDABILILTY OF ANTI-RETROVIRAL DRUGS (ARV) AMONG HIV-POSITIVE PERSONS IN RURAL AREAS OF ONDO STATE, SOUTH-WEST NIGERIA IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe11.3C02) Ogunro P1, Adeneye A.K.2, Adewole T.A.2, Ogunbamigbe T.3, Musa A.2, Oparinde D.1 Overall, most respondents who knew the benefits lauded ARV provision. Nonetheless, the drugs need be made affordable particularly for the majority earning low income to enhance accessibility. The results offer insights for ARV programme planning and operationalisation emphasizing the benefits and reducing stigmatisation. |
| WePe11.3C03 | TRENDS IN THE COST OF HIV MANAGEMENT: 1995 TO 2004 IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe11.3C03) Bernal J.A., Romero S.P., Escobar M.A., Garcia-Egido A.A., Gomez-Soto F., Fernandez F.J., Puerto J.L., Ruiz P., Gomez F.A. HIV patients on HAART not only had considerably less admissions to hospitals and milder HIV-associated complications but, an important global general management cost reduction in the short term (1-3 years) after initiation of HAART-PI. Although, clinical benefits persit after 7 years of therapy, global healthcare savings tent to decrease afterwards due to enhanced costs of pharmacy and laboratory tests. |
| WePe11.3C04 | EXPENDITURES AND COST-EFFECTIVENESS OF HAART IN MILITARY HIV-IINFECTED PATIENTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe11.3C04) Gutiérrez J.W.1, Shor-Posner G.2, Miguez Burbano M.2 These findings confirm the results showed by other studies that the morbidity and mortality decreased when we used the combination therapy. Indeed, the impact of HAART has improved the quality of life of the patients affected by AIDS and increased the survival. |
| WePe11.3C05 | COST OF SCALING-UP HAART FOR DEVELOPING AND MIDDLE-INCOME COUNTRIES. RESULTS OF A SURVEY CONDUCTED IN TEN MSF PROJECTS. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe11.3C05) Pascual F.1, Berman D.2, Thorn P.1, Perez C.3 There is little consistency of prices paid today for ARVs. The prices paid today by developing and middle-income countries for newer ARVs will render any scale-up impossible unless more quality generic sources are made available. |
| WePe11.3C07 | THE ESTIMATED COST OF PROVIDING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) IN SUB-SAHARAN AFRICA FOR THE YEARS 2007-15. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe11.3C07) Grimes R.M.1, Woeber S.2 This study points out the both the high cost of HAART and the enormous advantage of using generic HAART drugs in Africa. |
| WePe11.5 Cost-benefit of HAART |
|
| WePe11.5C01 | THE ROLE OF DAY-HOSPITAL CARE OF HIV DISEASE, NINE YEARS AFTER HAART INTRODUCTION IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe11.5C01) Manfredi R., Calza L., Chiodo F. Although DH resources did not vary, during the past decade an enlargement of disease spectrum, and an increase of absolute number of hospitalizations and occupancy and turnover rates, were found.A permanent monitoring of health care provisions at ID DH, may contribute to ensure adequate assistential planning, and resources allocation. |
| WePe11.5C02 | CLINICAL OUTCOMES AND COST SAVINGS ASSOCIATED WITH DISCONTINUATION OF THERAPY IN HIV IN HIV PATIENTS TREATED WITH HAART WHO NEVER MET CURRENT DHHS TREATMENT GUIDELINES IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe11.5C02) Keiser P.1, Armas L.2, Nassar N.1, Sanchez J.2, Sandoval J.2, Moreno S.2, McIntosh N.2 Discontinuation of therapy in patients who never met DHHS treatment guidelines appears to be safe with similar virologic, immunologic changes, no increase in health care utilization and is associated with significant cost savings. |
| WePe11.5C03 | SIX MONTH COST ANALYSIS OF FUZEON (ENFUVIRTIDE) IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe11.5C03) Howell S. The addition of Fuzeon (enfuvirtide) to HAART has marginal pharmacy costs as an fourth antiretroviral agent in salvage HAART. Despite the addition pharmacy costs there is a significant five time reduction in HIV/AIDS specific inpatient admission costs, a 60% reduction in outpatient claims and 20% reduction in medical claims. In the short term the use of Fuzeon (enfuvirtide) has both clinical and financial impacts. |
| WePe11.5C04 | COST-BENEFIT OF HAART AND ITS POTENTIAL FISCAL SAVINGS WITHIN THE PUBLIC SECTOR IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe11.5C04) Fieno J. The cost of the AIDS epidemic for the state is already high without treatment. The cost-benefit analysis demonstrates that the total cost of HAART is lower than originally thought, which offers a ray of hope. The Millennium Development Goals will never be achieved if the AIDS epidemic exhausts the medical and teaching corps of high HIV-prevalence countries as expected. The introduction of HAART can reverse this process and make these development goals attainable. |
| WePe12.1 Treatment of primary HIV infection |
|
| WePe12.1C01 | TIMES TO REACHING UNDETECTABLE VIRAL LOAD AND REBOUND FOR PERSONS TREATED DURING PRIMARY AND CHRONIC HIV INFECTION IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.1C01) Porter K., Bhaskaran K. Persons initiating HAART in more recent calendar years appear more likely to achieve viral suppression but also, surprisingly, more likely to experience a rebound. The higher chance of viral rebound following initiation of HAART in early infection may negate the results of higher chance of suppression during that time. Rebound may be more likely because persons initiating early in infection may be more likely to discontinue therapy. This will be investigated in further analyses. |
| WePe12.1C02 | LONG-TERM VIROLOGICAL AND IMMUNOLOGICAL EFFECTS OF HAART INITIATED IN THE FIRST 12 MONTHS AFTER HIV-1 SEROCONVERSION IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.1C02) Touloumi G.1, Pantazis N.1, Porter K.2 These results indicate that the effect of early HAART on CD4 and viral load may persist for about 5 years after which it appears to be reduced. Any beneficial effect on disease progression remains questionable. |
| WePe12.1C03 | TENOFOVIR IN NUCLEOSIDE-RESISTANT HIV-1 INFECTION: RESULTS FROM A 48- WEEK, OBSERVATIONAL, DESCRIPTIVE STUDY. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.1C03) Fernández Lisón L.C.1, Garrido Martínez M.T.1, Rodríguez-Gómez F.J.2, Lomas Cabezas J.M.2, Hevia Alonso A.3, Pujol de la Llave E.2 Tenofovir supposes an antiretroviral of high effectiveness in our hospital, with an optimum safety profile and an expected cost in a medium level within the HAART. |
| WePe12.1C05 | NAÏVE PATIENTS ANTIRETROVIRAL THERAPY: DIFFERENT REGIMENS SIMILAR OUTCOMES IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.1C05) Casotti J.A.S., Passos L.N., Feitosa D.S., Abrantes F.D.A., Pimentel T.D.C., Brasil A.A., Rodrigues M.M., Reuter T. All different regimens of HAART studied showed the same efficacy to suppress the VL and to recover the immune system over a period of 24 weeks. |
| WePe12.2 Initiation of therapy |
|
| WePe12.2C01 | IMMUNOLOGIC STATUS AT TIME OF INITIAL EVALUATION AT A UNIVERSITY HOSPITAL HIV CLINIC IN THE SOUTHEASTERN U.S.: CONSEQUENCES OF DELAYED DIAGNOSES. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.2C01) Mugavero M., Castellano C., Hicks C. Late diagnosis of HIV infection is a significant problem in North Carolina. Most patients establishing care at our clinic in recent years were diagnosed after having passed an important CD4 threshold for consideration of HAART initiation and nearly half were not diagnosed until after reaching the point at which preventive therapy for PCP is indicated. These results were true for all risk groups and did not differ significantly by socio-demographic characteristics. These findings suggest the need for improved approaches to HIV diagnosis for all groups. |
| WePe12.2C02 | DISCORDANT IMMUNOLOGICAL AND VIROLOGICAL RESPONSES TO HAART IN ARV NAÏVE HIV INFECTED INDIVIDUALS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.2C02) Sullivan A.K., Mandalia S., Tung M.-Y., Nelson M.R., Gazzard B.G. 24.9% of patients experience a discordant response at 12 months, affected by age, CD4 count, VL and rate of CD4 decline. DIR and DVR have a good treatment outcomes at 24 months. A less than 50 CD4 cell rise is more predictive of disease progression than a positive VL. |
| WePe12.2C03 | THE EFFECT OF YEAR OF TREATMENT AND NUCLEOSIDE ANALOGUE BACKBONE ON DURABILITY OF NNRTI BASED REGIMENS. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.2C03) Annan T., Mandalia S., Bower M., Gazzard B., Nelson M. We have shown in a large NNRTI-experienced cohort, that although in univariate analysis efavirenz appears to have a higher success rate, this is explained by differences in backbone and year. This may explain differences between reported cohort studies and the 2NN study. |
| WePe12.2C04 | THREE ONCE-A-DAY REGIMENS AS FIRST-LINE HAART IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.2C04) Maggiolo F.1, Ripamonti D.1, Migliorino G.2, Martinelli C.3, Sighinolfi L.4, Gregis G.1, Quinzan G.1, Abeli C.2, Airoldi M.1, Suter F.1 The studied once-a-day regimens show an high virologic efficacy and are well tolerated. In the case of virologic failure the resistance mutation pattern is highly influenced by the choice of NRTIs and about a third of the patients do not present any NNRTI related mutation. Once-a-day therapy favor adherence. |
| WePe12.2C05 | SIMPLICITY AND EFFICACY OF A ONCE-DAILY ANTIRETROVIRAL REGIMEN WITH DIDANOSINE (DDI), LAMIVUDINE (3TC) AND EFAVIRENZ (EFV) IN NAÏVE PATIENTS. THE VESD STUDY IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.2C05) Santos J.1, Palacios R.1, López M.2, Gálvez M.C.3, Lozano F.4, de la Torre J.5, Ríos M.J.6, López-Cortés L.F.7, Rivero A.8, Torres M.9 ddI-3TC-EFV administrated QD is an efficacious and safe regimen in naïve patients in a real life situation, even in immunosuppressed subjects and those with a high viral load. Associated adverse effects and virological failures were few. |
| WePe12.2C06 | EARLY SAFETY, TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ONCE DAILY (QD) LOPINAVIR/RITONAVIR (LPV/R) + TENOFOVIR (TDF) + LAMIVUDINE (3TC) AMONG HIV-INFECTED AFRICAN-AMERICAN MEN AND WOMEN NAÏVE TO HIV THERAPY - THE AAQD STUDY IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.2C06) Wohl D.1, Menezes P.1, Torres R.2, Vollmer K.3, Taiwo B.4, Avots M.1, Haley D.1, Golin C.1, Theodore D.1, Stephenson B.1, Rublein J.5, Kashuba A.1 Once daily TDF+3TC+LPV/r in AA pts with high prevalence of substance abuse and homelessness was effective at reducing HIV viral load. Preliminary PK data suggest no large differences in LPV concentration among AA pts compared to data from a diverse cohort. |
| WePe12.2C07 | THE LIFETIME COST OF HIV CARE IN THE UNITED STATES IN THE CURRENT TREATMENT ERA IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.2C07) Schackman B.R.1, Gebo K.A.2, Walensky R.P.3, Losina E.4, Muccio T.3, Sax P.E.5, Weinstein M.C.6, Seage G.R.3.6, Moore R.D.2, Freedberg K.A.3 Effective ART regimens have substantially improved survival and have greatly increased the lifetime cost of HIV-related medical care in the U.S. Antiretroviral drug costs and time of ART initiation play the most important roles in determining total lifetime cost. |
| WePe12.2C08 | LONG-TERM IMMUNOLOGICAL AND VIROLOGICAL RESPONSE TO HAART IN NON-CLINICAL TRIAL SETTING OF A DEVELOPING CARIBBEAN COUNTRY. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.2C08) Kilaru K.1, Kumar A.2, Sippy N.1, Carter A.2, Roach T.1 There was good immunologic and virologic response at 18 months after starting HAART despite low baseline CD4 cell counts in majority of patients. Virological Success was significantly higher in patients with adherence level above 90% and on NNRTI based regimens. Female gender and a baseline CD4 cell count of <50cells/ml were associated with significantly higher increases in CD4 cell counts. |
| WePe12.2C09 | NAÏVE PATIENTS BEGINNING HAART IN 2001 AND 2002 IN THE FRENCH HOSPITAL DATABASE ON HIV: COMBINATIONS PRESCRIBED AND VIROLOGICAL OUTCOMES. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.2C09) Costagliola D.1, Potard V.1, Rey D.2, Mokhtari S.3, Frison-Marin V.4, Pradier C.5, Rozenbaum W.6, Brun-Vezinet F.7 For first-line therapy, in this observational setting, EFV and LPV/r offered the best opportunity to achieve viral load below 500 copies/ml, whatever the level of baseline HIV-RNA after accounting for the propensity of receiving each ARV. |
| WePe12.2C10 | NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTI) DUAL DRUG REGIMEN IN THE ERA OF HAART IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.2C10) Selinger-Leneman H.1, Abgrall S.2, Mahamat A.3, Moreau J.4, Matheron S.5, Costagliola D.1 Patients with controlled HIV infection (no ADE, CD4>500, VL<500) were more likely to remain on ddr, as were patients initiating ddr before 1995, suggesting that these patients had a low need of ARV therapy when ddr was initiated. Two kinds of patients stopped completely ARV therapy: patients with high level of CD4 at initiation of ARV treatment, and patients with progressive HIV infection. |
| WePe12.2C11 | ACCURACY OF WORLD HEALTH ORGANISATION'S 2002 AND 2003 CRITERIA TO START HAART IN ABSENCE OF CD4 COUNT. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.2C11) Thai S.1, De Munter P.1, Jacques G.1, Van den Ende J.2, Schrooten W.3, Lynen L.2 Passing from the 2002 to the 2003 guidelines, results in a shift from high specificity to high sensitivity. The overall accuracy improves in this setting due to the predominance of advanced disease. TLC does not offer an additional benefit with the use of the 2003 guidelines to identify patients needing HAART. |
| WePe12.2C12 | INITIATION OF THERAPY WITH A SUBCUTANEOUSLY ADMINISTERED ANTIRETROVIRAL IN TREATMENT-EXPERIENCED HIV-INFECTED PATIENTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.2C12) Horne R.1, Fisher M.2 Physicians apply additional criteria when selecting suitable patients, beyond clinical factors, when initiating treatment with a subcutaneous agent such as enfuvirtide. This study identified a potentially important mismatch between physician and patient perceptions of subcutaneous therapy. Although the findings are limited by the qualitative methodology, they justify a more extensive study to quantify physician and patient perceptions and identify the prevalence and consequences of mismatch. |
| WePe12.2C13 | OUTCOMES OF PREVIOUSLY ANTIRETROVIRAL-NAÏVE PATIENTS RECEIVING KALETRA IN A SINGLE TREATMENT CENTRE IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.2C13) Smith C.1, Phillips A.1, Sabin C.1, Youle M.2, Lampe F.1, Johnson M.2 ART-naïve Patients in our clinic generally experience a good response to Kaletra. |
| WePe12.2C14 | ONCE DAILY HAART ACHIEVES MORE DURABLE VIROLOGIC SUPPRESSION THAN TWICE DAILY HAART IN AN AMBULATORY CLINIC, URBAN COHORT. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.2C14) Munsiff A.1, Byrne S.2, Kadakia H.3, Boyle B.4 Treatment with once-daily ART led to higher rates of virologic suppression, lower rates of viral rebound, and higher rates of adherence than treatment with twice-daily. |
| WePe12.2C15 | VIROLOGICAL DYNAMICS IN HIV-1-ASSOCIATED CNS-DISEASE IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.2C15) Arendt G.1, Loeffert S.1, Nolting T.1, Husstedt I.-W.2, Koutsilieri E.3, Maschke M.4, Sopper S.5, Riederer P.3, ter Meulen V.6 The data point to the virus opening BBB in early stages, where patients usually are not treated, invading the CNS and replicating there continuously at least in some individuals after therapy start and BBB closing up again. If these data can be verified in more patients, there would be a clear argument for integrating lumbar puncture in therapy start and therapy interruption decision making in HIV-1-positive individuals. |
| WePe12.2C16 | RESPONSE TO TREATMENT IN NON-B SUBTYPE HIV-1 NAÏVE PATIENTS IN LIGURIA, ITALY, FROM 1999 TO 2004 IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.2C16) Icardi G.1, Ventura A.1, Setti M.2, Bruzzone B.1, Calderisi S.1, Caligiuri P.1, Murdaca G.2 In western countries the most prevalent circulating HIV-1 strains are of clade B subtype of M type. Recent studies showed increasingly frequent detection of non-B clades and recombinant circulating forms (CRFs) with possible diagnostic and clinical implications. In this study, the prevalence of non-B clades and the response to HAART in a group of naïve HIV-1 positive patients have been evaluated. |
| WePe12.2C17 | WHO STAGE DEFINING CLINICAL CONDITIONS ASSOCIATED WITH UNDERESTIMATION OF THE NEED TO START HAART IN WHO 2002 AND 2003 GUIDELINES WHEN USING ONLY CLINICAL CRITERIA IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.2C17) Thai S.1, De Munter P.1, Arnould L.2, Jacques G.1, Huyst V.2, Van den Ende J.2, Schrooten W.3, Lynen L.2 Including WHO stage 3 in the clinical criteria to start HAART (2003 guideline) removed most of the false negatives between clinical criteria and CD4. The exclusion of patients with stage 2 based on herpes zoster and weight loss < 10% may not be justified. If herpes zoster would be considered a stage 3 condition, the sensitivity of the 2003 clinical criteria would approach 100% in our setting. |
| WePe12.2C18 | RATES OF VIRAL SUPPRESSION AND REGIMEN CHANGE ACCORDING TO INITIAL HAART REGIMEN. A COLLABORATIVE ANALYSIS OF 12 PROSPECTIVE COHORT STUDIES IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.2C18) Hogg R.1, Lundgren J.2, Costagliola D.3, D'Arminio Monforte A.4, Ledergerber B.5, de Wolf F.6, Fusco G.7, Staszewski S.8, Chene G.9, Phillips A.10, Gill J.11, Schmeisser N.12, May M.13, Sterne J.13, Egger M.14 Differences between regimens that are shown here could be due to unexplained heterogeneity or to variations in treatment use across cohorts. |
| WePe12.2C19 | INITIATION OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) IN ADVANCED NAÏVE SUBJECTS WITH NEUROLOGICAL DISORDERS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.2C19) Trotta M.P.1, Lorenzini P.1, Cingolani A.2, Bossolasco S.3, Larussa D.1, Moretti F.4, Bongiovanni M.5, Finazzi M.G.6, De Marco M.1, Vigo B.7, Mussini C.8, Ammassari A.2, d'Arminio Monforte A.5, Cinque P.3, Antinori A.1 Among advanced naïve patients with CNS-D, favorable outcomes was obtained after starting HAART. The initial drop in plasma viremia was strongly associated to subsequent virological response, whereas early immunological response indicates a good immunological and clinical outcome. |
| WePe12.2C20 | AN OBSERVATIONAL COHORT COMPARISON OF ZIDOVUDINE-LAMIVUDINE-EFAVIRENZ VS. TENOFOVIR-LAMIVUDINE-EFAVIRENZ IN ANTI-RETROVIRAL NAÏVE PATIENTS IN A LARGE URBAN CLINIC. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.2C20) Keiser P.1, Nassar N.1, Armas L.2, Sanchez J.2, Sandoval J.2, Moreno S.2 There was similar efficacy between tenofovir-lamivudine-efavirenz and zidovudine-lamivudine-efavirenz at 48 weeks in anti-retroviral naïve patients. |
| WePe12.2C21 | SHORT-TERM ADDITION OF LOPINAVIR/R DOES NOT ENHANCE THE ANTIRETROVIRAL ACTIVITY OF TFV/DDI/EFV IN NAÏVE PATIENTS WITH CD4 >200, BUT IS ASSOCIATED WITH A VIROLOGIC RESPONSE IN THOSE WITH LOWER CD4 COUNTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.2C21) Ferrer E.1, Niubo J.1, Podzamczer D.1, Gatell J.M.2, Maños M.1, Ruiz I.1, Dalmau D.3, Leon A.2, Knobel H.4, Polo C.1, Iniguez D.1 This small pilot study suggests that in pts with CD4>200, the short-term addition of lopinavir/r to a TFV/ddI/EFV regimen, does not confer a virologic/immunologic benefit. However, in pts with CD4<200 receiving a TFV/ddI as a backbone, the use of EFV+LPV/r is associated with a virologic response. |
| WePe12.2C22 | RELATIONSHIP BETWEEN MORPHOLOGICS CHANGES AND IMMUNE STATUS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.2C22) Martinez-Lopez E.1, Perez-Alvarez N.2, Negredo E.2, Canton A.1, Estany C.2, Clotet B.2, Sanmartí A.3 1. The worse the baseline immune status of patients, the lower fat and lean mass. 2. The introduction of antiretroviral therapy led to a quicker progression to lipoatrophy in subjects with lower baseline CD4 cell counts. |
| WePe12.2C23 | EFFICACY AND SAFETY OF ONCE-DAILY ABACAVIR/LAMIVUDINE FIXED-DOSE COMBINATION (ABC/3TC) + EFAVIRENZ (EFV): ESS30009 PLANNED 48 WEEK ANALYSIS. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.2C23) Gallant J.1, Rodriguez A.2, Weinberg W.3, Young B.4, Berger D.5, Lim M.6, Liao Q.6, Ross L.6, Johnson J.6, Shaefer M.6 ABC/3TC + EFV is an effective and well-tolerated once-daily regimen with a very low pill-burden. TDF + ABC/3TC should not be used as a three-drug regimen in naïve patients. Many subjects who initially received TDF + ABC/3TC and remained in follow-up on an SLR subsequently achieved suppression, although over one-third of this cohort had VL <400 c/mL at time of switch. |
| WePe12.2C24 | EFFICACY AND SAFETY OF A COMBINATION OF LOPINAVIR AND EFAVIRENZ OR NEVIRAPINE IN A NUKE FREE REGIMEN IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.2C24) Trein A.1, Langmann P.2, Zilly M.2, Klinker H.2, Schnaitmann E.1 The combination of LPV/r and EFV or NVP demonstrates high potency over 36 weeks.The therapy is generally well tolerated.Trough plasma levels were save over 36 weeks while taking the recommended dosage. |
| WePe12.2C25 | BASELINE CHARACTERISTICS OF PATIENTS ON HAART AT HOSPITAL NACIONAL CAYETANO HEREDIA, LIMA - PERU. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.2C25) López de Castilla D., Maldonado F., Gonzales E., Zamudio C., León J., Echevarria J., Seas C., Gotuzzo E. HAART was started in our hospital mainly among young men with severe immunosupression and substantially high viral loads. |
| WePe12.2C26 | COMPARATIVE ANALYSIS OF THE CLINICAL, IMMUNOLOGICAL AND VIROLOGICAL OUTCOMES OF INITIAL HAART BASED ON EFAVIRENZ OR RITONAVIR/LOPINAVIR IN THE CLINICAL SETTING. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.2C26) Moreno A., Perez-Elias M.J., Lopez D., Antela A., Casado J.L., Dronda F., Quereda C., Navas E., Fortun J., Moreno S. Despite a more advanced disease, initial r/LPV-based HAART yielded similar clinical, immunological and virological outcomes when compared to EFV-based regimes. Although toxicity was the most frequent reason to treatment change (77%), virological failure was more frequently among EFV patients. Both therapies showed similar durability. |
| WePe12.2C27 | EFFICACY AND SAFETY OF A QD REGIMEN (DIDANOSINE, LAMIVUDINE AND EFAVIRENZ) AS INITIAL THERAPY IN HIV-INFECTED PATIENTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.2C27) Sanchez-Conde M.1, Asensi V.2, Sanz J.3, Santos J.4, Palacios R.4, Sola J.5, Estrada V.6, Gonzalez-Lahoz J.1, Soriano V.1 A QD regimen based on ddI+3TC+EFV may shows potency and tolerance similar to that reported using other currently recommended triple antiretroviral regimens in drug-naïve patients. The efficacy of this regimen is not modified when administered with food. |
| WePe12.2C28 | FACTORS ASSOCIATED WITH DISCORDANT IMMUNOLOGICAL RESPONSE IN HIV PATIENTS TREATED WITH THE FIRST HAART REGIMEN IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.2C28) Tamargo L., Torralba M., Rubio R., Moreno V., Pulido F., Costa J.R., del Palacio A. Discordant response is associated in the first year in our study with higher age, chronic elevation of ALT/AST liver enzymes, lower VL pre-HAART and the use of NNRTI as the initial regimen. |
| WePe12.2C29 | EARLY HIGHLY ACTIVE ANTIRETROVIRAL THERAPY REDUCES THE RISK OF NON AIDS RELATED DEATH IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.2C29) Puoti M.1, Prestini K.1, Patroni A.1, Donato F.1, Gelatti U.2, Torti C.1, Quiros Roldan E.1, Paraninfo G.1, Moretti F.1, Forleo M.A.1, Nasta P.1, Casari S.1, Carosi G.1 An early start of HAART seem to be associated with a lower risk of non AIDS related death. |
| WePe12.3 Treatment simplification |
|
| WePe12.3C01 | FTC IN AN OUTPATIENT GROUP: SWITCH OF A STABLE VIRUS-CONTROLLED ART TO A FTC-CONTAINING REGIMEN IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.3C01) Fenske S. FTC as part of a combination therapy is a well tolerated and safe drug. There are no virological failures during the obervation period. |
| WePe12.3C02 | RANDOMIZED CONTROLLED TRIAL OF ONCE DAILY (QD) TENOFOVIR (TDF), 3TC AND LOPINAVIR/RITONAVIR (LPV/R) VERSUS REMAINING ON THE SAME REGIMEN IN HIV-INFECTED PATIENTS VIROLOGICALLY SUPPRESSED ON THEIR FIRST PI-CONTAINING HAART REGIMEN IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.3C02) Loutfy M.1, Baril J.G.2, Conway B.3, DeWet J.3, Trottier B.4, Thompson B.5, Martel A.6, Trottier S.7, Rouleau D.8, Shafran S.9, Rachlis A.1, Fraser C.1, Smaill F.10, Walmsley S.1, Montaner J.3, Kovacs C.11 Switching to a QD regimen of TDF+3TC+LPV/r resulted in similar viral responses in HIV-infected patients already virologically suppressed on their first PI-containing regimen compared to remaining on the same regimen. Switching to QD TDF+3TC+LPV/r led to minor GI AEs, but they both occurred and resolved early. If viral rebound did occur, it occurred early allowing for an immediate switch. |
| WePe12.3C03 | CAN EFAVIRENZ BE TAKEN IN THE MORNING? IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.3C03) Skeie L., Maeland A. Half of our patients on EFV evening dosing tolerated switching to morning dosing. Patients with sleeping difficulties, morning drowsiness or low adherence may benefit from switching to morning dosing of EFV. |
| WePe12.3C04 | NFV (625 MG NEW FORMULATION) BOOSTED WITH RTV ONCE DAILY IS NOT AN OPTION AS COMPARED TO TWICE DAILY REGIMEN. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.3C04) Landman R.1, Peytavin G.2, Descamps d.2, Yeni P.3, Katlama C.4, Dellamonica P.5, Girard P.M.6, Lafeuillade a.7, Reynes J.8, Trepo C.9, Michelet C.10, Lamotte c.2, Brun Vezinet F.2 A switch to NFV new formulation BID allowed a daily pills reduction and virological efficacy. NFV/RTV QD shows a slight increase in mild to moderate diarrhea and triglycerides, a lower Cmin, a lower virological efficacy and a higher switch or stop treatment rate as compared to NFV BID. |
| WePe12.3C05 | Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression. A randomized, controlled, open label, pilot, clinical trial (OK Study): 48 weeks analysis IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.3C05) Arribas J.R.1, Pulido F.2, Delgado R.2, Paño J.R.1, Lorenzo A.1, Miralles P.3, Arranz A.4, González-García J.1, Cepeda C.2, Hervás R.2, Montes M.L.1, Costa J.R.2, Peña J.M.1 Most of the patients maintained with L/r MT remain with undetectable viral load after 48-weeks. Failures of L/r MT were not associated with the development of primary resistance mutations in the protease gene and could be successfully reinduced adding-back prior nucleosides. |
| WePe12.3C06 | RISK FACTORS FOR LOSS OF VIROLOGICAL SUPPRESSION AT 48 WEEKS IN PATIENTS RECEIVING LOPINAVIR/RITONAVIR MONOTHERAPY IN THE OK CLINICAL TRIAL. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.3C06) Pulido F.1, Arribas J.R.2, Delgado R.1, Paño J.R.2, Lorenzo A.2, Miralles P.3, Arranz A.4, González-García J.2, Cepeda C.1, Hervás R.1, Montes M.L.2, Costa J.R.1, Peña J.M.2 Suboptimal adherence and a short time with undetectable viral load before monotherapy (probably also a proxy for suboptimal adherence) appear to be the main risk factors for losing virological suppression in patients randomised to MT with L/r. |
| WePe12.3C07 | THREE ONCE-A-DAY REGIMENS FOR SIMPLIFIED HAART IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.3C07) Maggiolo F., Ripamonti D., Gregis G., Quinzan G., Ravasio L., Airoldi M., Arici C., Suter F. The studied once-a-day regimen show an high virologic efficacy and are well tolerated. A simplification strategy to OD regimens may improve adherence to HAART and may reduce the metabolic burden induced by PI-based regimens. |
| WePe12.3C08 | LONG TERM OUTCOME OF SIMPLIFICATION OF ANTIRETROVIRAL TREATMENT AT A HOSPITALARY HIV CARE UNIT IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.3C08) Redondo C., Poza G., Galera C., Aroca P., Aguirre C. 1. Simplification of antiretroviral treatment with abacavir or NNRTIs is safe at long term in clinical practice. 2. Lipid profile improves with implification. 3. Virological failure is related to NRTIs use prior to HAART and if it happens it is during the first two years. |
| WePe12.3C09 | IMPACT OF RACE ON THE EFFICACY AND OCCURRENCE OF NERVOUS SYSTEM SYMPTOMS (NSS) IN HIV-INFECTED SUBJECTS FOLLOWING A SWITCH FROM A PROTEASE INHIBITOR (PI) TO AN EFAVIRENZ (EFV)-BASED REGIMEN IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.3C09) DeJesus E.1, Espinoza L.2, Sension M.3, Porter K.4, Maa J.4, Wang S.4, Seekins D.4 Continued viral suppression following a switch from a PI to an EFV-based regimen at Week 24 did not differ between white, black and Hispanic subjects. NSS were mild and occurred predominantly within the first four weeks after switching to EFV and were similar across all racial groups. |
| WePe12.3C10 | EARLY VIRAL REBOUND AFTER ENFUVIRTIDE DISCONTINUATION IN HIV-INFECTED PATIENTS ON LONG LASTING VIRAL SUPPRESSION IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.3C10) Bonjoch A.1, Puig J.1, Miranda C.1, Erkizia I.2, Perez N.1, Puig T.2, Ruiz L.2, Clotet B.3 Despite the sustained viral suppression in our pts, discontinuation of ENF shows a risk of early viral rebound. No differences between CD8+/CD38+ cells nor active drugs at baseline were detected in our patients regarding the maintenance of viral suppression at 12 weeks after ENF discontinuation. |
| WePe12.3C11 | SAFE AND EFFECTIVE SWITCH TO A TRIPLE NUCLEOSIDIC REVERSE TRANSCRIPTASE INHIBITORS REGIMEN IN A SUCCESSFULLY PRE-TREATED FRENCH HIV-INFECTED POPULATION. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.3C11) Cuzin L.1, Foucher Y.2, Agher R.3, Barone M.1, Billaud E.4, Daures J.2, Dellamonica P.5, Druart P.6, Duvivier C.3, Enel P.6, Jovelin T.4, Katlama C.3, Marchou B.1, Poizot-Martin I.6, Raffi F.4, Salmi D.7, Pugliese P.5 In this population of carefully selected patients, changing a successful HAART to a simple triple nucleosidic regimen (ZDV/3TC/ABC) is safe and effective, allowing a sustained increase in CD4 cells. |
| WePe12.3C12 | ONCE-DAILY VS. TWICE-DAILY LOPINAVIR/RITONAVIR IN ANTIRETROVIRAL-NAÏVE PATIENTS: 96-WEEK RESULTSv IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.3C12) Molina J.M.1, Wilkin A.2, Domingo P.3, Myers R.4, Hairrell J.5, Naylor C.5, Podsadecki T.5, King M.5, Hanna G.5 Through 96 weeks, a QD LPV/r-based regimen demonstrated similar (noninferior) antiviral activity and CD4 increases in antiretroviral-naïve patients compared to a BID LPV/r-based regimen. While a higher incidence of diarrhea was observed in the QD group, both regimens were well tolerated, and no protease inhibitor or tenofovir resistance was observed. |
| WePe12.3C13 | EFAVIRENZ AND DIDANOSINE ASSOCIATED WITH LAMIVUDINE OR TENOFOVIR AS ONCE-DAILY THERAPY IN CLINICAL PRACTICE. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.3C13) Knobel H.1, Arazo P.2, Teira R.3, Pedrol E.4, Pascual A.2, Santamaría J.M.3, Rubio M.5, Bisbe J.6, Domingo P.7, Cucurull J.8 Therapy based on EFV+ddI+3TC seems to be highly effective and well tolerated in different clinical practice scenarios; EFV+ddI+TDF should be used with caution and only in selected patients. |
| WePe12.3C14 | CLINICAL AND VIROLOGICAL OUTCOMES FOLLOWING SWITCH FROM A FIRST PROTEASE INHIBITOR (PI) CONTAINING HAART TO A THREE- (TDR) OR FOUR-DRUG REGIMEN (FDR) WITH EITHER EFAVIRENZ (EFV) OR NEVIRAPINE (NVP) AND/OR ABACAVIR (ABC). IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.3C14) Abgrall S.1, Yeni P.2, Bouchaud O.3, Costagliola D.4 Among pts with undetectable spVL, ABC was associated with a better clinical outcome, but a worse VO probably due to previous acquisition of NRTI resistance among ARV-experienced pts. Among pts with detectable spVL, FDR was associated with a better clinical outcome. NVP was associated with a worse VO in all groups of pts. |
| WePe12.3C15 | BOOSTED PI TO NVP SWITCH IN ADVANCED HIV DISEASE - INTEGRATING/ POTENCY, SIMPLIFICATION AND COST REDUCTION: A PILOT STUDY IN RESOURCE RESTRICTED SETTINGS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.3C15) Sawleshwarkar S.1, Vaidya S.2, Saple D.1 PI/r to NVP switch appears effective & feasible option in resource restricted settings. |
| WePe12.3C16 | EFFICACY AND SAFETY OF A QD SIMPLIFICATION REGIMEN WITH DIDANOSINE PLUS TENOFOVIR PLUS EFAVIRENZ — FINAL RESULTS OF THE EFADITE TRIAL IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.3C16) Barrios A.1, Negredo E.2, Vilaro J.3, Domingo P.3, Estrada V.4, Labarga P.5, Asensi V.6, Morales D.7, Galvez J.7, Santos J.8, Terron J.A.9, Casas E.10, Riera M.11, Vergara A.12, Perez-Guzman E.13, Galindo M.J.14, Maida I.1, Martin-Carbonero L.1, Barreiro P.1, Nuñez M.1, Blanco F.1, Garcia-Benayas T.1, Gonzalez-Lahoz J.1, Clotet B.2, Soriano V.1 Simplification to QD ddI-TDF-EFV provides virologic responses at 12mo. similar to those seen in pts who do not change therapy. CD4 drops in the QD arm (particularly with high ddI doses) and dyslipidemias in controls are the main concerns for each option in the long-term. |
| WePe12.3C17 | TENOFOVIR/LAMIVUDINE/EFAVIRENZ: EFFECTIVENESS AND SAFETY OF A SIMPLE, ONCE-A-DAY ANTIRETROVIRAL REGIMEN IN A COHORT OF HIV-INFECTED PATIENTS IN AN URBAN HIV UNIT IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.3C17) Hernando A.1, Maseda D.2, Pulido F.3, Rubio R.3, Cepeda C.3, Hervas R.3, Moreno V.3, Costa J.R.3 Tenofovir+lamivudina+efavirenz is an effective and safety once-daily antirretroviral regimen when administered in a real life setting. |
| WePe12.3C18 | IMPACT OF TWO SIMPLIFIED THERAPIES ON QUALITY OF LIFE AND ADHERENCE IN HIV-INFECTED PATIENTS WITH UNDETECTABLE VIRAL LOAD. SIMPLIFICHAART STUDY. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.3C18) Muñoz-Moreno J.A., Fumaz C.R., Bonjoch A., Ferrer M.J., Miranda J., Clotet B. Our results show that simplified therapies permit to preserve a good QOL, maintain an optimal ADH, and enhance pts’ satisfaction with their antiretroviral therapy. Treatment simplification appears to may be a recommended strategy to maintain an adequate QOL, and useful to maintain long-term ADH. |
| WePe12.3C19 | THERE IS NEED OF DRUG-CLASS SWITCH TO SIMPLIFY PI-BASED ANTIRETROVIRAL REGIMENS? RESULTS FROM TWO STRATEGIES: ATAZANAVIR VS EFAVIRENZ-BASED REGIMENS. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.3C19) Zaccarelli M., Liuzzi G., Trotta M.P., Marconi P., Sette P., Baldini F., Acinapura R., Soldani F., Antinori A. The two analyzed simplifying strategies resulted in similar efficacy and low rate of discontinuation due to adverse events. Advantages of switching to EFV are PI-sparing and lower pill burden; advantages of ATV/r are better lipid profile, no CNS side-effect and marginally lower risk of interruption. |
| WePe12.3C20 | THE STARS STUDY: ONCE DAILY ATAZANAVIR, LOW-DOSE RITONAVIR AND SAQUINAVIR IN SUBJECTS WITH HIV-1 INFECTION: 24 WEEK EFFICACY AND SAFETY RESULTS. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.3C20) Colson A.1, Hellinger J.2, Cohen C.1, McLaughlin K.1, Morris A.1, Habel A.1 After virologic suppression on the dual boosted combination of SQV and LPV/r, changing to once daily SQV, ATV, and low dose RTV maintains viral suppression and significantly improves specific lipid fractions. |
| WePe12.3C22 | LONG-TERM FOLLOW-UP OF A SIMPLICATION STRATEGY WITH AN ONCE-DAILY REGIMEN IN THE CLINICAL SETTING: A 96 WEEKS ANALYSIS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.3C22) Moya J., Casado J., Aranzabal L., Moreno A., Antela A., Moreno S. The use of a QD regimen with nevirapine or efavirenz is useful in maintaining virologic suppression, and increases significantly the adherence to therapy. However, nearly half of patients change therapy in the clinical setting due to reasons different to failure. |
| WePe12.4 Treatment interruption |
|
| WePe12.4C01 | MOTIVATIONS AND CONSEQUENCES OF TREATMENT INTERRUPTIONS FROM THE PATIENT PERSPECTIVE IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.4C01) Grierson J., Thorpe R., Pitts M. While clinical considerations are clearly important in the decision to interrupt treatment, social factors such as quality of life, and the burden of HIV positivity remain critical to our understandings of treatment breaks. |
| WePe12.4C02 | DIFFERENTIATION PATTERNS AND EPITOPE SPECIFICITY OF HIV-SPECIFIC CD8 T-LYMPHOCYTES IN EARLY TREATED PATIENTS WHO SPONTANEOUSLY CONTROL VIRAL REPLICATION AFTER LONG-TERM TREATMENT INTERRUPTION IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.4C02) D'Offizi G., Gioia C., Corpolongo A., Poccia F., Tozzi V., Martini F., Bellagamba R., Girardi E., Amendola A., Abbate I., Narciso P. In our patients, a spontaneous control of HIV replication was associated to the ability to induce a CD8 T cell maturation, and to boost a specific CD8 response to HIV epitopes after exposure to virus. In our view, these data underline the importance of a very early antiretroviral treatment of HIV patients, in order to save the capability to mount an effective anti-HIV CD8 T cell response, which is lost in lately treated chronic patients. |
| WePe12.4C03 | PREDICTORS OF CD4 DROP AFTER STRUCTURED TREATMENT INTERRUPTION IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.4C03) Loutfy M.1, Walmsley S.1, Singer J.2, LaPierre N.3, MacLeod J.4, Trottier B.5, Conway B.6, Trottier S.7, Thorne A.8, Zarowny D.8 In this group of STI patients, higher baseline CD4 was the dominant variable predictive of CD4 drop. |
| WePe12.4C04 | EFFECT OF PARITY AND TREATMENT EXPERIENCE ON THE VIROLOGIC AND IMMUNOLOGIC PATTERNS AMONG HIV-INFECTED PREGNANT WOMEN. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.4C04) Luciano A., Patel J. Women who stop ART in between pregnancy are not at increased risk for perinatal HIV transmission and showed a similar viral load decline following initiation of ART compared to women who were not on any prior ART.However, the impact of treatment interruption on long term maternal outcome or response to treatment is not known. |
| WePe12.4C05 | CD4-MONITORED TREATMENT INTERRUPTION INCREASES MTDNA CONTENT IN CELLS FROM HIV+ PATIENTS: A PROSPECTIVE STUDY. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.4C05) Mussini C.1, Pinti M.2, Bugarini R.2, Borghi V.1, Nasi M.2, Nemes E.2, Troiano L.2, Roat E.2, Lugli E.2, Guaraldi G.2, Bedini A.1, Sabin C.3, Esposito R.2, Cossarizza A.2 This study is the first showing that mtDNA content can increase in peripheral blood lymphocytes, but only after, at least, 6 months of treatment interruption. Thus interruptions of shorter periods, due to clinicians or patients decision, are unlikely to allow restoration of mtDNA and thus decrease HAART-related toxicity. |
| WePe12.4C06 | STOPPING ANTIRETROVIRAL THERAPY IN "PREMATURELY TREATED" HIV-1-INFECTED CHILDREN WITH FULLY SUPRESSION OF VIRAL REPLICATION IS SAFE IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.4C06) Seoane Reula M.E.1, León-Leal J.A.2, Leal M.2, Obando I.3, Muñoz-Fernández M.A.1 The children always presented a good %CD4 and remained asymptomatic thorough the interruption period, improved the quality of their lives, by being without HAART. Our results indicate that it is safe to stop ART in HIV-children, whose pre-treatment characteristics would not meet current criteria for starting therapy. |
| WePe12.4C07 | THE PSYCHOLOGICAL REASONS AND CONSEQUENCES OF UNSTRUCTURED THERAPY INTERRUPTIONS IN HIV+ SUBJECTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.4C07) Compostella S., Zeni C., Antonelli S., Casari S., Torti C., Torri T., Quiros R. E., Carosi G. High rate of disagreement was found in the patient-physician relationship regarding decision to stop therapy. Therapy interruptions is demanded by patients and carried out without informing physicians in many cases. Appropriate counselling interventions should be reinforced because TI is in fashion but may put patients at risk for clinical progression if not guided by CD4+ T-cell count and clinical evaluation. |
| WePe12.4C08 | CTN 164: A PROSPECTIVE RANDOMIZED MULTICENTER TRIAL OF STRUCTURED TREATMENT INTERRUPTION VERSUS IMMEDIATE SWITCHING IN HIV-INFECTED PATIENTS EXPERIENCING VIROLOGIC FAILURE ON HAART IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.4C08) Walmsley S.1, Thorne A.2, LaPierre N.2, Loutfy M.1, MacLeod J.3, Trottier B.4, Conway B.5, Trottier S.6, Harrigan R.7, Zarowny D.2, Singer J.2, CTN 164 Investigators f.2 This study failed to show a benefit of a 12 week STI prior to initiation of salvage ARV. Higher baseline CD4 was the dominant predictor of viral response. |
| WePe12.4C09 | PREDICTIVE VALUE OF HIV-SPECIFIC AND NONSPECIFIC PROLIFERATIVE RESPONSES AND CELL SURFACE MARKERS TO PREDICT CD4 COUNT CHANGE IN HIV-INFECTED PATIENTS EXPERIENCING VIROLOGIC FAILURE BEFORE UNDERGOING A TREATMENT INTERRUPTION: RETROSPECTIVE STUDY IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.4C09) Huang K.1, Loutfy M.R.2, Tsoukas C.1, Walmsley S.2, Bernard N.F.1 The presence of HIV-specific proliferative responses was associated with a smaller drop in the CD4 count during TI in patients experiencing virologic failure on therapy. The use of pre-TI immune proliferative responses and cell surface markers may have predictive value for CD4 count decline during TI. |
| WePe12.4C10 | THE FOTO STUDY 48 WEEK RESULTS: VIRAL SUPPRESSION CAN BE MAINTAINED WHEN ANTIRETROVIRALS ARE TAKEN FIVE CONSECUTIVE DAYS ON, AND TWO DAYS OFF EACH WEEK IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.4C10) Cohen C.1, Colson A.1, Morris A.1, Alberts L.2, Sheble-Hall A.1, Hussey S.1, Schulte M.3 In this pilot, ART 5 consecutive days per week maintains virologic suppression for at least 48 weeks in 100% on EFV/NRTI regimens; lower rates were seen with PIs. The 5/2 schedule is strongly preferred by subjects, and reduces ART costs by 28%. If results are confirmed, these results have enormous implications especially for developing nations. |
| WePe12.4C11 | TREATMENT INTERRUPTION GUIDED BY CD4+ IN HIV- INFECTED PATIENTS: LONG TERM ANALYSIS OF MORBIDITY AND INMUNOVIROLOGICAL EVALUATION IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.4C11) Genebat M., Gutiérrez S., Soriano-Sanabria N., Valladares A., Vivancos J., Leal M. HAART interruption guided by CD4+ cell count may be an appropriate approach to identify a great proportion of patients that, according to actual guidelines, would need no antiretroviral therapy. However, these patients must be closely evaluated. |
| WePe12.4C12 | GENETIC BASIS OF HIV-1 RESISTANCE MUTATION CLEARANCE IN THE PROTEASE GENE AFTER TREATMENT INTERRUPTION: A CASE STUDY OF A PEDIATRIC ANTIRETROVIRAL THERAPY FAILURE FOLLOWED BY STI. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.4C12) N. Martins A.1, A. Brindeiro P.1, de Oliveira T.2, B. Arruda M.1, P. M. Rubini N.3, A. M. de Sá C.3, Cassol S.4, Tanuri A.5, M. Brindeiro R.1 The majority of the virus population sampling (based on their segregated clones) isolated after treatment interruption clustered phylogenetically with the treatment failure samples, showing hight level of resistance to RT and PR inhibitors. Nevertheless, other few clones of the treatment interruption stage correlated closer to the first serology clones, showing a genotypic profile of hight level resistance only to RT inhibitors and polimorfisms that appear in a half of the samples from first serology. Proviral clones analyzed corroborated the results found, showing that multi-resistant clones found after failure may have generated a great extent of the heterogeneous reverted population of drug-susceptible virus after the interruption, although we could still find wild type-like clones arising from minor populations pre-existing in the treatment failure. |
| WePe12.4C13 | CD4 CELL COUNT GUIDED HAART INTERRUPTION: IS IT A RELIABLE STRATEGY IN RESOURCE-LIMITED SETTINGS? THE DREAM EXPERIENCE IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.4C13) Palombi L.1, Liotta G.1, Guidotti G.2, Perno C.F.1, Lourerio S.3, Germano P.4, Marazzi M.C.5 HAART interruption strategy in pregnant women had a major virological and immunological response. The observed mutations were consistently lower than those reported in mono or bi-therapy.HAART therapy during pregnancy with discontinuation based on CD4 cell criteria ,could consistently improve the impact of a long-term treatment strategy in settings that have to cope with resource constraints. |
| WePe12.4C14 | BIPHASIC INFLUENCE OF THE FACTORS INVOLVED IN THE IMMUNO-VIROLOGICAL DYNAMIC AFTER HAART INTERRUPTION IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.4C14) Soriano-Sarabia N.1, Vivancos J.1, de Felipe B.1, Lissen E.1, Muñoz-Fernández M.A.2, Vallejo A.1, Leal M.1 The different factors involved in viral and cellular post-interruption dynamic have a biphasic influence, and thymus plays a role with potential clinical importance in prolonged HAART interruptions. |
| WePe12.5 Treatment of HIV-2 |
|
| WePe12.5C01 | LONG-TERM VIRAL SUPPRESSION AND INCREASE IN CD4+ T CELLS IN HIV-2 INFECTED PATIENTS UNDER ANTIRETROVIRAL THERAPY IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.5C01) Gomes P.1, Camacho R.2, Mansinho K.2, Lourenço M.H.3, Taveira N.4 These results show that ART may lead to long-term suppression of HIV-2 replication with concomitant increase in the number of CD4 cells. Treatment may be more efficacious with a regimen including at least one PI. In our cohort, both the CD4 cell counts and viral load seem to be good markers to monitor the outcome of therapy. |
| WePe12.6 Resistance testing in clinical practice |
|
| WePe12.6C01 | HOW SALVAGEABLE ARE THE K65R AND L74V MUTATIONS? IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.6C01) Waters L., Mandalia S., Bower M., Gazzard B., Nelson M. The K65R mutation appears to be highly salvageable with a PI-based regimen, whether or not the backbone includes TFV, and less so with non-PI HAART. There is a trend for less success salvaging the L74V whether or not this includes a PI. |
| WePe12.6C02 | WHICH ANTIRETROVIRAL REGIMENS DRIVE THE K65R AND L74V MUTATIONS? IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.6C02) Waters L., Mandalia S., Bower M., Gazzard B., Nelson M. K65R is driven mainly by TFV/ddI +/-ABC (particularly with NRTI –only regimens). PIs appear to be protective. L74V is predominantly driven by ddI/ABC or ddI/TFV; although numbers are small, PIs don’t appear to confer protection. |
| WePe12.6C03 | OUTCOMES ANALYSIS OF HIV-INFECTED CHILDREN WITH SUSTAINED VIRAL LOAD (SVL) AND ANTIRETROVIRAL RESISTANCE IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.6C03) Malhotra A., Loomis C., Gaur S. Group 1 had significantly better laboratory outcomes and fewer mutations than Group 2. Despite differences in laboratory outcomes, there was no significant effect on growth or CDC Category B infections. |
| WePe12.6C04 | GLOBAL NEURAL NETWORK MODELS ARE SUPERIOR TO SINGLE CLINIC MODELS AS GENERAL QUANTITATIVE PREDICTORS OF VIROLOGIC TREATMENT RESPONSE IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.6C04) Revell A.1, Larder B.2, Wang D.2, Wegner S.3, Harrigan R.4, Montaner J.4, Lane C.5 Global ANN models can perform as accurately as local models, trained with data from a single clinic, in predicting response for patients from that clinic. Global models appear superior to local models for other clinics, suggesting that they may be the most powerful way to exploit ANN as a generally available treatment decision-making tool. |
| WePe12.6C05 | TREATMENT HISTORY DATA SIGNIFICANTLY INCREASE THE ACCURACY OF NEURAL NETWORKS IN PREDICTING VIROLOGIC RESPONSE TO COMBINATION THERAPY IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.6C05) Larder B.1, Wang D.1, Revell A.2, Harrigan R.3, Montaner J.3, Wegner S.4, Lane C.5 The addition of treatment history data significantly improved the accuracy of ANN confirming that historical exposure to antiretroviral drugs can influence response to a new regimen. This suggests that treatment history may act as a surrogate for minority mutant populations and can enable ANN to overcome this shortcoming of current genotyping. |
| WePe12.7 Adherance |
|
| WePe12.7C01 | THE CHALLENGES OF ADHERING TO ARV TREATMENT IN A RESOURCE POOR COUNTRY: A CASE STUDY OF MEMBERS OF AIDS ALLIANCE IN NIGERIA IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.7C01) Nwoke A., Farouk M. Many factors contribute to non-adherence to treatment in a resource poor country like Nigeria. Some of these factors as I have pointed out are availability and accessibility of drugs; these drugs have to be available at the right time and affordable at the right price. This means that people can afford them whether there is a break in the supply of government drugs or not. |
| WePe12.7C02 | PERSISTENT LOW VIREMIA AND FUTURE TREATMENT OPTIONS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.7C02) Dyner T., Boly L., Cafaro V. This cohort of patients preserved immunologic competence despite the presence of low level viremia. Future treatment options may not be jeopardized for patients who decide to continue regimens which are not fully suppressive. |
| WePe12.7C03 | DETERMINING BARRIERS AND PREDICTORS TO ADHERENCE IN CHILDREN ACCESSING HIV/AIDS TREATMENT IN UGANDA IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.7C03) Enzama R., Mugyenyi P. Knowing socio-cultural factors will lead to intervention strategies which require Education of health caregivers about the disease, goals of treatment, choosing a regimen that is as simple as possible, and providing intensive, individualized and logistical support to optimize maximal adherence. Providers and the caregiver/patient should collaborate to choose individualized regimen. Caregivers should be informed about side effects of treatment and how to manage them. Health care providers should assist caregivers and children to fit these medication regimens into their lives rather than getting them to fit their lives around the regimen. |
| WePe12.7C04 | IMPACT ON ADHERENCE OF DOSING SCHEDULE: A COMPARATIVE STUDY OF SIMPLE QD AND BID REGIMENS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.7C04) Rodriguez-Sagrado M.A.1, Perez-Elias M.J.2, Moreno S.2, Muriel A.3, Bermejo T.1, Delgado L.1, Prieto S.1, Jose Luis C.2, Moreno A.2, Dronda F.2, Antela A.2 Simple QD regimens (three pills once daily at bedtime) are associated with significantly better adherence than simple BID regimens (one pill twice daily). |
| WePe12.7C05 | ADHERENCE TO HAART ASSESSED BY PHARMACY REFILL DATA IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.7C05) Pires J., Ventura A., Madalena A. Pharmacy refill data is a simple and useful method to assess adherence of HIV patients to HAART. Adherence over 90% assessed by this method was associated with lower viral loads and increased rate of virological response. Antiretroviral adherence must be improved and monitored over time. |
| WePe12.7C06 | ADDRESSING ADHERENCE IMPROVES THE ACCURACY OF NEURAL NETWORKS' PREDICTIONS OF VIROLOGIC TREATMENT RESPONSE IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.7C06) Montaner J.1, Larder B.2, Wang D.2, Revell A.3, Wegner S.4, Harrigan R.1, Lane C.5 ANN models trained using data from highly adherent patients were significantly more accurate in their predictions of virologic response to combination therapy than those trained with data from less adherent patients. Further study is required to identify an appropriate adherence cut-off for inclusion of patients in ANN training sets. The performance of the high adherence models was encouraging given the small training sets and rigorous test. |
| WePe12.7C07 | ADHERENCE AND QUALITY OF LIFE WITH A ONCE-DAILY ANTIRETROVIRAL/ REGIMEN WITH DIDANOSINE (DDI), LAMIVUDINE (3TC) AND EFAVIRENZ (EFV) IN NAÏVE PATIENTS. THE VESD STUDY. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.7C07) Palacios R.1, del Arco A.2, Grana M.3, Gálvez M.C.4, López-Ruz M.A.5, Gutiérrez-Ravé V.6, Morales D.7, Vergara A.8, Terrón A.9, Peña D.10, Santos J.1 Treatment-naïve patients on a ddI-3TC-EFV QD regimen over 48 weeks demosnstrated hight levels of adherence. This well-tolerated and efficient regimen also helped the patients to maintain compliance and achieve a good quality of life and satisfaction with the therapy. |
| WePe12.7C08 | DISCORDANT IMMUNOLOGIC AND VIROLOGIC RESPONSES TO HAART ARE ASSOCIATED WITH INCREASED MORTALITY AND POOR ADHERENCE TO THERAPY. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.7C08) Moore D.1, Hogg R.1, Yip B.1, Wood E.1, Tyndall M.1, Braitstein P.2, Montaner J.1 Discordant responses are independently associated with an increased risk of mortality in patients receiving HAART and are associated with poor adherence to therapy. |
| WePe12.7C09 | CORRELATES OF NON-ADHERENCE TO ANTIRETROVIRAL THERAPY IN HIV-INFECTED PATIENTS: THE SWISS HIV COHORT STUDY IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.7C09) Glass T.1, De Geest S.2, Weber R.3, Vernazza P.4, Rickenbach M.5, Furrer H.6, Bernasconi E.7, Cavassini M.8, Hirschel B.9, Battegay M.10, Bucher H.1 Continuous investment in the behavioral dimension of HIV is crucial. |
| WePe12.7C10 | FACTORS ASSOCIATED WITH NON-ADHERENCE TO HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN THE LONG-TERM: A 5 YEAR FOLLOW-UP ANALYSIS WITH MISSINGNESS BIAS CORRECTION IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.7C10) Spire B.1, Carrieri P.1, Lewden C.2, Piroth L.3, Villes V.1, Cassuto G.-P.4, Boucherit S.5, Chêne G.2, Leport C.5, Raffi F.6 Reasons for non-adherence are multi-factorial and should be distinguished from those influencing care provision. Psycho-social interventions and identification of better tolerated regimens are needed to improve long-term adherence of HIV-infected patients to their life-lasting treatment. |
| WePe12.7C11 | DO WE REALLY KNOW WHAT PATIENTS THINK? PREFERENCES AND PRIORITIES OF HIV+ EXPERIENCED PATIENTS REGARDING A NEW DOSING REGIMEN (SAQUIR@ STUDY) IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.7C11) Pedrol E.1, Suárez-Lozano I.2, Sanz J.3, Ortega E.4, Vera F.5, Ribera E.6, Labarga P.7, López L.8, Escayola R.9 HIV+ patients with ART experience shows a preference for well-tolerated, effective regimens over LNP, and QD rather than BID therapies. As ART experience increases, the tendency to prefer tolerance and safety increases and the preference for QD regimens becomes less prominent. |
| WePe12.7C12 | AN INTERDISCIPLINARY MODEL OF INTERVENTION FOR ADHERENCE FAILURE (AF) IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.7C12) Bruzzese L., Valiente J., Figueroa M.I., Fleites A., Warth S., Flighelman M., Cahn P. This pilot interdisciplinary approach experience allowed 64% of AF patients to restart HAART. |
| WePe12.7C13 | EFFECTIVENESS OF A DIRECTLY ADMINISTERED ANTI-RETROVIRAL THERAPY (DAART) INTERVENTION IN FOSTERING ADHERENCE IN MOMBASA, KENYA IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.7C13) Sarna A.1, Hawken M.2, Geibel S.3, Kaai S.3, Mandaliya K.4 Preliminary analysis indicate high rates of adherence and improvements in weight gain and CD4 counts in both groups. Further analysis of differences in CD4 counts and other variables will determine whether DAART patients are responding better to ART than non-DAART patients. |
| WePe12.7C14 | LOPINAVIR-BASED THERAPY IS ASSOCIATED WITH IMPROVED PATIENT ADHERENCE COMPARED TO OTHER PROTEASE INHIBITORS. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.7C14) Moore D., Hogg R., Yip B., Wood E., Montaner J. Lopinavir appears to be associated with improved adherence to therapy compared to other PIs. However, study subjects differed from each other in several important baseline characteristics. |
| WePe12.7C15 | REDUCED RATES OF VIRAL LOAD SUPPRESSION AT SIX TO 12 MONTHS BY SAQUINAVIR AND NELFINAVIR ARE NOT SOLELY EXPLAINED BY REDUCED ADHERENCE TO THERAPY. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.7C15) Moore D., Hogg R., Yip B., Wood E., Montaner J. Saquinavir and nelfinavir were less likely to achieve viral load suppression compared to other PIs. This was not solely accounted for by differences in adherence to therapy. |
| WePe12.7C16 | REPEATED MEASURES ANALYSES OF DOSE TIMING OF ANTIRETROVIRAL MEDICATION AND ITS RELATIONSHIP TO HIV VIROLOGIC OUTCOMES IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.7C16) Liu H.1, Miller L.G.2, Golin C.E.3, Hays R.D.1, Wu T.4, Wenger N.S.1, Kaplan A.H.5 We identified several measures of dose timing error that explain HIV virologic outcome not captured by traditional adherence measures that measure only percent adherence. Clinical interventions that promote medication adherence need to encourage patients not only to take as many of their pills as possible but also to take them as scheduled. |
| WePe12.7C17 | LOW ADHERENCE TO ANTIRETROVIRAL THERAPY AMONG A COMMUNITY WITH ENDEMIC RATES OF INJECTION DRUG USE IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.7C17) Shannon K.1, Kerr T.1, Lai C.1, Ishida T.1, Montaner J.S.G.2, Hogg R.S.3, Tyndall M.W.2 Adherence to antiretroviral therapy has become the major challenge to achieving a successful HIV treatment outcome. This large population-based study illustrates obstacles to sustained treatment among urban populations with high rates of injection drug use. Clearly innovative strategies that address the social barriers facing marginalized populations are urgently needed to support the long-term continuation of HAART. |
| WePe12.7C18 | SYMPTOMS OF ANXIETY AMONG HIV-INFECTED NAÏVE PATIENTS DECREASE AFTER INITIATING ANTIRETROVIRAL THERAPY (ARV) IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.7C18) Campos L.N., Guimarães M.D.C. 1. This study highlights the importance of detecting psychological distress by simple screening methods; 2. It is considerably high the prevalence of anxiety among HIV-seropositive individuals prior to initiating ARV therapy, although it reduces after onset of therapy; 3. Prevalence of depression did not decrease significantly probably due to its chronicity; 4. Special attention should be given to young people, women, those who live alone, in poor living conditions, or show disbelief on ARV therapy. |
| WePe12.7C19 | IMPACT OF ANXIETY AND DEPRESSION ON THE QUALITY OF LIFE OF HIV-INFECTED PATIENTS PRIOR TO INITIATING ANTIRETROVIRAL TREATMENT IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.7C19) Campos L.N.1, César C.C.2, Guimarães M.D.C.1 This study highlights the major role of anxiety and depression in the QL of HIV-infected patients. Other vulnerable populations that deserve special attention and individualized approach in the health care service are: patients with low income, advanced HIV disease, poor social support, fragile personal relationships and those who have feelings of discrimination or maintain unprotected sexual intercourses. Therefore, interventions in this population should consider the need of multiprofessional personnel and interdisciplinary actions in the approach of HIV-infected patients prior to initiating antiretroviral therapy. |
| WePe12.7C20 | THE APPROPRIATE INDICATIONS OF ONCE-DAILY ANTIRETROVIRAL REGIMENS IN TREATMENT NAÏVE PATIENTS WITH HIV IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.7C20) Nelson M.1, Van Lunzen J.2, Smets L.3, Stoevelaar H.J.4 Although the panel results indicate that QD-regimens may be an appropriate initial strategy for a substantial part of treatment-naïve patients, their use in clinical practice seems to be relative low. Further research should focus on the specific factors in favour or against the prescription of QD-regimens in real-life practice. |
| WePe12.7C21 | KNOWLEDGE OF ARV DRUG RESISTANCE AND REASONS FOR POOR DRUG ADHERENCE AMONG HIV POSITIVE PATIENTS ON ANTIRETROVIRAL THERAPY AT THE JOS UNIVERSITY TEACHING HOSPITAL, JOS, PLATEAU STATE, NIGERIA. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.7C21) Falang K.1, Agbaji O.2, Idoko J.2, Kanki P.3 Medication adherence can be improved by reinforcing (through patient education and counseling) many of the information concerning HIV and ARV drugs many patients already know. It is recommended that in our setting like in most resource limited settings, these issues need to be critically looked at so that the optimum benefit of ARV drug therapy can be derived. Furthermore, the use of fixed dose combinations (FDC) will greatly improve adherence. |
| WePe12.7C22 | DOES PSYCHOLOGICAL STATE PREDICT PATIENT ABILITY TO ADHERE TO HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART)? IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.7C22) Grimes D.E.1, Grimes R.M.1, Patel P.N.2, Ross M.W.1, Sharma G.1 Psychological state, as measured by the POMS and the MAHS does not predict patient adherence to HAART for patients initiating therapy or patients who are restarting therapy. |
| WePe12.7C23 | NON-ADHERENCE AMONG BRAZILIAN PATIENTS INITIATING ANTIRETROVIRAL THERAPY AND PUBLIC HEALTH IMPLICATIONS. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.7C23) Bonolo P.F.1, Guimarães M.D.C.1, César C.C.2, Acúrcio F.A.3, Ceccato M.G.B.1, Pádua C.A.M.1, Álvares J.3, Campos L.N.1, Carmo R.A.4 Our data has pointed out the importance of clinical and health service characteristics as potential indicators of non-adherence after initiating therapy. Early assessment and intervention strategies should be priorities in these AIDS-public referral centers. Feasible and reliable indicators for routine monitoring of adherence should be incorporated in clinical practice. |
| WePe12.7C24 | METHOD OF EVALUATING ADHERENCE AND EFFICACY OF HAART IN HIV-INFECTED INJECTION DRUG-USERS (IDUS) RECEIVING DIRECTLY OBSERVED THERAPY (DOT) IN A METHADONE MAINTENANCE PROGRAM IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.7C24) Raffa J.1, Grebely J.2, Tossonian H.2, Trotter B.2, Rashidi B.2, Li A.1, McLean M.3, de Vlaming S.3, Conway B.2 Our data suggest that the minimum standard to maintain virologic suppression may be less than previously appreciated. It may thus be that for patients enrolled in a HAART DOT program and showing a good initial response to therapy, step-down programs requiring less stringent supervision may be feasible, given that lesser degrees of adherence may be sufficient to avoid virologic breakthrough. Different parameters may apply to PI and NNRTI-based regimens, and this should be the subject of further evaluation. |
| WePe12.7C25 | DIFFICULTIES RELATED TO ANTIRETROVIRAL THERAPY REPORTED BY PATIENTS INITIATING TREATMENT IN PUBLIC HEALTH CENTERS IN BRAZIL. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.7C25) Freitas F., Campos L., Alvares J., Freitas M.I., Bonolo P., Guimarães M.D. 1.This analysis highlights the importance of assessing factors that may contribute to poor adherence using simple questions. 2. Strategies to enhance adherence to ARV therapy should consider the occurrence of adverse reactions, in the first month, followed by posology, immunological and clinical status of the patient. |
| WePe12.7C26 | ENHANCEMENT OF COMPLIANCE USING ALTERNATE DAY REGIMEN OF HAART WITH EFFICACY MAINTAINED IN INITIALLY GOOD RESPONDING PATIENTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.7C26) Jun J.B., Choi S.H., Cho Y.K., Woo J.H. This study implicates compliance was enhanced as total numbers of oral intake reduced and that alternate-day regimen of HARRT was not inferior to everyday regimen in efficacy after patients initially responded well. Economic load was reduced. |
| WePe12.7C27 | PREGNANT WOMEN LIVING WITH HIV: BARRIERS ON THE ADHERENCE TO ANTIRRETROVIRAL TREATMENT IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.7C27) Ramos J.1, Morales M.1, Duran A.2, Losso M.2 The most frequently found barriers in the adherence to the antirretroviral treatment were described, being the main barrier: the schedule problems. As far as the knowledge of the guidelines of medicines: more than a half of the mothers interviewed, does not know what conduct must be followed, after the forgetfulness of a doses. The same percentage of the patients does not have the knowledge about the disagreeable effects that the medication can produce, whereas a high percentage knows the rest of the medicine guidelines or properties. |
| WePe12.7C28 | SELF-EFFICACY OF HIV-INFECTED PEOPLE IN ADHERING TO HAART PRIOR TO TAKING MEDICATION IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.7C28) Thapinta D.1, Chariyalertsak S.2, Oberdorfer A.3, Suwanteerangkul J.3, Guest P.4, Sarna A.5, Wu A.6 Self-efficacy among HIV-infected people who were about to start HAART was high. The findings showed a high commitment to achieve high adherence to HAART. Further studies should focus on how much this level of self-efficacy can be achieved and maintained in actual practice. |
| WePe12.7C29 | EFFECTS OF TAKING DIDANOSINE CAPSULES (DDI-EC) WITH AND WITHOUT FOOD ON VIROLOGICAL FAILURE AND TREATMENT DISCONTINUATION: THE FOODDIE STUDY. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.7C29) Lopez J.1, Moreno S.2, Jimenez-Oñate F.3, Clotet V.4, Rubio R.5, Hernandez-Quero J.6 In presence of good adherence to therapy (> 80% of the prescribed doses), ddI can be administered with food without and increase on virological failure or HAART discontinuation. |
| WePe12.7C30 | IMPACT OF AN EDUCATIONAL INTERVENTION ON ANTIRETROVIRAL THERAPY IN HIV-1 INFECTED PATIENTS IN MOROCCO IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.7C30) Ouagari Z.1, El Fajali N.1, Maaroufi A.2, Quozbor K.3, Bensghir R.1, Himmich H.1 The results illustrate the feasibility of ART in developing countries in conjunction with Educational Intervention, which helped to maintain and to improve high levels of ART adherence, in addition to providing psychological support for patients. |
| WePe12.7C31 | ADHERENCE TO ANTIRETROVIRAL THERAPY AND EMERGENCE OF RESISTANT HIV: A LONGITUDINAL REPEATED MEASURES ANALYSIS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.7C31) Miller L.1, Liu H.2, McCutchan J.A.3, Keiser P.4, Kemper C.5, Witt M.1, Leedom J.6, Forthal D.7, Richman D.3, Seefried E.3, Rigby A.3, Hermes A.8, Haubrich R.3 Adherence was associated with new phenotypic resistance in antiretroviral-experienced patients, but the relationship was complex and non-linear. Higher viral load and time on antiretrovirals were highly predictive of new resistance. This suggests that new resistance may be minimized in antiretroviral-experienced patients by avoiding lengthy antiretroviral exposure without optimal viral suppression. |
| WePe12.7C32 | THE ART ADHERENCE IN A COHORT OF HIV POSITIVE IN ITALY(VENETIAN COHORT): THE SWITCH FROM PI TO NNRTI INCREASED THE ADHERENCE AND DECREASED FOR LONG TIME THE VIRAL LOAD IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.7C32) Raise E.1, Panese S.2, Rosini G.1, Eseme F.1, Ebo F.1 The ART adherence is associated with a decrease of mortality , the number of pills per day is very important to determine a high adherence in order to obtain a restore of CD4 cells and a decrease to an undetectable level for V.L. |
| WePe12.7C33 | LONG-TERM ADHERENCE TO FIRST-LINE HAART IN A HOSPITAL-BASED COHORT: PREDICTORS AND IMPACT ON VIROLOGICAL RESPONSE AND RELAPSE. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.7C33) Parruti G.1, Manzoli L.2, Marani Toro P.1, D'Amico G.1, Rotolo S.3, Graziani V.1, Staniscia T.2, Pieri A.1, Schioppa F.2, Consorte A.1, Alterio L.1, Graziani R.V.1, Marani Toro G.1 Our study provides further evidence that less toxic HAART regimens may help durable adherence. It also highlights marriage, for the first time to our knowledge, as a major determinant of long term adherence to HAART. This finding seems to be relevant in the present scenario of world-wide scaling-up of HAART for HIV infected patients. |
| WePe12.7C34 | IMPACT OF THE LIPODYSTROPHY SYNDROME IN ADHERENCE AND ATTITUDES TOWARD ANTIRETROVIRAL DRUGS. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.7C34) Marín A., Casado J., Aranzabal L., Moya J., Moreno A., Antela A., Perez-Elías M.J., Moreno S. The lipodistrophy syndrome and especially the psychosocial repercussions associated can alter the adherence to HAART, by decreasing the patient's confidence and satisfaction with the drugs. |
| WePe12.7C35 | SELF-REPORTED ADHERENCE TO HAART IS A RELIABLE AND COST EFFECTIVE TOOL IN LOW RESOURCE SETTING. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.7C35) Ezechi O.1, Onwujekwe D.1, Odunnukwe N.1, Adewole T.1, Aboweyere J.1, Ezecobi P.1, Gbajabiamilla T.1, Herbertson E.1, Adu R.1, Musa S.1, Rabiu O.1, Audu R.1, Lemoha E.1, Idigbe O.1, Ekong E.2 This study demonstrates that self reported adherence is a useful adherence monitoring tool in low resource setting. |
| WePe12.7C36 | ASSESSMENT OF ANTIRETROVIRAL ADHERENCE IN DJIBOUTI IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.7C36) Fatouma M.1, Ammar A.2, Kibangou N.1, Mohamed A.K.3, Comolet T.4, Coulaud X.5, Kraemer P.6, Matera D.7, Osman Glele C.5, Ali B.8, Saleh B.3, Maizar S.8, Madian A.9 Adverse effects, low level socio-economic, matrimonial situation and travel influence the adherence. It is necessary to set up consultation of adherence for the unit of the patients of this cohort and to ensure a partnership with the countries bordering to ensure a supply in HAART in the event of rupture during travel. |
| WePe12.7C37 | COST OF TREATMENT: THE SINGLE BIGGEST OBSTACLE TO TREATMENT ADHERENCE IN MIDDLE CLASS MUMBAI, INDIA IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.7C37) Naik E.1, Tash K.2, D'Souza K.1, Menezes L.1, Pazare A.3, Wable G.3, Sinnott J.1 Our study population was representative of the lower middle class of India with the exception of high educational achievement. This economic group is most affected by HIV. Our study highlights that an educated, employed group found that cost of treatment was a tremendous obstacle to adherence. Additionally, it showed a significant increase in adherence when education on ART was employed. Reducing the cost of medication and teaching how anti viral medications work will improve adherence. Secondary efforts such as resistance reduction, improved patient outcomes and better quality of life will result. Finally, condom use must be emphasized. |
| WePe12.7C38 | DETERMINANTS OF ADHERENCE TO HAART IN CHILDREN. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.7C38) Ferreira F.F., Dias A., Pinto J. The patients in the study have high levels of adherence. Adherence was not influenced by the current ARV regimens. Patients reporting a good adherence were significantly more likely to present virologic and immunologic response in comparison to the non-adherent group. |
| WePe12.7C39 | FACTORS ASSOCIATED WITH MEDICATION ADHERENCE AMONG PATIENTS RECEIVING ANTIRETROVIRAL THERAPY IN THAILAND IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.7C39) Maneesriwongul W.1, Williams A.2, Tulathong S.3 The factors identified in this study are useful information in planning intervention to promote medication adherence among patients receiving antiretroviral therapy in Thailand. This study also experienced relative ease of administration of the 30-day visual analog scale, and suggested that this is a practical method to assess adherence in resource-poor settings. |
| WePe12.8 Immune therapy |
|
| WePe12.8C01 | RESPONSES TO IL-2 IN SUBJECTS THAT RECEIVED POTENT ANTIRETROVIRAL THERAPY (ART) ALONE FOR 18 MONTHS AS COMPARED TO THOSE TREATED WITH ART PLUS IL-2. (ACTG 5051) IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.8C01) Pollard R.1, Landay A.2, Aga E.3, Bosch R.3, Fox L.4, Mitsuyasu R.5 Patients receiving ART alone for 18 months responded similarly to IL-2 as patients on 12 weeks of ART. Those who previously responded to IL-2 maintained CD4 cells for 18 months. IL-2 was relatively well tolerated. |
| WePe12.8C02 | INTRAVENOUS IMMUNOGLOBULINS (IVIG) IN HIV-1 INFECTED THERAPY NAÏVE PATIENTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.8C02) Vermeulen J.N.1, Prins J.M.2, Jurriaans S.3, Miedema F.4, Lange J.M.A.1, Schuitemaker H.4 In these HIV-1 infected patients IVIG caused a temporary decrease in immune activation and an increase in CD4-counts, despite an increase in pVL. This transient increase in pVL may be the result of decreased clearance of HIV-1 virions due to saturation of Fc-receptors caused by the raised IgG plasma levels after IVIG-infusion. Our results suggest that immunomodulatory therapy in HIV-1 infection could indeed be effective. |
| WePe12.8C03 | EFFECT OF IL-15 ON RELEASE OF HIV SUPPRESSIVE FACTORS FROM NK AND CD8 T-CELLS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.8C03) d'Ettorre G., Andreoni C., Cuomo R., Zaffiri L., D'Agostino C., Massetti A.P., Vullo V., Mastroianni C.M. These data indicate that both CD8 and NK are able to secrete high levels of ß-chemokines that are further increased after treatment with IL-15. However, the amount of ß-chemokines produced by NK after stimulation with IL-15 reach the levels that are able to suppress HIV replication. In conclusion, NK cells represent an important target for immunotherapeutic agents, as IL-15.Grant ISS 30F33. |
| WePe12.8C04 | REISHI: A NOVEL INHIBITOR OF TNF PRODUCTION AND NFκβ ACTIVATION IN HIV INFECTION IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.8C04) Leonard J., Majd I., McGann M., Novack J., Wenner C. Reishi suppresses TNF production when taken orally, and suppresses both TNF production and activated NFκß in vitro. These data warrant further study of Reishi's effects in HIV+ individuals to determine whether its TNF and NFκß inhibiting activities lead to suppression of HIV replication alone or in combination with conventional antiretroviral regimens. |
| WePe12.8C05 | THERAPY OF SHIV INFECTED MACAQUES WITH ANTISENSE DNA OF IL-4 IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.8C05) Dhillon N.1, Dhillon S.1, Adany I.1, Li Z.1, Villinger F.2, Narayan O.1, Buch S.1 This is the first demonstration of effective SHIV inhibition in targeted macaque tissues by intravenous injection of cytokine antisense DNA complexed with cationic lipids. The therapeutic effect of the ASIL4 suggests indirectly that the acute immunosuppressive disease caused by SHIVs is mediated in part by IL-4 that causes enhanced virus replication via receptor usage, and simultaneously by suppressing anti-viral CD8 T cell responses. |
| WePe12.8C06 | ANTI-CD4 AUTOIMMUNITY IN HIV-1 SUBTYPES B AND C INFECTED PATIENTS: A PHASE II MULTICENTER TRIAL OF T-CELL VACCINATION IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.8C06) Abulafia Lapid R.1, Bentwich Z.2, Maayan S.1, Keren Zur Y.1, Abramovitz J.1, Cohen I.3, Atlan H.1 We propose that T-cell vaccination with autologousCD8 T cells with autoimmune anti CD4 activity, may decrease autoimmunity to CD4 and increase CD4 T-cell numbers. If confirmed, this approach may be applied to HAART receiving patients in order to further increase CD4 levels and may also lead to better control of the viral infection. |
| WePe12.9 Treatment failure and salvage therapy |
|
| WePe12.9C01 | ONCE-DAILY SALVAGE REGIMENS FOR MULTIEXPERIENCED HIV-INFECTED PATIENTS. DATA FROM BMS STUDY 900: ATAZANAVIR (ATV) EARLY ACCESS IN SPAIN IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.9C01) Moreno S.1, Dronda F.1, Antela A.1, Vendrell B.2, Pérez-Molina J.A.2, Alvarez C.2, Gutierrez C.1, Pérez-Elías M.J.1, Moreno A.1, Casado J.L.1 Multiexperienced patients, including those with more than 5 PI mutations, may benefit from simple regimens that include low numbers of pills administered once daily. |
| WePe12.9C02 | EARLY HIV-RNA RESPONSE PREDICTS CLINICAL OUTCOMES IN A LATE SALVAGE POPULATION: RESULTS FROM THE OPTIMA STUDY. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.9C02) Singer J.1, Wu W.2, Cameron D.3, Holodniy M.4, Brown S.5, Kyriakides T.6, Babiker A.7 This analysis supports the hypothesis that early virologic response in a late salvage population is predictive of AIDS and death. This analysis provides some basis for extrapolating from virologic to clinical benefits in similar populations. |
| WePe12.9C03 | THE RADATA-FUZEON COHORT – T-20 IN DAILY CLINICAL PRACTICE: VIROLOGICAL RESPONSE AT WEEK 24 IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.9C03) Lorenzen T.1, Arasteh K.2, Fätkenheuer G.3, Fenner T.4, Gute P.5, Knechten H.6, Kurowski M.7, Lunzen J.V.8, Rockstroh J.9, Salzberger B.10, Staszewski S.11, Stoll M.12, Plettenberg A.1 45 % of pts. showed virological suppression <500 copies with a T-20 containing regimen after 24 weeks. Highly indicative risk factors for not being suppressed could not be identified, although patients in group III had lower CD4 cells and slightly higher viral loads. In contrast to randomized trials number of active drugs was not predictive, nor were the number of mutations. |
| WePe12.9C04 | AIDS-DEFINING EVENTS AND SERIOUS ADVERSE EVENTS (SAE) IN PATIENTS WITH ADVANCED HIV DISEASE IN THE OPTIMA TRIAL: WHAT AFFECTS PATIENTS QUALITY OF LIFE MOST? IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.9C04) Anis A.H.1, Sun H.2, Singer J.1, Cameron D.W.3, Owens D.K.4, Brown S.5, Sculpher M.J.6, Holodniy M.7, Schechter M.T.1 AIDS events and deaths are the traditional primary outcomes in HIV clinical trials. However, according to patient self-reported measures of quality of life, SAEs are equally if not more important, and should be elevated to primary outcomes, particularly in studies of later stage HIV disease. On behalf of the OPTIMA Study group. |
| WePe12.9C05 | LONG LASTING VIRAL EFFICACY AND SAFETY OF ENFUVIRTIDE CONTAINING THERAPY IN HIV-1 SPANISH INFECTED PATIENTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.9C05) Bonjoch A., Miranda C., Puig J., Perez-Alvarez N., Clotet B. Results of long term follow up under routine conditions of enfuvirtide strategies, confirm findings of clinical trials regarding long-lasting viral efficacy, immunological recovery and safety profile of a salvage therapy including enfuvirtide in very experienced HIV-infected patients. |
| WePe12.9C06 | IMMUNO-VIROLOGICAL OUTCOME OF AN HAART REGIMEN CONTAINING T-20, ATAZANAVIR AND TENOFOVIR VS T-20 PLUS OPTIMIZED BACKGROUND IN HIV-POSITIVE SUBJECTS WITH MULTIPLE TREATMENT FAILURES IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.9C06) Bongiovanni M.1, Cicconi P.1, Tordato F.1, Merli S.2, Capetti A.3, Bini T.1, d'Arminio Monforte A.1 T-20-containing-HAART was associated with a slight but persistent increase of CD4 and with a decrease of HIV-RNA. The efficacy of T-20 plus ATV and TDF showed to be comparable to T-20 plus OB. Longer studies with more patients are needed to confirm such results. |
| WePe12.9C07 | IN WHICH PATIENTS AND WITH WHICH DRUGS MAY TENOFOVIR/DIDANOSINE (TDF/DDI) BE USED AS A BACKBONE? IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.9C07) Olmo M.1, Podzamczer D.1, Moreno S.2, Knobel H.3, Ribera E.4 TDF/ddI (250 mg) is well tolerated and combined with a PI seems to be useful in simplification/rescue scenarios, while combined with NNRTI should be used only in virological suppressed pts. CD4 count improved among responders. Prospective studies are warranted. |
| WePe12.9C08 | VIROLOGICAL AND CLINICAL OUTCOMES IN PATIENTS WITH MULTI (THREE)-CLASS DRUG RESISTANT (MDR) HIV IN THE UK. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.9C08) Grover D.1, Allen L.2, Pillay D.3, Green H.4, Copas A.2, Forsyth S.1, Edwards S.1 Active management of patients with MDR HIV-1 is associated with delayed time to death. Resistance test guided therapy may confer virological benefit. |
| WePe12.9C09 | EFFICACY OF TENOFOVIR PLUS DIDANOSINE BACKBONE IN ASSOCIATION WITH PI OR NNRTI IN HIV-INFECTED SUBJECTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.9C09) Bongiovanni M.1, Chiesa E.1, Tordato F.1, Cernat R.1, Melzi S.2, Capetti A.3, Di Biagio A.4, Biasi P.1, Casana M.1, Ligabò V.1, Migliorino G.2, d'Arminio Monforte A.1, Bini T.1 In our study the use of TDF and DDI as HAART-backbone was associated with a good virologic outcome after 1 year. No differences were observed regrding the third antiretroviral drug associated to this combination. Subjects with a long therapeutic history and with higher HIV-RNA at baseline have a lower probability of reaching VS. |
| WePe12.9C10 | USE OF TENOFOVIR PLUS DIDANOSINE BACKBONE IN HIV-INFECTED SUBJECTS FAILING HAART IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.9C10) Bongiovanni M.1, Chiesa E.1, Cernat R.1, Biasi P.1, Melzi S.2, Capetti A.3, Tordato F.1, d'Arminio Monforte A.1, Bini T.1 In our study the combination of TDF and DDI plus a third antiretroviral drug was associated with a good virologic outcome after 12 months. Subjects with higher HIV-RNA at baseline and with a long duration of HAART have a lower probability of developing VS. |
| WePe12.9C11 | 24 WEEKS FOLLOW-UP WITH ATV AND SQV/R IN PROTEASE INHIBITOR (PI) EXPERIENCED HIV1- INFECTED PATIENTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.9C11) Knechten H., Wiesmann F., Höhn C., Ehret R., Braun P. Our first data showed that ATV/SQV/r could be a potent therapy option for patients experiencing strong side effects or a loss of virological control due to resistance against NRTI and NNRTI even if they were treated with protease-inhibitors previously. |
| WePe12.9C12 | 96 WEEK DATA ON THE EFFICACY & SAFETY OF FOSAMPRENAVIR/LOPINAVIR/R DUAL PROTEASE INHIBITOR THERAPY IN A CLINIC COHORT & THE IMPACT OF DRUG LEVELS ON VIROLOGICAL RESPONSE. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.9C12) Slater C., Castelino S., McCormick S., Tong C., Peters B., Kulasegaram R. FPV with LPV/r was effective & well tolerated in our cohort despite the unfavourable drug interaction. Greater virological failure was associated with low drug levels but was not statistically significant; interpretation was compounded by poor adherence. T1 was more efficacious than T2, and LPV levels appear key in determining response. |
| WePe12.9C13 | CHANGE IN INJECTION ATTITUDES AND PATIENT-REPORTED OUTCOMES AMONG PATIENTS WITH ENFUVIRTIDE (ENF) EXPERIENCE IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.9C13) Gallant J.E.1, Mackowiak J.I.2, Dusek A.3, Miralles D.3, Falcon R.W.4, DeMasi R.3 Among active ENF users, satisfaction with therapy and concerns about self-injection improved compared to recalled pre-treatment perceptions. In contrast, patients who had discontinued ENF reported recalled concerns both before and at the end of treatment, especially relating to injection site reactions. Patients' initial assumptions about their ability to take ENF may not be predictive of their satisfaction with therapy. |
| WePe12.9C14 | A NOVEL, DUAL PROTEASE INHIBITOR ANTIRETROVIRAL REGIMEN CONTAINING ATAZANAVIR AND FOSAMPRENAVIR IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.9C14) Slim J., Najjar M., Fallon S., Smith S. Our study suggests that the regimen of boosted ATV and fAPV is a safe and effective HIV-1 treatment regimen. This combination is well tolerated, offers favorable pharmacokinetic interactions, and does not appear to select for resistant virus. A larger, prospective controlled study should be undertaken to evaluate this once-a-day, NRTI-sparing treatment option. |
| WePe12.9C15 | WHEN TO SWITCH REGIMENS: THE KHAYELITSHA EXPERIENCE IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.9C15) Boulle A.1, Coetzee D.1, Hilderbrand K.2, Goemaere E.2 After the adherence intervention many patients had viral loads below 400 copies/mL, preventing unnecessary switching to second-line. At the same time most patients with confirmed viral rebound above 5,000 copies/mL were correctly identified in time to prevent the accumulation of multiple thymidine analogues. |
| WePe12.9C16 | FOSCARNET USED IN SALVAGE THERAPY OF MULTIDRUG RESISTANT HIV-1 INFECTED PATIENTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.9C16) Katlama C.1, Canestri A.1, Wirden M.2, Marguet F.1, Ghosn J.1, Ouagari Z.1, Boubezari I.1, Ktorza N.1, Agher R.1, Bossi P.1, Caumes E.1, Calvez V.2 Foscarnet in addition to HAART induces a profound reduction in VL in patients severely immunosuppressed, with no therapeutic options. This may allow to wait for more potent regimens. |
| WePe12.9C17 | EFFECT OF HEPATITIS C CO-INFECTION ON THE DURABILITY OF AN INITIAL HIGHLY ACTIVE ANTIRETROVIRAL THERAPY REGIMEN AMONG HIV-INFECTED PATIENTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.9C17) Hooshyar D., Napravnik S., Miller W.C., Eron Jr J.J. HIV-infected patients with HCV experienced slightly shorter time on their initial HAART regimen than those without HCV, but reasons for discontinuation or modification were similar by HCV serostatus. |
| WePe12.9C18 | THE LONGITUDINAL PATTERN OF HEALTH UTILITY AND ITS DETERMINANTS AMONG PATIENTS ON SALVAGE REGIMENS WITH OR WITHOUT A PRIOR TREATMENT INTERRUPTION. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.9C18) Anis A.H.1, Sun H.2, Singer J.1, Daphne G.2, Li X.3, Cameron D.W.4, Owens D.K.5, Brown S.6, Holodniy M.7, Kyriakides T.7, Babiker A.8, Sculpher M.J.9, Yu W.7, Wong H.2, Youle M.10, Schechter M.T.1 To date, SAEs and not AIDS events, have been the main cause of QoL decrements in the OPTIMA Trial. Secondary factors, such as PVL and time, probably reflect a negative psychological impact on patient self-reported perceived QoL as late stage HIV progresses. For the OPTIMA trial group. |
| WePe12.9C19 | VIROLOGICAL AND IMMUNOLOGICAL CONSEQUENCES OF SUSTAINED LOW-LEVEL VIRAEMIA (SLLV) IN PATIENTS RECEIVING HAART IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.9C19) Welz T.1, Bansi L.2, Sabin C.A.2, Easterbrook P.1 Fewer than 5% of patients receiving HAART develop SLLV. Although SLLV appears to have no adverse immunological consequences in the short-term, 44% eventually developed a VL>20,000. These findings have important implications for the management of patients who develop SLLV. The impact of SLLV on the development of drug resistance needs to be further evaluated. |
| WePe12.9C20 | LIMITED EVOLUTION OF VIRAL-LOAD (VL) AND RESISTANCE MUTATIONS(RM) IN HEAVILY PRE TREATED PATIENTS WITH LOW HIV-RNA PLASMA LEVEL PROSPECTIVELY RANDOMIZED TO MAINTAIN OR SWITCH THEIR CURRENT HAART IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.9C20) Nasta P.1, Castelnuovo F.1, Paraninfo G.1, Bella D.1, Matti A.1, Gatti F.1, Cocca G.2, Rizzardini G.2, Zoboli G.3, Magnani G.3, Nigro M.C.4, Colombo M.C.5, Calzetti C.6, Francesco B.7, Celesia M.8, Santoro D.5, Russo R.8, Carosi G.1 Based on preliminary analysis a limited evolution in VL, CD4-cell-count and RM were observed in 48 weeks follow-up in heavily pre-treated-low-viremic-pts prospectively randomized to maintain their current HAART. Early switch to an optimised lopinavir/ritonavir-containing regimen resulted in a profound VL decline with CD4-cell-count gain. The proportion of patients who discontinued their HAART for any reason was not significantly higher in arm A than in B.The rate of treatment limiting adverse event was not significantly higher in arm |
| WePe12.9C21 | LOPINAVIR/SAQUINAVIR REGIMENS ARE AN EFFECTIVE ALTERNATIVE IN THE SETTING OF EXTENSIVE RESISTANCE IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.9C21) Jacques de Moraes M., Carvalho e Silva de Carvalho M., Krzesinski A.L. The prevalence of dislipidemia remained unchanged at 75% through the period. SQV/LPV combination is an effective alternative to delay immunologic worsening for patients with limited therapeutic options. |
| WePe12.9C22 | HIGH LONG-TERM EFFICACY AND SAFETY (144 WEEKS) OF ENFUVIRTIDE IN HEAVILY PRETREATED HIV-1 INFECTED PATIENTS IN THE SWISS HIV COHORT STUDY IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe12.9C22) Elzi L.1, Kaufmann G.1, Weber R.2, Hirschel B.3, Cavassini M.4, Furrer H.5, Bernasconi E.6, Vernazza P.7, Klimkait T.8, Rickenbach M.9, Battegay M.1 Our data indicate long-term virological and immunological efficacy of ART+T-20. After stopping T-20, most but not all pts demonstrate virologic failure. |
| WePe13.9P Clinical trials |
|
| WePe13.9P01 | THE FIRST RUSSIAN CANDIDATE HIV VACCINE "VICHREPOL" WAS APPROVED FOR FIRST STAGE OF CLINICAL TRIALS. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe13.9P01) Karamov E.1, Pavlova T.1, Kornilaeva G.1, Korobova S.2, Nikolaeva I.2, Sidorovich I.2 The first vaccine candidate (VICHREPOL) was evaluated by National Regulatory Authority (L.A.Tarassevich State Institute for Standardization and Control of the Medical and Biological Preparations). Pre-clinical evaluation has shown the high immunogenic and safety of the preparation of candidate vaccine VICHREPOL with built-in adjuvant PO. At present this vaccine candidate was approved by National Regulatory Authority of Ministry of Health of Russian Federation for clinical trials phase I. |
| WePe13.13P Planning for vaccine efficacy trails |
|
| WePe13.13P01 | IMMUNOLOGICAL AND HEMATOLOGICAL REFERENCE RANGE DETERMINATIONS FOR HIV-1 NEGATIVE RURAL PLANTATION WORKERS IN KERICHO, KENYA IN PREPARATION FOR HIV-1 VACCINE TRIALS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe13.3P01) Foglia G.1, Kibaya R.1, Darden J.2, Sateren W.3, Langat L.1, Langat W.1, Kiptoo I.1, Bautista C.3, Wasunna M.4, Michael N.5, Birx D.5 The determination of normal reference ranges for potential vaccine cohorts is important. This study provides data on a healthy rural Kenyan gender and age-diverse group. Data will be presented comparing HIV-1 negative and HIV-1 positive Kenyans by gender and age group. Understanding differences will be important in providing care and treatment for HIV-1 infected persons. |
| WePe13.13P02 | RETENTION AT THE ONE YEAR FOLLOW-UP AMONG VOLUNTEERS IN THE COMMUNITY-BASED STUDY OF HIV INFECTION AMONG PLANTATION WORKERS IN KERICHO, KENYA IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe13.13P02) Foglia G.1, Langat L.1, Sateren W.2, Langat W.1, Kiptoo I.1, Kibaya R.1, Kimutai R.1, Bautista C.2, Renzullo P.3, Birx D.4 The 1 year retention rates at the Kericho HIV-1 vaccine cohort development study are similar to the recently published results of the AIDSVAX B/B efficacy trial. Evaluation of positive and negative predictors of volunteer retention will facilitate focused group education and mobilization of targeted volunteers to maximize follow-up in future HIV-1 efficacy trials. |
| WePe13.13P03 | RECRUITMENT, ADHESION AND FEASIBILITY OF LONG-TERM FOLLOW UP OF VOLUNTEERS IN AN HIV INCIDENCE COHORT OF HOMOSEXUAL AND BISEXUAL MALE IN BELO HORIZONTE, BRAZIL IN PREPARATION FOR HIV VACCINE TRIALS – PROJECT HORIZONTE – 1994 – 2005 IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe13.13P03) Greco D.B.1, Andrade J.C.1, Greco M.1, Oliveira E.I.1, Silva A.P.1, Utsch M.J.1, Ribeiro F.A.1, Cardoso F.2, Antunes C.M.F.2 Mouth-to-mouth was crucial for recruitment with the drawback of less diversity of volunteers, justifying the need for other recruitment strategies. Long-term follow up is feasible albeit adhesion is a problem in incidence trials where individuals are by definition healthy with no objective or immediate gains in their participation. On the other hand adhesion improves significantly after the third visit, occurring progressively with the participation on the activities offered (safe sex forums, cultural gatherings, discussion on various aspects of HIV, vaccine workshops). With respect to incidence, the numbers are low, probably reflecting counseling, information fora and condom distribution that will also be mandatory in vaccine trials. |
| WePe13.13P04 | INFORMATION AND COMMUNICATION TECHNOLOGY (ICT): A CRITICAL TOOL FOR HIV VACCINE CLINICAL TRIALS IN RESOURCE-CONSTRAINED SETTINGS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe13.13P04) Lima R.1, Mark D.1, Branch G.1, Muluubya A.2, Verlinde C.1, Tarragona T.3, Gilmour J.1, Fast P.1, Ketter N.4 IAVI has been successful at implementing a site-specific ICT infrastructure in resource-constrained settings, despite barriers and few local resources or reliable telecommunication networks to support large-scale quality assured clinical trials. Continued use of site-appropriate ICT solutions will help to provide real-time safety data and fulfill IAVI's mission to accelerate the delivery of an AIDS vaccine to the world. |
| WePe13.13P05 | RISK ASSESSMENT IN VOLUNTARY COUNSELING TESTING AT ITAJAÍ, BRAZIL. RCP STUDY: PRELIMINARY DATA. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe13.13P05) Carvalho I.F.1, Patrianova L.K.1, Silva T.J.1, Marchi V.1, Moraes A.S.1, Santos M.1, Rodrigues R.2, Silva I.O.3, Brigido L.4, Knoll R.K.1 This preliminary study on risk characteristics of VCT in Itajaí suggests a limited use of condoms with frequent unprotected sex. IDU, a major problem a few years ago, is rarely reported by this population. Follow up evaluation and ongoing molecular characterization of incident infection will contribute to the understanding of epidemic in the region and provide feasibility information to future trials with prevention innovations. |
| WePe13.13P06 | A CROSS SECTIONAL STUDY TO ASSESS RECRUITMENT AND HIV PREVALENCE IN POTENTIAL VOLUNTEERS FOR AN HIV VACCINE EFFICACY TRIAL IN RURAL UGANDA IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe13.13P06) Ruzagira E.1, Bwanika A.1, Kamali A.1, Grosskurth H.1, Ketter N.2 A high recruitment rate was achieved with reasonably high uptake of HIV test results. Based on previous prevalence and prospective incidence studies in the same district, it is estimated that HIV prevalence rate of 11% correlates with HIV incidence rate of 1-2%, with potentially much higher incidence in people under age 45, those with a history of GUD, and women and men from selected communities. |
| WePe13.13P07 | COMMUNITY PARTICIPATION IN VOLUNTARY COUNSELLING AND TESTING IN HIV IN A STUDY PREPARING FOR HIV PREVENTIVE VACCINE EFFICACY TRIALS IN MASAKA, DISTRICT, UGANDA IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe13.13P07) Basajja V.1, Ruzagira E.1, Bwanika A.1, Kamali A.1, Ketter N.2 Active community mobilization strategies established were successful at achieving a significantly higher HIV VCT uptake of both. |
| WePe13.13P08 | SELECTING PREDICTORS OF HIV INFECTION IN HIGH RISK POPULATION IN PREPARATION FOR HIV VACCINE EFFICACY TRIALS IN NAIROBI, KENYA. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe13.13P08) Mutua G.1, Odada J.1, Maina A.1, Ngugi E.2, Nyange J.1, Gachira J.1, Mahira R.1, Oyugi F.1, Price M.3, Bwayo J.2, Anzala O.2 Recruit of a potential a higher risk population is possible and the highest incidence may be in women and men under age 40. Predictors of prevalent HIV may not reflect risk factors of incident HIV infection. HIV infected women who reported condom use may be aware of their HIV status, and were taking action to protect themselves and their partners. |
| WePe13.13P09 | ENROLLMENT OF HIV DISCORDANT COUPLES FOR HIV PREVENTION TRIALS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe13.13P09) Vwalika C.1, Rwanda Zambia HIV Research Group Z.E.H.R.P.2 It is possible to recruit and retain sufficient numbers of HIV discordant couples for Phase II-b clinical trials. Phase III trials will require substantial expansion of CVCT services. |
| WePe13.13P10 | WILLINGNESS TO PARTICIPATE IN HIV VACCINE TRIALS AMONG COLLEGE STUDENTS IN SOUTHERN BRAZIL IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe13.13P10) De Souza R.1, De Souza C.1, Maggi A.2, Bisol M.1, Wagner T.2 Our survey on willingness to participate in future HIV vaccine trials in this population indicated that 40.7% to 72.3% of the participants would be part of a trial, considering respondents that needed additional information to participate. This finding suggests that college students may be an alternative cohort, suitable for future HIV prevention trials. Addressing barriers and concerns by providing information through appropriate agencies may lead to successful HIV vaccine trials with college students in southern Brazil. |
| WePe13.13P11 | RESEARCH CAPACITY PROJECT (RCP STUDY): A COLLABORATIVE STRATEGY TO FOSTER SCIENTIFIC RESEARCH IN HIV/AIDS AT PUBLIC HEALTH SERVICES (SUS) OF BRAZIL IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe13.13P11) Rodrigues R.1, Barcellos N.T.2, Silva I.B.3, Knoll R.4, Thomaz M.5, Stella I.6, Neves F.R.H.L.7, Brito A.8, Silva I.O.9, Brigido L.F.M.10 The needed capacity building slows down the process but the work within clinical centers may provide stability and foster collaborative research with established centers at the country and abroad. Extra mural activities may improve community involvement beyond CABs. Further integration of these activities to global efforts may accelerate and help in the standardization of different procedures. |
| WePe13.13P12 | ASSESSING THE ATTITUDES OF HIV SEROPOSITIVE BLACK MEN AND WOMEN TOWARDS PARTICIPATION IN HIV VACCINE CLINICAL TRIALS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe13.13P12) King W.D.1, Ramey R.2, Jones S.3, Clemons K.2, Wyatt G.4 Preparing Black seropositives for HIV vaccine clinical trials will require community based and individual education; ensuring access to the clinical trial by its location and available amenities such as compensation; having a diverse research team that the participant trusts and full disclosure about side effects and efficacy of the vaccine. |
| WePe16.1B HIV-induced immune dysfunction and activation |
|
| WePe16.1B01 | EVOLUTION OF T CELL ACTIVATION DURING STRUCTURED TREATMENT INTERRUPTIONS (STIS) IN A GROUP OF PATIENTS TREATED WITH AN ANTIVIRAL DRUG (DDI) AND A CYTOSTATIC DRUG (HYDROXYUREA). IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe16.1B01) Benito J.M., López M., Ballesteros C., Barreiro P., Soriano V. In patients treated with ddi-HU, STIs have only a moderate impact on T cell activation and in CD4 looses. Viral reservoirs did not increase with STI but instead decreased. |
| WePe16.1B02 | ASSOCIATIONS AMONG VIRAL REPLICATION, ACTIVATION MARKERS AND CD8 SUBSETS IN HIV-INFECTED INDIVIDUALS NAÏVE TO, OR FAILING TREATMENT IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe16.1B02) Routy J.-P.1, Mercier F.1, Grignon C.1, Gimmig S.2, Yassine-Diab B.2, Young M.1, Sekaly R.-P.2, Tremblay C.2, Boulassel M.-R.1 These data suggest that a substantial proportion of TCM cells expressing immune activation markers with a high degree of susceptibility to apoptosis, is present in subjects with active viral replication, thus providing an explanation for the ineffectiveness of these cells in controlling HIV. |
| WePe16.1B03 | MULTI-PARAMETRIC ANALYSIS OF T-CELL TURNOVER IN SIV-INFECTED MACAQUES IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe16.1B03) Meier-Schellersheim M.1, Paul W.E.1, Picker L.J.2, Grossman Z.1 Proliferation and death of most activated T-cells in SIV-infected macaques occur in the form of proliferation bursts followed by death of most of the progeny within days to weeks, resembling clonal expansion and contraction during conventional immune responses. Persistence of activation bursts implies that the level of stimulation of T-cell clones fluctuates in space and time, facilitating cycles of activation and control. Such mode of chronic activation imposes constraints on the continuity and rate of viral replication. These findings highlight the need to discern deleterious effects of immune activation from adaptive response aspects and self-regulatory aspects, and to selectively target host mechanisms that contribute to the first. |
| WePe16.2B Cellular suppressive factors |
|
| WePe16.2B01 | RESTRICTION OF RETROVIRAL INFECTION BY TRIM5A IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe16.2B01) Keckesova Z., Ylinen L., Towers G. Our data will help us to better understand the TRIM5a antiviral mechanism and could provide a basis for novel therapeutic strategies. |
| WePe16.3B Innate immunity |
|
| WePe16.3B01 | THE EXPRESSION OF NATURAL CYTOTOXICITY RECEPTORS NKP46 AND NKP44 ON CIRCULATING CD56 BRIGHT NK CELLS CORRELATE WITH VIREMIA DURING THE ACUTE PHASE OF HIV INFECTION IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe16.3B01) Fortis C., Mantegani P., Galli L., Tambussi G., Lazzarin A. The prevalence of CD56bright NK cells bearing activating receptors during the acute phase of HIV infection in patients with high viremia (>215.000 HIV-RNA copies/ml) suggest an unbalance of the NK cell function with a prevalence of regulatory over cytotoxic activity. |
| WePe16.3B02 | EFFECT OF LOPINAVIR (LPV) AND ATAZANAVIR (ATV) ON PROTEASOME ACTIVITY OF JURKAT, U937 AND HEL299 CELL LINES. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe16.3B02) Tronconi E.1, Groettrup M.2, Valerio A.1, Mazza F.1, Cargnel A.1, Atzori C.1 20S proteasome is influenced by PIs drugs, an unexpected modulation on the eukaryotic cell structure. HEL299 behaviour reflected the results obtained in our Pc in vitro model, where PIs inhibited microrganisms proliferation, explaining the differences noticed by other authors in an axenic model. Data obtained in lympho-monocytes, add a further evidence of aspecific effect of PIs on human cells, underlying the need to further decipher the mechanisms by which LPV and ATV interact with host cells, in addition to the well-known antiviral effect. |
| WePe16.3B03 | THE POTENTIAL ROLE OF MANNOSE-BINDING LECTIN(MBL) IN SUSCEPTIBILITY AND PROGRESSION OF HIV-1 INFECTION IN CHILDREN. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe16.3B03) Dzwonek A.1, Novelli V.2, Bajaj-Elliott M.3, Clapson M.2, Klein N.4 From these results it would appear that MBL deficiency is more frequent in patients with severe disease as assessed by CD4%. The frequency of MBL genotypes were higher in children on HAART compared with LTNP-s or ARTN. The detection of MBL mutations may be a useful predictor to identify children with delayed disease progression who, consequently, may not require immediate antiretroviral treatment. |
| WePe16.3B04 | INNATE SUPERANTIBODIES TO HIV GP120 IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe16.3B04) Planque S.1, Hanson C.V.2, Salas M.2, Taguchi H.1, Bangale Y.1, Nishiyama Y.1, Paul S.1 Immunological factors underlying the varying susceptibility of different individuals to HIV infection and disease progression are not fully understood. Our results suggest the potential protective role of innate superantibodies to gp120, particularly at mucosal surfaces at which IgA Abs are the primary defense mediators, and support further study of superantibody properties and regulation in infected individuals. |
| WePe16.3B06 | INDUCTION OF INFLAMMATORY CYTOKINES AND APC MATURATION BY HBD-3. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe16.3B06) Funderburg N., Sieg S., Feng Z., Weinberg A., Lederman M. HBDs induce activation and maturation of APCs, increasing expression of co-stimulatory molecules (CD80, 86, and 40), as well as inducing expression of inflammatory cytokines (IL-6, IL-8, IL-1b). Thus, HIV-1 induced mucosal expression of hBDs may link the innate and adaptive immune systems, resulting in the activation and maturation of multi-lineage APCs. |
| WePe16.3B07 | PERSISTENT VIRAL REPLICATION LEADS TO A DEPLETION OF NK CELL PERFORIN LEVELS STARTING IN ACUTE HIV-1 INFECTION IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe16.3B07) Alter G., Teigen N., Staller K., Johnston M., Burgett N., Rosenberg E., Altfeld M. Overall, it appears that NK cells from subjects identified during acute HIV-1 infection have high perforin content that correlates with their ability to degranulate following stimulation. In contrast, persistent viral replication leads to a depletion of perforin levels in the presence of increased NK cell degranulation following stimulation. This data suggests that HIV-1 replication leads to a depletion of perforin content of NK cells early in infection resulting in impaired cytolytic capacity of these cells. |
| WePe16.3B08 | TLR EXPRESSION AND SIGNALING IN HIV-INFECTED CELLS. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe16.3B08) Quigg-Nicol M.1, Andrade A.2, Mathys J.-M.1, Koziel H.3, Skolnik P.1 Impairment in the innate immune response of HIV-infected cells to bacterial antigens, as manifested by TNFα production, may be related to decreased TLR2 and TLR4 cell surface expression that is mediated by post-transcriptional processes or decreased MD-2 expression. |
| WePe16.4B HIV-specific humoral immunity |
|
| WePe16.4B01 | PROTECTIVE EFFECT OF DENGUE INFECTION AGAINST HIV-1: DENGUE VIRUS AND HIV-1 NEF HOMOLOGY IN THE SAME EPITOPE AWL THAN ALPHA-DEFENSIN AND ORIENTIA TSUTSUGAMUCHI. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe16.4B01) Tran M.K.G.1, Maurisson G.2, Richert A.3, Caprani A.3 An epitope is found common to dengue virus and HIV-1 Nef explaining the protective effect of dengue virus against HIV-1 infection. Interestingly, this motif AWL is repeatedly found in many viruses and pathogens which also are all protective against HIV-1; this epitope mimicks alpha-defensin, a natural immunity protein. A vaccine based on HIV-1 Nef epitope centered on AWL can be designed with heat shock protein presentation to dendritic cells (Srivastava P). |
| WePe16.4B02 | LACK OF NEUTRALIZING ANTIBODY RESPONSE TO HIV-1 PREDISPOSES TO SUPERINFECTION IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe16.4B02) Smith D.1, Strain M.1, Frost S.1, Pillai S.1, Wong J.2, Wrin T.3, Petropolous C.3, Little S.1, Richman D.4 Two individuals identified with HIV superinfection had less cross-protective and autologous neutralizing antibody responses than those not superinfected, suggesting that neutralizing antibody protects against superinfection with considerable implications for vaccine development. |
| WePe16.5B HIV-specific cellular immunity |
|
| WePe16.5B01 | QUALITATIVE ANALYSIS OF HIV-1-SPECIFIC CD8+ T CELL CLONES IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe16.5B01) Mashishi T.1, Pettengel C.1, Wey E.1, Ronston T.1, Easterbrook P.2, Conlon C.3, Rowland-Jones S.1, Dong T.1 The fact that Clone A3 could recognize more naturally-occurring variants of FL8 strongly suggests that it is able to better tolerate potential escape mutants within FL8 than other Vb13.2 CD8+ T cells with shorter CDR3 region. The level of TNFa and IFN? production corresponds to the cytolytic strength of a CD8+ T cell. These findings suggest that effective control of HIV in vivo might be conferred by CD8+ T cells that have multiple effector functions, and able to tolerate potential escape mutants within immunodominant epitopes. |
| WePe16.5B02 | REDUCED RISK OF SEROCONVERSION IN HIV EXPOSED, UNINFECTED (EU) INDIVIDUALS WITH HIV-SPECIFIC T CELL PROLIFERATION. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe16.5B02) Makedonas G.1, Bruneau J.2, Lowndes C.3, Alary M.3, Peretz Y.1, Sekaly R.-P.2, Tsoukas C.1, Bernard N.1 HIV exposure is associated with the development of HIV-specific cells able to expand in response to HIV stimuli. Persistently seronegative EUs with HIV-specific proliferative responses are at a reduced risk of seroconverting compared with similarly exposed EU who lack these responses (OR= 21.67, 95% Confidence interval: 0.9706 to 483.6)]. Persistently seronegative EU subjects exhibit HIV-specific T cell functions that are consistent with those of memory T cells. |
| WePe16.5B03 | RELATIONSHIP BETWEEN THE LEVEL OF HIV-1 PROVIRAL DNA AND HIV-1-SPECIFIC CYTOTOXIC T LYMPHOCYTE RESPONSE IN HIV-1 INFECTED KOREANS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe16.5B03) Choi J.Y.1, Song Y.G.1, Kang M.W.2, Choe K.W.3, Park S.-C.4, Kim J.M.1 CTL response was affected by plasma HIV RNA, not by proviral DNA. Because neither HAART nor HIV-1 specific CTL are able to eliminate the proviral reservoir, another strategy is required in order to eradicate HIV infection. |
| WePe16.5B04 | SPECIFIC HIV-1 CD4+ RESPONSES IN NAÏVE AND HAART RECEIVING PATIENTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe16.5B04) Tsalimalma K.1, Solakidi S.1, Dimitrakopoulou A.1, Kordossis T.2, Choremi-Papadopoulou H.1 The observed significant increase in IL-2 secretion in response to SEB and the significant decrease of IFN-? secreting cells in response to HIV-p55 in HAART patients might suggest a relation of CD4+T cell responses with control of viremia, due to antiretroviral therapy. |
| WePe16.5B05 | IMMUNE RESPONSES IN CHRONICALLY CLADE C INFECTED CHILDREN ON CONTINOUS HAART AND STI IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe16.5B05) Reddy S.1, Bobat R.2, Kiepiela P.2, Kindra G.2, Chetty S.2, Rathnavalu P.2, Mazibuko T.2, Mkhize P.2, Moodley E.S.2, Coovadia H.M.2, Day C.2, Walker B.3, Goulder P.4 Preliminary data indicate that STI in chronic paediatric infection is of short duration (1 week). HAART reduced both viremia and T cell responses in treated infants. HIV-Gag specific CD4+ T cell responses were maintained even on HAART. |
| WePe16.5B06 | CD4+ CD25+ REGULATORY T CELLS ARE DETECTABLE IN PERIPHERAL BLOOD OF HIV-INFECTED PATIENTS TREATED WITH IL-2 IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe16.5B06) Weiss L.1, Donkova-Petrini V.2, Aouba A.2, Levy Y.3 Among CD4+CD25+ T cells expanded in IL-2 treated HIV-infected patients, cells exhibiting Treg function are detected. Whether these Treg cells contribute to decrease immune activation and/or participate in vivo to immune deficiency by inhibiting specific T cell responses remains to be clarified. |
| WePe16.5B07 | STABILITY OF HIV-SPECIFIC IMMUNE RESPONSES DURING THE NATURAL EVOLUTION OF INFECTION IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe16.5B07) Peretz Y.1, Alter G.2, Boisvert M.P.1, Tsoukas C.M.1, Bernard N.F.1 We interpret these results to mean that in the absence of therapy induced viral suppression, virus/host interactions drive changes in HIV-specific recognition and that these perturbations are greater in untreated PI and chronically infected patients compared to treated PI patients. |
| WePe16.6B HIV-specific mucosal immunity |
|
| WePe16.6B01 | CHARACTERIZATION OF HIV NEUTRALIZING IGA BY SCREENING A PHAGE-DISPLAY FAB IGA LIBRARY DERIVED FROM MUCOSAL CELL FROM HIV HIGHLY EXPOSED BUT IGG SERO NEGATIVE INDIVIDUALS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe16.6B01) Tudor D.1, Derrien M.1, Drillet A.S.1, Alfsen A.1, Reynes J.M.2, Buisson Y.2, Bomsel M.1 Several neutralizing anti- gp41 Fabs have been characterized and a new neutralizing epitope on gp41 has been revealed. |
| WePe16.6B02 | NEW PERFORIN REAGENTS FOR THE STUDY OF RHESUS MACAQUES: AN IMPROVED TOOL FOR ANALYSIS OF ACUTE SIV SPECIFIC CELLULAR IMMUNE RESPONSES IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe16.6B02) Quigley M.F.1, Critchfield J.W.2, Zuber B.3, Abel K.4, Miller C.J.4, Shacklett B.L.2, Sandberg J.K.1 The novel perforin monoclonal antibodies are a valuable tool to quantify cytotoxic T-lymphocytes in rhesus macaque lymphoid tissue and blood. Their application in studies of SIV-specific CD8 T cell function and CD4 T cell depletion will be further developed. |
| WePe16.7 Immune reconstitution |
|
| WePe16.7B01 | RECOMBINANT GROWTH HORMONE INDUCES HIV-1-SPECIFIC CD4 AND CD8 T-CELL RESPONSES IN PATIENTS ON EFFECTIVE ANTIRETROVIRAL THERAPY IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe16.7B01) Imami N.1, Moyle G.2, Gazzard B.2, Gotch F.1 The implication of these data is that concomitant administration of rhGH with effective ART results in a dose-dependent reversal of both the CD4 and the CD8 T lymphocyte dysfunction commonly observed in HIV-1-positive patients. Such immune-based therapeutic strategies in treated chronic HIV-1 infection may enable the induction of virus-specific CD4 T cells essential for the subsequent "kick-start" and expansion of specific CD8 T cells. |
| WePe16.7B02 | IMMUNERECONSTITUTION AFTER AUTOLOGOUS BONE MARROW TRANSPLANTATION (ASCT) IN HIV-INFECTED PATIENTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe16.7B02) Simonelli C., Bortolin M.T., Pratesi C., Tedeschi R., Rupolo M., Talamini R., Michieli M., De Paoli P., Tirelli U. No differences in the dynamic of immunereconstitution were observed between HIV+ and HIV- pts; HAART was able to control viral replication even when the nadir of immunedepression occurred. Moreover no significant changes of genotyping profile were noticed in the few pts who discontinued HAART. Supported by ISS grants. |
| WePe16.7B03 | CD4+ COUNT DROP ON TENOFOVIR-DIDANOSINE, AS COMPARED WITH TENOFOVIR-LAMIVUDINE OR DIDANOSINE-LAMIVUDINE, IN HIV PATIENTS WITH SUSTAINED VIROLOGICAL RESPONSE: A COMPARATIVE STUDY. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe16.7B03) Torres R.1, Cervero M.1, Jusdado J.J.1, Agud J.L.1, Del Alamo M.2, Garcia E.3, Serranos N.3, Solis J.1 DDI+TDF containing treatment schedules seem unadvised, because of lowering of CD4 counts, while helper-cell increased on DDI+3TC or TDF+3TC. The differences were clinically significant. At 12 months, treatment arms not containing the putatively detrimental DDI+TDF combination had at least 139 CD4/µL higher counts. |
| WePe16.7B04 | IMMUNOLOGIC RECONSTITUTION THROUGH 6 YEARS IN ANTIRETROVIRAL-NAÏVE SUBJECTS TREATED WITH LOPINAVIR/RITONAVIR (LPV/r) IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe16-7B04) Landay A.1, da Silva B.2, King M.2, Albrecht M.3, Benson C.4, Eron J.5, Glesby M.6, Gulick R.6, Hicks C.7, Kessler H.1, Murphy R.8, Thompson M.9, White C.10, Wolfe P.11, McMillan F.2, Braun N.2, Calhoun D.2, Hanna G.2 After 6 years of treatment, CD4, CD3, CD19, and CD16+56+ counts were generally within laboratory normal ranges. Regardless of baseline CD4, CD4 cell counts and markers of activation normalized by year 6. |
| WePe16.7B05 | IMMUNE RECONSTITUTION IN PATIENTS INITIATING HAART WITH CD4 < 200 CELLS/μLL IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe16.7B05) Ferrer E.1, Podzamczer D.1, Ruiz I.1, Esteve A.2, Miró J.M.3, Jaen A.2, Riera S.4, Tural C.5, Segura F.6, Force L.7, Vilaró J.8, Masabeu A.9, Altes J.10, García I.11, Sued O.3, Gatell J.M.3, Casabona J.2 Lower CD4 count is the strongest variable associated to not reaching CD4 > 200 in immunossuppressed pts initiating NNRTI or PI-based HAART regimens. In those with virologic response, older age is another obstacle for immune reconstitution. |
| WePe16.7B06 | ANTIRETROVIRAL TREATMENT INTENSIFICATION LEADS TO ACCELERATED CD4 LYMPHOCYTE RECOVERY. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe16.7B06) Smith K.1, Aga E.2, Valdez H.3, Bosch R.2, Kuritzkes D.4, Landay A.1, Garren K.5, Rooney J.6, Patterson B.7, Connick E.8, Silicano R.9, Lederman M.10, ACTG 5136 Protocol Team A.11 Intensification of ART in subjects with long term viral control may lead to improvements in total CD4 lymphocyte recovery primarily via restoration of memory cells. |
| WePe16.7B07 | TIPRANAVIR/RITONAVIR (TPV/R) DEMONSTRATES SUPERIOR IMMUNOLOGIC RESPONSE TO COMPARATOR PROTEASE INHIBITORS (CPIS) IN A PI-EXPERIENCED POPULATION WITH ADVANCED DISEASE IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe16.7B07) Grinsztejn B.1, Hicks C.2, Cahn P.3, Villacian J.4, McCallister S.4 TPV provides a significantly greater CD4+ response than CPI in PI-experienced patients. In patients with very advanced disease, combination of TPV with T20 provides a robust immunological response. |
| WePe16.7B08 | BENEFICIAL EFFECTS OF A SWITCH TO A LOPINAVIR/R (LPV/R)-CONTAINING REGIMEN FOR PATIENTS WITH PARTIAL OR NO IMMUNE RECONSTITUTION WITH HAART DESPITE COMPLETE VIRAL SUPPRESSION IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe16.7B08) Pitrak D.1, Estes R.1, Tschampa J.2 The mean CD4+ increase for patients switched to a regimen containing LPV/r was greater compared to patients who remained on their current regimen. Ex vivo apoptosis of both naïve and memory CD4+ cells was reduced, while no change in intracellular viral load was observed. This suggests that the benefit of LPV/r may be due to an immunologic effect that is independent of antiviral activity. |
| WePe16.7B09 | IMMUNE RECONSTITUTION IN SEVERELY IMMUNODEFICIENT HIV PATIENTS IS BIASED TOWARDS TYPE 2 IMMUNE RESPONSES IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe16.7B09) French M.A.1, Keane N.M.1, Phung S.2, Price P.1 Immune reconstitution on ART is associated with a T2 bias in some patients who had nadir CD4+ T-cell counts of <50/mL, which may be associated with some OIs occurring at increased CD4+ T-cell counts. A high serum IgE level may be a marker of low CD4+ T-cell IFN-γ responses. |
| WePe16.7B10 | DIFFERENT PROFILE OF IMMUNE RECONSTITUTION AFTER HAART IN CHILDREN AND ADULTS WITH HIV-INFECTION IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe16.7B1110) Resino S.1, Seoane E.1, Pérez A.1, Ruiz-Mateos E.2, Leal M.2, Fernadez M.1 The restoration of CD4+ and CD8+ T cells after HAART in HIV-infected adults seems to be mainly the consequence of antigen-independent peripheral expansion of T-cells, although a role of the thymus in immune reconstitution in adults cannot be discarded. |
| WePe16.7B11 | FLOW CYTOMETRY AND MOLECULAR EVALUATION OF TCR REPERTOIRE AND T CELL CLONALITY ON HIV INFECTED INDIVIDUALS, BEFORE AND DURING ANTIRETROVIRAL THERAPY. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe16.7B11) Giacoia-Gripp C.B.W.1, Neves Jr. I.2, Galhardo M.C.2, Morgado M.G.1 In general, no specific Vb utilization was observed among the HIV individuals before and after ART. Differential immune responses to HIV or other important antigens are being focused by these cells, although this process could be restrict to the individual preexisting repertoire. |
| WePe16.8 Viral escape and immune pressure |
|
| WePe16.8B01 | IMPACT OF SEQUENCE VARIABILITY ON LEVEL, PHENOTYPE AND FUNCTION OF ANTI-HIV GAG SPECIFIC CD8+ CYTOTOXIC LYMPHOCYTES IN A COHORT OF UNTREATED CHRONICALLY HIV-INFECTED PATIENTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe16.8B01) López M., Soriano V., Lozano S., Gonzalez-laHoz J., Benito J.M. An immune selection pressure on SL9 exists in chronically untreated HIV-infected patients and escape mutations may play an important role as mechanism to evade the immune response. |
| WePe16.8B02 | COMPOUND CD8+ T CELL EPITOPE FLANKING MUTATIONS FAVORED DURING ACUTE INFECTION ALTER PROTEASOMAL PROCESSING OF HIV-1 NEF IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe16.8B02) Milicic A.1, Price D.2, Zimbwa P.1, Booth B.1, Brown H.1, Easterbrook P.3, Olsen K.1, Robinson N.1, Gileadi U.1, Sewell A.1, Cerundolo V.4, Phillips R.1 We describe an example of HIV genomic variation leading to intra-epitope proteasomal cleavage and consequent immune escape. Along with previous reports, these results suggest that the extent of HIV escape might be significantly underestimated if only epitope variants are considered as the potential source of immune escape. |
| WePe16.8B03 | DE-NOVO GENERATION OF HIV-1-SPECIFIC CD8+ T CELL RESPONSES DIRECTED AGAINST A CTL ESCAPE VARIANT IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe16.8B03) Allen T., Yu X., Kalife E., Reyor L., Lichterfeld M., Allgaier R., Rosenberg E., Walker B., Altfeld M. These data demonstrate that de novo responses against CD8 epitope escape variants can be generated in chronic HIV-1 infection following viral escape. These data provide the rationale for developing vaccines to induce CD8+ T cell responses directed against both the wild-type and variant forms of CD8 epitopes to prevent the emergence of CTL escape variants. |
| WePe16-9B Long-term nonprogressors and HIV-2 infection |
|
| WePe16.9B01 | "IMMUNE RESPONSE GENE EXPRESSION ANALYSIS FROM HIV+ LONG-TERM NONPROGRESSORS AND PROGRESSORS (CD4+ CELLS/MM3 <200) COMPARED TO HEALTHY INDIVIDUALS" IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePe16.9B01) Mairena E., Fonseca S., Coutinho da Silva A., Drigo S., Nogueira L., Kalil J., Cunha-Neto E. The upregulation of immune genes is consistent with an increased immune activation among the HIV+ progressor patients. On the other hand, LTNP showed more than 100 downregulated genes, such as genes involved in apoptosis, while progressors showed only 14 downmodulated genes. The reasons why LTNP show downregulation of multiple novel immune genes is currently being pursued. Candidate genes can be individually explored. Support by FAPESP and CNPq. |
| LATE BREAKER - POSTER EXHIBITIONS Wednesday |
|
| WePeLB3.2 Pharmacological monitoring of ARV therapy |
|
| WePeLB3.2C01 | PHARMACOKINETICS AND SAFETY OF A DOUBLE BOOSTING REGIMEN OF ATAZANAVIR (ATZ), PLUS LOPINAVIR (LPV), PLUS MINIDOSE RITONAVIR IN MULTIDRUG-TREATED HIV-INFECTED PATIENTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePeLB3.2C01) Azuaje C.1, Lopez R.1, Ribera E.2, Falco V.2, Imma O.1, Crespo M.1, Diaz M.1, Pou L.1, Monterde J1, Pahissa A.1 Treatment with atazanavir plus lopinavir/ritonavir is well tolerated and provides elevated plasma concentrations of both PIs. This combination could be a good option for patients with multiple treatment failures in whom it's difficult to design effective therapy. |
| WePeLB4.1 Resistance surveillance |
|
| WePeLB4.1C01 | LONG-TERM RISK OF DEVELOPMENT OF DRUG RESISTANCE AFTER STARTING ANTIRETROVIRAL THERAPY IN AUSTRIA IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePeLB4.1C01) Sarcletti M.1, Sturm G.2, Puchhammer-Stöckl E.3, Geit M.4, Schmied B.5, Zangerle R.1 Linear regression curves may be used as model to calculate the development of cumulative drug resistance. |
| WePeLB4.4 Resistance testing in clinical practice |
|
| WePeLB4.4C01 | DISTRIBUTION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 PROTEASE AND REVERS TRANSCRIPTASE MUTATION PATTERNS IN NORTHEAST BRAZIL IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePeLB4.4C01) Medeiros M.1, Lima A.1, Arruda E.2 In a sample of 101 sequences, the top patterns PI, NRTI and NNRTI mutations accounted for 49, 38.5 and 40.9% respectively, of sequences with drug resistance mutations. Characterization of the phenotypic and clinical significance of these common patterns may lead to improved treatment recommendations for a large proportion of patients for whom antiretroviral therapy is failing. |
| WePeLB6.2 Clinical trials of new drugs/pro-drugs |
|
| WePeLB6.2C01 | TMC114/R WELL TOLERATED IN 3-CLASS EXPERIENCED PATIENTS: WEEK 24 PRIMARY ANALYSIS OF POWER 1 (TMC114-C213) IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePeLB6.2C01) Grinsztejn B.1, Arasteh K.2, Clotet B.3, Cunha C.A.4, Goffard J.C.5, Spinosa Guzman S.6, Hill A.6, Molina J.M.7, Tanski C.6, Walgraeve H.6 In 3-class-experienced patients, TMC114/r was generally well tolerated and AE incidence was not dose related. Incidence of AEs of all grades was similar for TMC114/r and controls. When corrected for drug exposure, incidence of most common AEs was lower than for controls. |
| WePeLB08.8 Anatomical and cellular reservoirs |
|
| WePeLB8.8B01 | DIVERGENT HIV-1 EVOLUTION IN SPINAL TUBERCULOSIS GRANULOMAS: ASSOCIATION WITH IMMUNOLOCALIZED CD68+ MACROPHAGES IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePeLB8.8B01) Danaviah S.1, Chelule P.1, Gordon M.1, de Oliveira T.1, Naicker T.2, Dorsamy V.2, Graham N.1, Kumar K.P.S.3, Govender S.3, Cassol S.4 Restricted migration may be responsible for the observed granuloma-specific evolution. The relationship between CD68+ macrophages, their phagocytic potential and HIV-1 diversity warrants further investigation. |
| WePeLB08.9 Host genetic factors |
|
| WePeLB8.9B01 | ACCELERATING EFFECT OF HLA-BW6 HOMOZYGOSITY ON DISEASE PROGRESSION IN CHINESE HIV-1 INFECTED PATIENTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePeLB8.9B01) Qing M., Xie J., Wang A., Li T. HLA-Bw4 homozygosity may have a protection role in HIV-1 infection. More importantly, the HLA-Bw6/Bw6 homozygosity is associated with the faster disease progression in HIV-1 infection. |
| WePeLB10.4 Harm reduction and IDU-related strategies |
|
| WePeLB10.4P01 | THE BREAKFAST BUFFET: LATE NIGHT HARM REDUCTION SERVICES FOR INJECTION DRUG USING MSM IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePeLB10.4P01) Rose V., Raymond H.F., Klein C., Bachrach A., McFarland W. We successfully reached a high risk, disenfranchised population of MSM-IDU through mobile harm reduction, and demonstrated the feasibility, acceptability and utility of late night services. Late night mobile needle exchange served a largely hidden population of methamphetamine using MSM-IDU. Late night outreach and roving needle exchange delivery systems should be routinely provided to reduce HIV/STD infections. |
| WePeLB11.5 Cost - Benefit of HAART |
|
| WePeLB11.5C01 | COST EFFECTIVENESS OF CD4 LABORATORY MONITORING IN HAART IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePeLB11.5C01) Bishai D.1, Colchero M.A.1, Durack D.2 As the price of CD4 testing falls into the $3-5 range it will be both cost-saving and life saving to adopt this approach in populations such as the one we model. HAART programs that fail to invest in CD4 monitoring when the price comes into the $5 range will be wasting both precious lives and precious resources. |
| WePeLB11.5C02 | COST-EFFECTIVENESS OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN SOUTH AFRICA IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePeLB11.5C02) Badri M.1, Wood R.1, Maartens G.2, Mandalia S.3, Bekker L.-G.1, Penrod J.R.4, Platt R.W.5, Beck E.J.6 HAART is a cost-effective intervention in South Africa, and cost-saving when HAART prices are further reduced. |
| WePeLB13.13 Planning for vaccine efficacy trails |
|
| WePeLB13.13P01 | SUCCESSFUL RECRUITMENT OF 2,000 VOLUNTEERS FOR HIV PREVALENCE STUDY AT A RURAL SUGAR PLANTATION IN KAKIRA, UGANDA IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePeLB13.13P01) Katende M.J.1, Tibenderana E.1, Mulindwa M.1, Mulindwa M.1, Lieven A.V.2, Ketter N.3, Price M.3, Mugyenyi P.1 Recruitment into this study was excellent. While an occupational cohort has benefits in terms of population stability and follow up rates, HIV prevalence was higher in people residing outside. |
| WePeLB16.1 HIV-induced immune dysfunction and activation |
|
| WePeLB16.1B01 | APPEARANCE OF IMMATURE/TRANSITIONAL B CELLS IN HIV-INFECTED INDIVIDUALS WITH ADVANCED DISEASE CORRELATES WITH INCREASED LEVELS OF IL-7 IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePeLB16.1B01) Malaspina A., Moir S., Ho J., Wang W., Howell M., O'Shea M.A., Roby G., Rehm C., Mican J.M., Chun T.-W., Fauci A.S. We describe a population of immature B cells that is overly represented in HIV-infected patients and associated with profound lymphopenia, high level of HIV replication, and increased levels of IL-7. These findings argue for the existence of IL-7 dependent pathways that regulate B cell differentiation and that become dysregulated in the setting of HIV disease. |
| WePeLB16.1B02 | CATHEPSIN B AND CYSTATIN A AS INDICATORS OF A SEPARATE APOPTOTIC PATHWAY IN HIV-1 INFECTION IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePeLB16.1B02) Voltersvik P.1, Bostad L.2, Dyrhol-Rise A.M.3, Åsjö B.1 A 2-fold higher Cathepsin B/Cystatin A ratio was found in patients before HAART suggesting a HIV-1 driven cathepsin-dependent pathway of apoptosis. Thus, Cathepsin B and Cystatin A possibly represent an apoptotic pathway distinguishable from the FAS-FAS Ligand pathway. |
| WePeLB16.3 Innate immunity |
|
| WePeLB16.3B01 | DIFFERENCES IN THE RECOGNITION OF HLA-A AND HLA-B MOLECULES EXPRESSIING THE BW4 EPITOPE BY DIFFERENT KIR3DL1 ALLELES IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePeLB16.3B01) Thananchai H.1, Dong T.1, Gillespie G.1, McVicar D.2, Bashirova A.2, Parham P.2, Carringtion M.2, Rowland-Jones S.1 This is the first study to show that KIR3DL1 can interact with an HLA-A molecule. Furthermore, we demonstrate that the interaction of KIR3DL1 with HLA-A24 and HLA-B57 is KIR subtype dependent. |
| WePeLB16.4 HIV-specific humoral immunity |
|
| WePeLB16.4B01 | MONOCLONAL AND POLYCLONAL ANTI-HIV IGG EFFICIENTLY INHIBIT HIV-1 REPLICATION ON IMMATURE DENDRITIC CELLS WITHOUT INDUCTION OF MATURATION IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePeLB16.4B01) Holl V., Peressin M., Schmidt S., Decoville T., Aubertin A.M., Moog C. Our results demonstrate the participation of FcgammaRs in the inhibition of HIV by IgG. As IgG different from neutralizing IgG could be involved in this HIV inhibition, such antibodies should be considered in the further development of HIV-1 vaccine candidate. |
| WePeLB16.5 HIV-specific cellular immunity |
|
| WePeLB16.5B01 | ANALYSIS OF HIV-1 SPECIFIC CYTOTOXIC T LYMPHOCYTE RESPONSES IN CHINESE HIV/AIDS PATIENTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePeLB16.5B01) Jiao Y., Han y., QIU Z., Li T. No significance relation between the HIV Specific CTL and disease progression in Chinese HIV/AIDS patients.These data demonstrate that different characteristics of CTL responses exist in HIV-infected patients with different disease progression. They may further suggest that CTL may play different roles in different disease stages. |
| WePeLB16.9 Long-term non progressors and HIV-2 infection |
|
| WePeLB16.9B01 | MAPPING OF MHC CLASS I EPITOPES AND ANALYSIS OF CD8+ T-CELL RESPONSES TO THE ENTIRE EXPRESSED GENOME OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 2 (HIV-2) BY EX-VIVO IFN-γ ELISPOT ASSAY IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. WePeLB16.9B01) Leligdowicz A.1, Duvall M.1, Dong T.1, Jaye A.2, Whittle H.2, McMicheal A.1, Rowland-Jones S.2 Using a 3-dimensional matrix allows highly sensitive, specific, and rapid identification of peptides containing MHC class-I/class-II epitopes and minimization of the number of cells and assays required to identify epitope-containing peptides. Fine mapping and HLA-restriction of individual peptides will allow characterization of HIV-2-specific CD8+ T-cell phenotype and function using tetramer technology. |
050724
Main Table of Contents
Copyright © 2005 - International AIDS Society (IAS). All information and content relating to the abstracts from the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.